text stringlengths 102 99.6k | url stringlengths 31 426 | crawl_date timestamp[us, tz=UTC]date 2022-04-01 00:29:49 2022-09-19 04:34:15 |
|---|---|---|
AUGUSTA, Ga. (AP) — The introduction differs slightly from tournament to tournament, though the general theme never changes.
“The defending Masters champion.”
Those words, or some version of them, have been what Hideki Matsuyama has heard on the first tee of whatever tournament he’s played over the last year. And last week at the Valero Texas Open, the words seemed to resonate differently — because that’s when Matsuyama realized that his reign is about to end.
“It was a little sad,” Matsuyama said.
There’s one way to avoid that, of course: He just needs to successfully defend his Masters title, something nobody has done at Augusta National since Tiger Woods in 2002. Matsuyama, the first Japanese man to win a major championship, is hoping a balky neck that has been bothering him for a few weeks is good enough on Thursday to give him a legitimate chance of winning the Masters again.
He went 6 under in a seven-hole stretch of the back nine in the third round last year to take command, then held on with a final-round 73 to beat Will Zalatoris by a shot. Matsuyama has won twice more since: the Zozo Championship in Japan in October, then the Sony Open in Hawaii in January.
“It’s been a great year,” Matsuyama said. “It’s great to be back here at Augusta. I feel very proud and honored to be here as the defending champion. It’s been a great year with wins at Zozo and Sony. Last couple of weeks, though, have been a struggle. Hopefully I can find my game and be a worthy defending champion.”
That last part is the mystery. The neck has even him guessing.
The issue with the left side of his neck first presented itself during the second round at Bay Hill last month. He got through that tournament, tying for 20th, and went to Texas last week pain-free and feeling good for a couple of days.
Then came Wednesday, it stiffened up again and Matsuyama eventually withdrew.
“I haven’t really been able to hit a full shot, a 100% full shot in a long time, so that’s still a question,” Matsuyama said. “But I feel like the treatment I’ve been receiving is helping. I’m on the road to full recovery. … I think by Thursday I’ll be ready to play my best, hopefully.”
He showed last year that his best is more than enough.
Matsuyama first came to Augusta National as an amateur in 2011, getting to the Masters after winning what was then called the Asian Amateur and is now called the Asia-Pacific Amateur. It’s a relatively new tournament, having been contested only 12 times and won by 10 men — three of whom are in this Masters field.
They all played a practice round together this week as well; Matsuyama was joined by reigning Asia-Pacific winner Keita Nakajima and 2018 winner Takumi Kanaya.
“Following the footsteps of Takumi Kanaya and Masters champion Hideki Matsuyama, it’s an honor to do that,” Nakajima said.
Matsuyama expected his playing partners to pepper him with questions about how to play this and that at Augusta National.
Turns out, he was the one driving the conversation.
“If I can be an inspiration to them, it makes me very happy,” Matsuyama said. “Hopefully last year’s Masters win will help inspire and encourage a lot of young people in Japan to take up golf and follow in my footsteps. … I don’t know if they were bashful or what, but I was hoping to be able to talk more with them.”
Which, given Matsuyama’s penchant for privacy, is a bit of a surprising take. He’s polite in interviews, even smiling a bit and giving knowing nods when his best lines drew laughs after getting translated for largely English-speaking reporters on Tuesday, yet would never be described as an open book.
Matsuyama kept the menu for Tuesday night’s Masters Club Dinner — it’s more commonly called the Champions Dinner — largely under wraps until it was announced that morning. None of his selections was particularly surprising, especially since the theme was to celebrate the best of Japanese fare.
Sushi, sashimi and nigiri were to be served as appetizers, along with Yakitori — essentially meaning grilled — chicken skewers.
Miso-glazed black cod with a Japanese broth would be offered, as would the centerpiece: A5 Wagyu ribeye of beef, arguably the finest cut in the world, served with mushrooms and vegetables along with a sansho daikon ponzu, a sauce that gets a bit of a spicy kick from Japanese radishes.
For dessert, Japanese strawberry shortcake — sponge cake with Amaou strawberries, generally considered Japan’s best kind, ones that are typically available only through winter and some of spring in that country.
“I’m really looking forward to the Champions Dinner,” Matsuyama said.
It’ll provide him a chance to enjoy a perk that he’s rarely partaken in since winning the Masters. He’ll get to wear his green jacket.
Matsuyama carried the jacket — Masters winners get to take it off the Augusta National property for a year before it’s supposed to be returned — onto a commercial flight out of Atlanta the day after winning it a year ago. He tends not to wear it. He’s even leery of sending it out for dry cleaning.
“I thought about it and it needed to be cleaned, but I just was so worried that something might happen to it,” Matsuyama said. “So I didn’t want to let it out of my sight. I just spent a year looking at it. I haven’t really worn it that much, but I look at it a lot. And now I wish I would have worn it more.”
The introduction on tee boxes changes now. The jacket gets returned. He’ll drape one over the shoulders of a new champion Sunday.
That is, unless he wins the Masters again.
___
More AP golf: https://apnews.com/hub/golf and https://twitter.com/AP_Sports | https://cw33.com/sports/ap-sports/matsuyama-returns-to-masters-enjoying-perks-of-a-champion/ | 2022-04-05T18:56:21Z |
Investigation: No retaliation against COVID-19 whistleblower
TALLAHASSEE, Fla. (AP) — A state investigator’s report says there’s nothing to indicate the Florida Department of Health told an employee to falsify COVID-19 data and she wasn’t fired out of retaliation. The report released this month investigated claims made by former department employee Rebekah Jones. Jones received national attention when she raised question about the state’s COVID-19 dashboard and claimed she was fired for exposing problems. The state said she was fired for insubordination after being reprimanded several times. An inspector general’s 268-page report found no evidence of wrong doing or retaliation by the department. | https://localnews8.com/news/2022/05/27/investigation-no-retaliation-against-covid-19-whistleblower/ | 2022-05-27T22:55:02Z |
LOS ANGELES, Aug. 19, 2022 /PRNewswire/ -- On Thursday, INDIEV revealed exclusive new footage of the INDI One driving through Beverly Hills. The footage marks a pre-production milestone, driving down historic Rodeo Drive just blocks from INDIEV's first Brand Experience Center. Media members, local government and green energy leaders, and Los Angeles influencers were given test rides in the INDI One, the first time that test rides of the INDI One have been publicly available on the west coast.
"It was a smooth quiet ride in the INDI One, but the kicker is being able to game on a full-blown PC with VR" DaPoets, Tech influencer
"I'm so excited to be a part of the edge of the future here at INDI" -Stephanie Heiner, INDI Innovator
"It really put the future of technology into perspective for me" -Alliestrasza, streamer & influencer
"The INDI One is the car for live streamers!" -Nezst, Twitch streamer
Alongside the new footage, updated specifications for the Standard and Premium Trim packages were unveiled:
Range- 230mi
0-60mph- 6.7s
Torque– 410 Nm
Battery- 76 kWh
Horsepower– 275 hp
Top Speed- 120mph
Charging- 100 kW DC
Powertrain- Single Motor RWD
Starting Price- $45,000
Range- 300mi
0-60mph- 4.2s
Torque– 730 Nm
Battery- 95 kWh
Horsepower– 475 hp
Top Speed- 130mph
Charging- 150 kW DC
Powertrain- Dual Motor AWD
Starting Price- $69,000
Colors- Pacific Pearl, Premiere, Melrose, Laguna, Griffith, Beverly Blush, Silverlake, City Nights, & Sunset
L/W/H- 189"|78"|67"
Trunk Cargo Space- 43 cu ft
The INDI One can be reserved directly at this link, with reservation deposits costing $100 for the Standard Trim and $200/$400 for the Premium Trim. Parties interested in becoming INDI One Innovators or distributors can contact Innovators@indiev.com & distributor@indiev.com.
Contact:
Ellen Lee, GM of Marketing
media@indiev.com
INDIEV was founded in Los Angeles in 2017 on the idea that the future of personal mobility will no longer be defined solely by horsepower or top speed, but rather from the connectivity, customizability, and processing power offered to drivers and passengers. Anchored by the Vehicle Integrated Computer, INDIEV hopes to bring tremendous computing power and endless options for creativity into personal transportation.
At INDIEV, We Do Cars, and You Do You.
To find out more about INDIEV, please visit www.INDIEV.com and our social platforms: Instagram, TikTok, Twitter, Facebook, LinkedIn
View original content to download multimedia:
SOURCE INDI EV | https://www.kxii.com/prnewswire/2022/08/19/indiev-all-electric-crossover-exclusive-driving-footage-indi-one-beverly-hills-updated-specifications-revealed/ | 2022-08-19T13:44:41Z |
Thibodeux, Neal are the foundation of Giants rebuild
By TOM CANAVAN
AP Sports Writer
EAST RUTHERFORD, N.J. (AP) — The New York Giants’ first draft under general manager Joe Schoen is history. The former Buffalo Bills assistant GM handled it well, filling major needs by taking edge rusher Kayvon Thibodeaux and offensive tackle Evan Neal with the fifth and seventh picks overall. He added two extra picks by moving down twice in the second round on Friday and then spent the rest of the draft filling needs by selecting players who showed versatility. The Giants finished taking six defensive players and five on offense. New York had a 4-13 record last season. | https://localnews8.com/sports/ap-national-sports/2022/04/30/thibodeux-neal-are-the-foundation-of-giants-rebuild/ | 2022-05-01T04:53:01Z |
- Company intends to grow its market share in the global solar energy market with the release of this new IGBT
SEOUL, South Korea, June 17, 2022 /PRNewswire/ -- Magnachip Semiconductor Corporation ("Magnachip") (NYSE: MX) announced today that the company has unveiled a new 650V insulated-gate bipolar transistor (IGBT) for solar inverters.
As environmental impacts from climate change are becoming more severe, the use of renewable energy like solar power continues to expand globally to reduce carbon emissions. Omdia, a global market research firm, estimates that the global market for IGBTs in the renewable energy sector will grow 15% annually from 2022 to 2025. In March 2022, Magnachip developed a new 650V IGBT built with advanced "field stop trench technology" for fast switching speed and high breakdown voltages and the company will begin mass production of it this month.
The current density of this new 650V IGBT was improved by 30% compared to the prior generation by adopting the latest technology. This IGBT is also designed to provide a minimum short-circuit withstand time of 5µs and it is optimized for parallel switching because of its positive temperature coefficient. The parallel switching of this IGBT will increase the load current and thus the maximum output power.
In addition, the 650V IGBT features anti-parallel diodes for fast switching and low switching loss, while guaranteeing a maximum operating junction temperature of 175°C. Based on standards issued by the Joint Electron Device Engineering Council (JEDEC), this new IGBT can be widely used for applications requiring strict power level and high efficiency, such as solar boost inverters and converters, uninterruptible power supplies and universal power inverters.
"Magnachip's first IGBT was introduced in 2013, and since then, we have been committed to developing high-efficiency products for a variety of markets, while strengthening our presence around the world," said YJ Kim, CEO of Magnachip. "With this new product, we are expanding our efforts to deliver high-performance products for the eco-friendly renewable energy market."
Magnachip's IGBT products for the solar energy market
Magnachip is a designer and manufacturer of analog and mixed-signal semiconductor platform solutions for communications, IoT, consumer, computing, industrial and automotive applications. The Company provides a broad range of standard products to customers worldwide. Magnachip, with more than 40 years of operating history, owns a portfolio of approximately 1,150 registered patents and pending applications, and has extensive engineering, design and manufacturing process expertise. For more information, please visit www.magnachip.com. Information on or accessible through Magnachip's website is not a part of, and is not incorporated into, this release.
CONTACTS:
View original content to download multimedia:
SOURCE Magnachip Semiconductor Corporation | https://www.mysuncoast.com/prnewswire/2022/06/17/magnachip-unveils-new-650v-igbt-solar-inverters/ | 2022-06-17T11:34:37Z |
The summer seasons kicks off at Temple swimming pools Saturday.
Lions Junction Family Water Park, 5000 S. Fifth St. in Temple, opens at noon Saturday. The water park will be open through Sept. 5.
Lions water park will operate from noon to 8 p.m. Tuesday through Saturday and from noon to 6 p.m. Sunday until Aug. 14. On Aug. 20, the operating days will adjust to weekends only. Season passes are now on sale online.
Three community swimming pools will be open Saturday through Aug. 14. Outdoor facilities are: Clark Pool, located at 1808 Curtis B. Elliott Drive, and Walker Pool is at 2603 N. Third St. Summit Recreation Center Pool, 620 Fryers Creek Drive, requires a membership.
Sammons Park Indoor Pool, 2220 W. Ave. D, offers senior swim times and classes as well as open swim periods and family swim times.
Temple splash pads, open until Oct. 2, are located at West Temple Park, 121 S. Montpark Road; Miller Park, 1919 N. 1st St.; Jaycee Park, 2302 W. Ave. Z and Ferguson Park, 1203 E. Adams.
In Belton, Summer Fun Water Park, 1410 Waco Road, opened May 7.
Belton has two splash pads that will be open until Labor Day. They are located at Harris Community Park, 312 N. Alexander St., and South Wall Tiger Park, 1895 S. Wall St.
The city of Morgan’s Point Resort recently opened its community swimming pool. The pool is located at 60 Morgan’s Point Resort Blvd. near Lake Belton.
Temple said its aquatics staff will offer swim lessons this summer. Water park and pool rentals are currently unavailable.
Lifeguards and other seasonal positions are still being hired in Temple. Visit templeparks.com/lifeguards for details.
To learn more about Temple pools, visit templeparks.com/aquatics. | https://www.tdtnews.com/news/central_texas_news/article_d54da3cc-e39a-11ec-a5a4-b3f320146ccc.html | 2022-06-04T01:58:52Z |
Homebuyers stymied by fewer homes, high prices, rising rates
LOS ANGELES (AP) — Shortly after moving to South Florida for a new job with the U.S. military, Shannon Kaufman and his wife, Wendy, signed up for a whole other mission: buying a home.
For months, they scoured listings, strategizing late into the night on which homes to target and working out how much they could afford, even if it meant using some of their retirement savings.
After visiting 200 listings and making offers on 15 homes that ultimately didn’t pan out, the Kaufmans finally found a home that fits at least some of their needs. They’ll be renting it, however.
“We found a place that’s smaller than we want, but it’ll work until we have something built or until the market cools off,” said Shannon Kaufman, 47.
America’s housing market has grown increasingly frenzied, and prices are out of reach for many buyers, especially first-timers. This spring, traditionally the busiest season for home sales, is more likely to deliver frustration and disappointment for aspiring homebuyers than it is homeownership.
The number of homes for sale nationally remains near record lows, fueling fierce competition among buyers vying for fewer homes. From Los Angeles to Raleigh, North Carolina, when a house does hit the market, it typically sells within days.
Bidding wars are common, often driving the sale price well above what the owner was asking. And would-be buyers planning to finance their purchase with a home loan are often losing out to investors and others able to buy a home with cash. A quarter of all homes sold in February were purchased with cash, up from 22% a year ago, according to the National Association of Realtors. Real estate investors accounted for 19% of transactions in February, up from 17% a year ago.
Nichol Khan, a project manager, and her husband Ed moved to Mesa, Arizona, from Phoenix two years ago to shorten their commute to work. Home prices in the Phoenix area have jumped 20% from a year ago to $500,000, according to Realtor.com.
“The prices just keep going up and up,” Khan said.
The couple has lost out on more than a dozen homes they bid on. Some of the homes ended up selling for less in cash than the couple had offered.
“We don’t have $500,000 in cash,” said Khan, 42. “We just could not be competitive with that.”
Fewer homes on the market and high prices have been the hallmark of the housing market for the past 10 years or so. Now, rising mortgage rates further complicate the homebuying equation. Higher rates could limit the pool of buyers and cool the rate of home price growth — good news for buyers. But higher rates also weaken their buying power.
The average rate on a 30-year home loan has climbed to around 4.7%. A year ago, average rates hovered just above 3%, according to mortgage buyer Freddie Mac. The increase follows a sharp move up in 10-year Treasury yields, reflecting expectations of higher interest rates overall as the Federal Reserve moves to hike short-term rates in order to combat surging inflation.
Would-be buyers who applied for a home loan in February faced a median monthly mortgage payment of $1,653, including principal and interest, an increase of 8.3% from a year ago, according to the Mortgage Bankers Association.
“It’s hard to believe, but I do think it’s going to be tougher this year, in some respects, than it was in previous years,” said Danielle Hale, Realtor.com’s chief economist. “So far, at least, we have seen the number of homes for sale continue to decline and prices continue to rise. Those two factors combined suggest that the competitive market is going to keep buyers on their toes.”
Buyers should set their sights on homes that are listed well within what they can afford, experts say.
“You should be looking 15%-20% below their limit; that gives them room for appraisal gaps, it gives them room for negotiating,” said Tracy Hutton, a broker with Century 21 in Indianapolis.
Being well prepared sometimes isn’t enough when a homeowner prefers to accept an all-cash offer, rather than sell to a buyer with financing.
Wendy Kaufman in South Florida couldn’t even get into an open house for a property on the market after she revealed the couple had a mortgage backed by the Veterans Administration.
“When they saw I had a VA preapproval they said, ‘Sorry we don’t want to work with you.’” she said.
Sometimes, buyers don’t have a chance to make an offer before a home is snapped up, sight unseen.
In the Miami area, so-called “blind offers” have become common as a way to get around other buyers, said Rafael Corrales, a Redfin agent.
One reason is the ultra-low level of homes for sale, which for the greater Miami metropolitan area, was down 55% in February from a year ago, according to Realtor.com.
While every market is unique, there is one common hurdle across the U.S.: affordability. The median U.S. home price jumped 15% in February from a year earlier to $357,300, according to the National Association of Realtors.
The San Jose, California, metro area had 40% fewer homes for sale in February than a year ago, according to Realtor.com. Buyers there have to navigate some of the most expensive home prices in the nation. The median home listing price climbed 13.3% to about $1.36 million in February from a year earlier.
The market trends are a bit more welcoming for buyers in the Midwest, including the Indianapolis metropolitan area, where the number of homes for sale was down about 23% from a year ago. The median home price there stood at $287,000 in February, up 8.5% from a year earlier.
In Raleigh, home listings were down a whopping 55% in February from a year earlier. Competition for fewer homes helped push the median home price to $430,000, a 9% increase from February 2021.
Those trends made for a more competitive market for first-time buyers like Lisa Piercey and her husband, Alex Berardo. First-time buyers made up 29% of all homes sold nationally last month. That share has averaged 31% annually over the past 10 years.
The couple began looking in December for homes at $350,000 or below. They offered $5,000 over the asking price on two properties but lost out to rival bidders.
“That was all we could afford,” said Lisa Piercey, a 32-year old project manager. “It’s really defeating, really disappointing.”
In the end, the couple bought a townhome in a new construction community, though they see it as a stepping stone to a more spacious house with a big yard.
“Its big enough that we can still start our family and then move when the market hopefully dies down in a couple of years,” she said.
Copyright 2022 The Associated Press. All rights reserved. | https://www.kxii.com/2022/04/13/homebuyers-stymied-by-fewer-homes-high-prices-rising-rates/ | 2022-04-13T16:59:24Z |
MEDELLIN, Colombia, July 12, 2022 /PRNewswire/ -- The Green Coffee Company (GCC), a Legacy Group portfolio company, is pleased to announce the acquisition of an additional 1,389 acres of coffee farmland, making GCC Colombia's new #1 largest coffee producer.
This purchase is GCC's second key acquisition during 2022 and solidifies the company's position as Colombia's new #1 largest coffee producer. The acquisition brings GCC's total landholdings to 6,372 acres, with a total coffee tree count of 7.2 million.
Located in Salgar, Colombia adjacent to the Green Coffee Company's current farms, this new acreage will allow the business to further benefit from economies of scale through lower cost of production, greater ease of farm management and optimization of existing infrastructure capacity. The company has grown exponentially since its inception less than five years ago to reach this #1 position, and has a goal of becoming the world's largest producer of arabica coffee within the next 2-3 years.
GCC is appropriately positioned to execute on its upcoming Series C equity funding round, which is expected to be formally announced in Q3 2022. Proceeds from the capital raise will be used to (a) further expand operations in Colombia, building on its dominant market position, and (b) build a U.S.-based coffee roasting operation to expand its value chain.
The investment offering will be open to accredited individual investors, institutional investors and coffee industry participants. If you would like to participate in GCC's upcoming Series C offering, please contact Legacy Group, the company's asset manager, at investor.relations@legacy-group.co, or visit their website at https://legacy-group.co/ for more information and to be added to our mailing list.
The Green Coffee Company is a consolidated coffee farming operation headquartered in the U.S. with operations based in Medellin, Colombia. The company's innovative business model allows for complete control of the supply chain: from cultivation, through processing, to direct trade with end-clients. GCC's holistic approach to the coffee sector and commitment to best environmental practices not only establishes the long-term profitability and sustainability of the business, but also improves the quality of the coffee produced on the farms.
Follow Legacy Group on Linkedin for communications related to the Green Coffee Company and other alternative investment opportunities: at https://www.linkedin.com/company/legacygroup/.
View original content to download multimedia:
SOURCE Legacy Group | https://www.mysuncoast.com/prnewswire/2022/07/12/green-coffee-company-is-now-colombias-1-largest-coffee-producer/ | 2022-07-12T11:21:54Z |
Mother breaks back saving stepdaughter from a house fire
LYNCHBURG, Va. (WSET) – A woman in Virginia is in the hospital after hurting her back while catching her stepdaughter who jumped out the window to escape a house fire.
Crystal Dawson says she was just being a mom, but that’s an understatement.
She has a shattered vertebra in her spine and is unable to walk.
Dawson woke up around 1 a.m. Friday to make her baby a bottle when she saw the flames. She and her husband got the baby out of the house, but their other two children were still upstairs.
“I was scared. I was crying,” Brianna Dawson said. “I was like, ‘Dad, I can’t get out. I can’t get out.’”
Brian Dawson tried to go up the stairs for the kids, but the flames pushed him back.
Brianna got her brother, Christian, to her room and told him they had to jump from the second-floor window.
“My wife knew I could not catch him because of my back injury,” Brian said. “My son jumped and did a tuck and roll.”
Brianna was scared to jump, but Crystal assured the girl she would catch her.
“When I tried to catch my daughter, she landed on my chest,” Crystal explained.
She said she just did what any mother would do.
“No mom is going to stand there and let their kids die because of a house fire,” Crystal said. “They’re going to do everything they can, and if that means that I died in place of her, I would have done it in a heartbeat.”
The Dawsons say Crystal will need to have surgery.
Copyright 2022 WSET via CNN Newsource. All rights reserved. | https://www.wibw.com/2022/05/23/mother-breaks-back-saving-stepdaughter-house-fire/ | 2022-05-23T20:22:05Z |
With Three Entrances, Montana is the Ideal Location for Experiencing the Park
HELENA, Mont., May 13, 2022 /PRNewswire/ -- Located in Montana, Idaho and Wyoming, Yellowstone National Park – the world's first national park – is celebrating its 150th anniversary this year. Encompassing 2.2 million acres, Montana has three of the five entrances to the park, including the only entrance that's accessible to year-round vehicle traffic through Gardiner.
In 2021, Yellowstone National Park welcomed 4.86 million visitors and 2022 is shaping up to be another busy year as visitors celebrate one of the most special places in the world. And while people will be visiting the park en masse this summer, here are the best ways to experience it without the masses.
- Time it Right. No matter when you visit this summer, chances are that you'll find crowds of people if you go during the day. Time your trip so you're up early to catch the rising steam at Grand Prismatic Spring, watch Old Faithful erupt after the sun goes down and soak in the experience against a star-filled sky or get up with the sun to watch its rays spread over Yellowstone's diverse landscapes.
- Hike it Out. The truth is that most visitors to Yellowstone National Park stick to the roads. If you really want to get away from other people, you should hit the trails. With 900 miles of trails throughout the park, there are plenty to choose from. Keep in mind that you should always hike with a friend, be prepared, carry (and know how to use) bear spray and give wildlife a wide berth.
- Go With a Guide. While you can visit the park on your own, one of the best ways to have a deeper experience is to go with a guide or outfitter on a horseback ride or llama trek. There are also seasoned guides who offer activities like backpacking, biking, fishing and photography, as well as road-based tours.
And while Yellowstone National Park will remain a bucket-list destination, there are plenty of things to see and do outside of the park's boundaries. Visitors are easily able to exit one of the park's three entrances in Montana on their way to other adventures, including:
- Driving the Beartooth Highway. A wonder in and of itself, the Beartooth Highway is a National Scenic Byway that weaves through both Montana and Wyoming and is accessible by exiting Yellowstone's northeast entrance. The 68-mile-road extends from Cooke City, Montana to Red Lodge, Montana, and gives its passengers jaw-dropping views and access to high alpine lakes and trails in the Beartooth Mountains.
- Visit Red Lodge. Surrounded by the Beartooth and Absaroka mountains, Red Lodge is one of Montana's most charming small towns. With a historic and strollable downtown, Red Lodge is a place to put on your must-visit list. It's also a launching point for outdoor recreation and adventures, including hiking, horseback trail rides and river trips.
- Stroll Gardiner. Steps from the park's north entrance is the town of Gardiner. Home to just under 900 residents, in the summer this gateway community is hopping. From August 23 – 28, there will be several tips on display at the tipi village project at the historic Roosevelt Arch. You can also fish, raft and float with several local outfitters in Gardiner, as well as soak in nearby hot springs in Paradise Valley.
- Walk Through Montana History. Visitors who base their trip in West Yellowstone (or leave the park through its west entrance) are less than 90 minutes from Virginia City and Nevada City, two of the most well-preserved ghost towns in the country. During the summer season (Memorial Day – September), visitors can take history tours, check out local shops and saloons, stay the night in a historic property, pan for gold or travel by stagecoach.
- Learn more about Yellowstone
National Park and the ways to celebrate its 150th anniversary at VisitMT.com.
ABOUT VISIT MONTANA
Visit Montana markets Montana's spectacular unspoiled nature, vibrant and charming small towns, breathtaking experiences, relaxing hospitality, and competitive business climate to promote the state as a place to visit and do business. For more information, go to VISITMT.COM.
View original content to download multimedia:
SOURCE Visit Montana | https://www.wibw.com/prnewswire/2022/05/13/ways-get-off-the-beaten-path-during-yellowstone-national-parks-150th-anniversary/ | 2022-05-13T19:50:18Z |
Temple Civic Theatre, one of Central Texas’ longest continuously running community theatres, has announced its 2022-23 season lineup and its new Managing/Artistic Director, Natasha Tolleson.
Tolleson recently retired from Temple Independent School District after 31 years as the head of the Temple High School Theatre Arts Department. She moved to Temple when her husband, Richard, took a job as a weatherman at a local television station.
In 2018, she was selected as Educator of the Year by the Texas Educational Theatre Association. The award was presented at the group’s TheatreFest 2018 convention in Dallas.
In UIL one-act play competitions, her teams have won the 5A state championships two times — “Ruthless!” in 2007 and “Bug” in 2016. Her one-act teams have been to state nine times and have been named a District Champion for the past 30 years in a row (as of 2022).
Her students have entered the UIL Theatrical Design competition every year, and won the state championship in group design the first year of the contest (2008) and again in 2014.
In the first year of the UIL Film Contest, Tolleson’s students won the state championship in division two, narrative (2014). She also serves as the UIL Coordinator at Temple High, and coaches prose and poetry interpretation and literary criticism. In 2011, she was named one of the Top 15 UIL Sponsors in Texas.
In International Thespian Society competition, she has had more than 100 students advance from state to the international contest. In 2020, her tech design team won the Texas Thespian State Championship. At the 2017 state festival, she had more events advance than any other troupe in Texas. Her students have been featured on the main stage seven times since 2004. In 2014, she was inducted into the Texas Thespians Hall of Fame.
Tolleson holds a bachelor of arts degree in theatre from the University of Arkansas, Fayetteville. She is a certified International Baccalaureate Theatre Teacher and was named a “Master Teacher” by the University of Texas at Austin. Many of her former students now work in the theatre and entertainment industry.
She and her husband, Richard, have three children (Alexandra, Spencer and Emma), and two granddaughters (Charlotte and Penelope).
Ruby Jett, president of the TCT Board of Governors, said Natasha is a fabulous director.
“No stranger to TCT, both as a performer and director, Natasha brings an intimate familiarity with our space that will elevate every production. A familiar personality to the Central Texas community, she will enhance our business and patron relationships and help us revitalize this wonderful place that has brought so much entertainment to our community,” Jett said.
Season lineup
TCT has also announced its mainstage and youth season productions for the 2022-2023 season.
The TCT mainstage series shows are:
“Agatha Christie’s Murder on the Orient Express,” Sept. 30-Oct. 2, and Oct. 6-9
“Elf, the Musical,” Dec. 9-11 and Dec. 15-18
“Love/Sick” Feb. 17-19, 2023, and Feb. 23-26, 2023
“The 25th Annual Putnam County Spelling Bee,” April 14-16, 2023, and April 20-23, 2023
“The Play that Goes Wrong,” June 2-4, 2023, and June 8-11, 2023
“The Spongebob Musical,” July 28-30, 2023, and Aug. 3-6. 2023
The TCT youth productions will be:
“The Legend of Sleepy Hollow,” Oct. 14-16
“Disney’s Madagascar Jr.,” Feb. 2-5, 2023, and Feb. 9-12, 2023
“Seussical KIDS,” March 17-18, 2023
“Disney’s The Little Mermaid Jr.,” Aug. 18-20, 2023
Regular membership includes one ticket per each mainstage show. Memberships cost $100 for adults, $90 for senior/military and $65 for student/children. A flex pass, which provides six tickets to any show in the mainstage series, is available for $110.
For more information about the theater, visit templecivictheatre.com. | https://www.tdtnews.com/life/article_d26fa3a6-d83e-11ec-98ca-cf415d2f549a.html | 2022-05-22T07:39:58Z |
New vulnerability discovery in common CAN-FD vehicle communication protocol
YPSILANTI, Michigan, June 14, 2022 /PRNewswire/ -- CYMOTIVE Technologies, the leading provider of smart mobility cyber solutions, today announced its participation in the international automotive security event ESCAR USA taking place on June 15 -16, 2022. CYMOTIVE's Principal Cyber Security Researcher, Matan Ziv, will present his research on the first day at 9:45 am EST entitled "CAN-in-CAN Attack for Bypassing Security", revealing a new potential attack on the CAN-FD (Controller Area Network Flexible Data-Rate) vehicle communication protocol. Matan has named the vulnerability "CANCAN", referring to an ancient proverb on looking inside a person for hidden truth.
Vulnerabilities in these common communication protocols carry significant ramifications for the cybersecurity readiness of many vehicle models. The CANCAN vulnerability allows one CAN-FD message to hide inside another. As the encapsulating message hiding the other will appear as valid, the CANCAN vulnerability may be used for circumventing various security measures.
"We applaud Matan Ziv and the CYMOTIVE cybersecurity research team for this milestone in securing the automotive eco-system," said Tsafrir Kats, CEO and Co-founder of CYMOTIVE Technologies. "The CANCAN vulnerability may affect any vehicle component implementing the CAN-FD protocol and those protocols currently in development, such as CAN-XL, unless specifically addressed. We encourage all car manufacturers and their suppliers to take note and consider mitigation of this vulnerability."
CYMOTIVE is also a sponsor of the ESCAR USA event taking place in the Ann Arbor Marriott Ypsilanti at Eagle Crest, in Ypsilanti, Michigan. If interested in meeting the CYMOTIVE cyber experts attending ESCAR, please contact us here.
For full details of the ESCAR USA, the program may be found here.
For the full research paper, "CAN-in-CAN Attack for Bypassing Security", click here.
About CYMOTIVE Technologies
Founded in 2016 by top tier Israeli security experts, CYMOTIVE Technologies designs, develops and deploys cybersecurity solutions to solve the most complex challenges in the smart mobility market. With teams working from Israel, Germany, Sweden, and the U.S, CYMOTIVE offers a full lifecycle platform of solutions for secured development to post-production stages in the smart mobility ecosystem. The company's customers include several manufacturers, smart cities and top tier suppliers of vehicles, fleets and other embedded solutions. For more information, visit www.cymotive.com
Media inquiries:
susan.becker@cymotive.com
View original content:
SOURCE CYMOTIVE Technologies | https://www.mysuncoast.com/prnewswire/2022/06/14/cymotive-technologies-present-new-vulnerability-automotive-cyber-escar-usa/ | 2022-06-14T11:56:51Z |
Stars top line Pavelski-Robertson-Hintz all 70-point scorers
By STEPHEN HAWKINS
AP Sports Writer
DALLAS (AP) — Joe Pavelski is a point-a-game player at 37 years old for the Dallas Stars. He is part of the top line with 40-goal scorer Jason Robertson and his fellow 20-something forward Roope Hintz. Coach Rick Bowness said that line has carried Dallas all season. The wild-card Stars are the only of the 16 teams heading into the playoffs while being outscored this season The Pavelski-Robertson-Hintz line has combined for 230 points. That is four shy of matching the highest-scoring trio that was part of the team’s first season in Dallas nearly three decades ago. | https://localnews8.com/sports/ap-national-sports/2022/04/28/stars-top-line-pavelski-robertson-hintz-all-70-point-scorers/ | 2022-04-28T22:18:04Z |
NEW YORK, May 10, 2022 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Everbridge, Inc. (NASDAQ: EVBG) between November 4, 2019 and February 24, 2022, inclusive (the "Class Period") of the important June 3, 2022 lead plaintiff deadline.
SO WHAT: If you purchased Everbridge securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Everbridge class action, go to https://rosenlegal.com/submit-form/?case_id=3095 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Everbridge was experiencing integration problems with respect to its acquiring nine separate companies; (2) Everbridge was using the revenues from these acquisitions to mask increasingly stagnant organic growth; and (3) Everbridge was failing to disclose that the COVID-19 pandemic was having a material impact on the size of the deals that Everbridge was able to obtain, with a negative effect on the Company's revenue growth. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Everbridge class action, go to https://rosenlegal.com/submit-form/?case_id=3095 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
View original content to download multimedia:
SOURCE Rosen Law Firm, P.A. | https://www.wibw.com/prnewswire/2022/05/11/rosen-national-trial-lawyers-encourages-everbridge-inc-investors-with-losses-secure-counsel-before-important-deadline-securities-class-action-evbg/ | 2022-05-11T05:37:31Z |
NASSAU, Bahamas, May 17, 2022 /PRNewswire/ -- A rebirth is on the horizon for Grand Bahama Island. The Bahamas Ministry of Tourism, Investments & Aviation (BMOTIA) made the long-awaited announcement that an offer has been accepted for the purchase of Grand Lucayan, a beachfront resort located in the bustling city of Freeport.
Electra America Hospitality Group (EAHG) has entered into an agreement with Lucayan Renewal Holdings to buy the resort for $100 million.
CEO and Principal of Electra America Hospitality Group Russell Urban said the company was very interested in the resort for many reasons, among them is the "opportunity to reinvent, renaissance, rebirth, and revive" the island of Grand Bahama. "We saw this as a very unique opportunity in a world class location to create energy and to revive a community that has been so ravaged over recent years," he said. "So, we are very very pleased and humbled to be chosen for this amazing opportunity."
The deal is a part of an initiative called "The Return of the Grand Life to Grand Bahama," which seeks to re-establish the destination as the vibrant entertainment hub it once was.
"The sale of Grand Lucayan is only the beginning of the revival that we are witnessing in Grand Bahama Island," said the Honourable I. Chester Cooper, Deputy Prime Minister and Minister of Tourism, Investments & Aviation. "We are committed to pumping a renewed spirit back into this special island, while bringing thousands of jobs to Bahamians."
Minister for Grand Bahama the Honourable Ginger Moxey also applauded the choice of Electra America Hospitality Group as the right fit for Grand Bahama. "They recognize the role of corporate citizens, and the need for a holistic approach to enhancing communities where they do business, and appreciate the significance of this property to the people and economy of Grand Bahama," she said.
With nearly $300 million in renovations planned, the new-and-improved Grand Lucayan will be transformed into an environmentally sustainable luxury hotel with approximately 200 rooms and 24 villas; an upscale convention-style hotel with more than 500 rooms that will cater to meetings, groups, and incentive travellers; as well as a family-friendly resort. To become environmentally sustainable, the property will utilise solar energy, establish a recycling program, and plant a garden to supply farm-to-table dining.
Electra America Hospitality Group also plans on revitalizing the resort's golf course by adding a country club and villas for golf aficionados. A casino, world-class bars and restaurants, as well as a variety of pools, spas, and fitness facilities are also in the works, Bahamian art, culture, and entertainment will be infused throughout.
Construction is set to begin this summer and will be completed by 2025.
ABOUT THE BAHAMAS
Explore all the islands have to offer at www.bahamas.com or on Facebook, YouTube or Instagram.
PRESS INQUIRIES
Anita Johnson-Patty
Bahamas Ministry of Tourism, Investments & Aviation
ajohnson@bahamas.com
Weber Shandwick
Public Relations
Bahamas@webershandwick.com
View original content to download multimedia:
SOURCE The Bahamas Ministry of Tourism, Investments & Aviation | https://www.mysuncoast.com/prnewswire/2022/05/17/bahamas-accepts-purchase-offer-grand-lucayan-resort-marking-beginning-grand-bahama-islands-rebirth/ | 2022-05-17T20:38:47Z |
SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has entered into an equity purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor.
Under the terms of and subject to satisfaction of the conditions contained in the agreement, Kintara will have the right in its sole discretion, but not the obligation, to sell to LPC up to $20 million worth of shares of its common stock from time to time over the 36-month term of the agreement. Kintara controls the timing and amount of any future sales of its shares of common stock and LPC is obligated to make purchases in accordance with the terms of the purchase agreement, subject to various limitations contained in the agreement, including those under the Nasdaq listing rules. Any common stock that is sold by Kintara to LPC under the agreement will occur at a purchase price that is based on the market prices prevailing at the time of each sale to LPC. There is no upper limit to the price per share that LPC may pay for future stock issuances under the purchase agreement, and LPC has agreed not to cause or engage in any direct or indirect short selling or hedging of Kintara's common stock. No warrants are being issued in this transaction and the purchase agreement does not contain any rights of first refusal, participation rights, penalties or liquidated damages provisions in favor of any party. Kintara may terminate the purchase agreement at any time, at its sole discretion, without any cost or penalty.
The Company expects this commitment from LPC will provide financial flexibility and is aligned with Kintara's long-term strategy for value creation. Kintara intends to use any net proceeds from the sale of its common stock to LPC for working capital and general corporate purposes, including development expenses for VAL-083 and REM-001.
"We are excited to enter into this transaction with Lincoln Park Capital and believe that this agreement provides us an opportunity to access capital in a very efficient manner," said Robert E. Hoffman, President and Chief Executive Officer of Kintara. "We believe that the financial flexibility provided by this agreement will further support our clinical development efforts with VAL-083 in glioblastoma and REM-001 in cutaneous metastatic breast cancer."
Additional information regarding the purchase agreement is set forth in a Current Report on Form 8-K, which Kintara will file with the Securities and Exchange Commission (SEC).
The securities described above are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-254662) filed with the SEC on March 24, 2021 and declared effective on April 1, 2021. The offering of the securities described herein will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by request from Kintara Therapeutics at 9920 Pacific Heights Blvd., Suite 150, San Diego, CA 92121 or at (858) 350-4364.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for glioblastoma (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).
VAL-083 is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the Global Coalition for Adaptive Research registrational phase 2/3 clinical trial titled Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study to support the development and commercialization of VAL-083 in GBM.
Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the Equity Purchase Agreement or the use of proceeds pursuant to the Equity Purchase Agreement. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2021, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.
Investors:
CORE IR
516-222-2560
ir@coreir.com
Media:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download multimedia:
SOURCE Kintara Therapeutics | https://www.mysuncoast.com/prnewswire/2022/08/03/kintara-therapeutics-enters-into-equity-purchase-agreement-up-20-million-with-lincoln-park-capital/ | 2022-08-03T13:13:27Z |
RIO DE JANEIRO (AP) — A federal prison guard and alleged supporter of President Jair Bolsonaro killed a local official from the leftist Workers’ Party in the Brazilian state of Parana, according to state police. The shooting death comes ahead of a highly polarized presidential election in October.
On Saturday night, Jorge Jose da Rocha turned up uninvited at the birthday party of local Workers’ Party official, Marcelo Arruda, and shot him, Parana state police said. Citing several witnesses, police said Da Rocha had shouted his support for Bolsonaro before firing at the victim.
During the assault, Arruda, also a municipal guard, fired back at the attacker, who is now in hospital, the state’s public security secretary said.
Politicians condemned the attack.
“The Brazilian people are a people of peace. And we need to regain normalcy in our country,” former President Luiz Inácio Lula da Silva wrote on Twitter on Monday. Da Silva is expected to run against Bolsonaro in October.
Gleisi Hoffmann, leader of the Workers’ Party, lamented “a tragedy resulting from the intolerance of those people,” and shared several photos of Arruda, a father of four, on his birthday party wearing a black T-shirt with an image of Da Silva.
Bolsonaro condemned the attack. “We are against any act of violence,” he said in a Monday interview at the presidential palace in Brasilia, according to newspaper O Globo. Bolsonaro reminded reporters that he was knifed and nearly died on the campaign trail in 2018.
But the far-right president also repeatedly accused the left of stoking political violence. | https://cw33.com/news/international/ap-international/brazil-leaders-call-for-calm-after-party-officials-killing/ | 2022-07-12T14:21:02Z |
Award-winning Media Company Scales with Series B Raise to Increase Differentiation Through Expanded Content Platforms, Introduce New Categories, and Increase Global Presence & Distribution
LOS ANGELES, June 6, 2022 /PRNewswire/ -- Religion of Sports, the award-winning sports media production company, has raised $50 million in a Series B fundraising round with the intent to develop new ownable content IP, further scale its substantial creator network, and increase global strategic partnerships. Already one of the most prolific, premium content studios, the Emmy Award-winning company's funding round is led by Shamrock Capital, with support from Elysian Park Ventures and Cerro Capital.
Following a momentous year of growth in athlete storytelling, Religion of Sports has rapidly evolved into much more than just a content creation company. The new capital will allow Religion of Sports to provide additional value to consumers by capitalizing on the gap in the marketplace around premium IP, and to further differentiate from relative offerings with the inclusion of a top-tier non-fiction studio arm and expansion into new formats, categories, genres, and markets globally. The expansion will also include ventures into non-sports territory, as well as production projects in the realms of entertainment, business and music, seeking to build out the best creator network in the industry.
"Religion of Sports has grown at a pace we could have only dreamed about five years ago," said Tom Brady. "We have some of the most talented people in the industry, who share the same passion for sports storytelling that has an impact on culture and audiences around the world. I am so honored and proud to be part of this team who continue to find ways to push the envelope and rewrite the traditional approach to thought-provoking , meaningful and entertaining content. I look forward to what the future holds for us at Religion of Sports as we continue to expand our slate and pursue more collaborative projects with new partners."
"The possibilities of content are continuing to grow at Religion of Sports, and I am proud to have been here from the beginning," said Michael Strahan. "The team remains committed to raising the standard of non-fiction storytelling in not just sports but also beyond, and I can't wait to welcome new formats, partners and audiences into our world. From athletes to trailblazers, to important societal themes and world events, there are such incredible and emotional stories to be told and I look forward to jointly developing and introducing groundbreaking work with this team. Evolution and diversity are key, and we're just getting started!"
Religion of Sports recently expanded into the NFT marketplace through a partnership with Autograph to release one-of-a-kind digital collectibles with Simone Biles, and also with ESPN's "Man In The Arena: Tom Brady" series. These projects represent the natural extension of premium content into new verticals that Religion of Sports will continue to pursue.
"We've seen a growing demand for sports storytelling across media avenues, a demand that Religion of Sports continues to meet, but we're ready and eager to expand into new territories and solidify ourselves as an all-encompassing media powerhouse," said Ameeth Sankaran, CEO, Religion of Sports. "We are excited to expand our mission on a larger scale while enabling our talent partners to tell more expansive versions of their story."
"As longtime investors in media and entertainment, the concept of great storytelling is often central to our investments," said Mike LaSalle, Partner, Shamrock Capital. "We believe Religion of Sports is a master at crafting narratives about some of the most relevant and universal subject matters today – resilience, competition, mental health and the pursuit of greatness. We couldn't be more excited for the future of Religion of Sports as it continues to expand its storytelling scope across diversified, premium content."
Religion of Sports gained recognition for its work in partnership with prominent athletes to tell stories that matter, most recently producing two-time Emmy nominated "Man In The Arena: Tom Brady" with ESPN, Emmy nominated "Simone vs. Herself" with Facebook Watch, and Emmy Award-winning "Greatness Code," which recently premiered its second season on Apple TV+, featuring Russell Wilson, Lindsey Vonn, Bubba Wallace, Leticia Bufoni, Scout Bassett, and Marcus Rashford. In addition, two Religion of Sports podcasts, "Crushed" and "False Idol", received Ambies nominations, with "False Idol" also winning a gold medal for sports podcasts at the New York Festivals Radio Awards. The company will continue to expand their content slate with upcoming projects including a flagship interview series podcast called "In the Moment", untitled projects with Showtime, Netflix, Skydance Sports, a documentary produced by Chris Pratt featuring two-time Olympic wrestler Helen Maroulis, another documentary about Wilt Chamberlain with Village Roadshow Television executive produced by Happy Madison and Kevin Garnett, projects with Trevor Noah, Draymond Green, Dr. Ibram X. Kendi, and many more. Later this year, Religion of Sports will also launch a wellness content brand centered around peak performance.
"For me, Religion of Sports was never about a business plan or a market strategy - it was about exploring an idea that was deeply personal to me: why sports matter. Because no matter where you go in the world - from the biggest cities to the most rural villages - people are obsessed with sports. Early on, I became an evangelist and I recruited whomever I met into my cult - notably my two co-founders Michael Strahan and Tom Brady. Over the years, we've had the privilege of producing many stories, some with athletes themselves, others around the fans and the games themselves, that are anchored in that same core idea - sports matter. Most importantly, countless other talented creators have become a part of our community and taught me so much - not just in the non-scripted space, but also audio, scripted, social and more. Now with Shamrock aboard, we're poised for even more growth and fun. And I couldn't be more excited about the future of the ROS faith," said Gotham Chopra.
Earlier this year, Religion of Sports announced plans to develop, finance, and produce a slate of sports-related content for multiple platforms, with projects across scripted television, documentary, and audio including the first scripted project called, "The Owl", a rags-to-riches story about an orphaned Mexican-American boxer. The recent investment from Shamrock Capital will be used to fund these and other growth initiatives as Religion of Sports scales into a leading media company and content platform.
Willkie Farr & Gallagher LLP served as legal advisor to Shamrock Capital on the transaction.
About Religion of Sports
Founded in 2017 and headquartered in Santa Monica, California, Religion of Sports is an award-winning media company founded by Tom Brady, Michael Strahan, and Gotham Chopra. To believe in the power of sports is to experience religion, and the company's work is defined by thoughtful, elevated stories that explore a range of themes and uncover why sports matter. Through scripted and unscripted video, podcasts, feature films and social content Religion of Sports distills the spirituality, science and humanity that unites elite performers and people of all kinds. Since its inception, the company has built an impressive array of work in collaboration with the world's most elite athletes, distributed across big- and small-screens for digital broadcast/streaming platforms Facebook Watch, Apple TV+, ESPN, Showtime, Fox Sports, NBC Sports and many more. "Tom vs Time", "Greatness Code", and "Man in the Arena" went on to win Sports Emmy awards.
In 2021, Religion of Sports experienced a banner year, having grown the company exponentially and expanding its production capabilities. In addition, three highly anticipated documentary projects were launched back-to-back in the 3rd and 4th Quarters of 2021, featuring Simone Biles ("Simone vs. Herself"), Russell Westbrook ("Passion Play") and Tom Brady ("Man In The Arena"). On the audio front, the company produced a companion podcast to run alongside the "Man In The Arena" docuseries, and debuted three original, investigative podcasts - "Lost in Sports", "Crushed", and "False Idol" – the latter two of which were Ambies-nominated for 2022 Best Sports Podcast.
Through the lens of sport, Religion of Sports tells stories that make believers. More at religionofsports.com.
About Shamrock Capital
Shamrock Capital is a Los Angeles-based investment firm with approximately $3.6 billion of assets under management. Shamrock Capital invests exclusively in media, entertainment, communications, and related sectors through a multi-fund strategy centered on private equity investments, as well as ownership and financing of content and media rights. The firm was originally founded in 1978 as the family investment company for the late Roy E. Disney and has since evolved into an institutionally backed firm with a leading group of investors, including endowments, foundations, and sovereign wealth and pension funds. Shamrock Capital partners with strong management teams and takes an active, collaborative approach to creating value in each investment. For more information, visit www.shamrockcap.com.
View original content to download multimedia:
SOURCE Religion of Sports | https://www.mysuncoast.com/prnewswire/2022/06/06/religion-sports-raises-50m-become-studio-future-with-accelerated-leadership-storytelling-investment-new-ip-content-expansion/ | 2022-06-06T12:47:21Z |
NEW YORK, Aug. 9, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating PBF Logistics LP (PBFX), relating to its proposed acquisition by PBF Energy Inc. (PBF) Under the terms of the merger, each outstanding common unit of PBFX that PBF does not own will be converted into 0.270 shares of PBF Energy Class A common stock and $9.25 in cash. Click here for more information: https://www.monteverdelaw.com/case/pbf-logistics-lp. It is free and there is no cost or obligation to you.
We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018-2021 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2021 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.
If you own common stock in PBFX and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.
Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341
Attorney Advertising. (C) 2022 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
View original content to download multimedia:
SOURCE Monteverde & Associates PC | https://www.kxii.com/prnewswire/2022/08/09/investor-alert-mampa-class-action-firm-announces-investigation-pbf-logistics-lp-pbfx/ | 2022-08-09T19:06:27Z |
I’m often asked whether consumers are better or worse off since the modern consumer movement took hold in the 1960s.
Let’s look at the record. Motor vehicles are much safer, less polluting and more fuel efficient now, but not nearly what they should be. Today, consumers have warranty rights, recall rights, equal credit opportunity rights they did not have back then. Labeling also has improved. There is no more lead in gasoline and paint, though lead water pipes still contaminate some drinking water systems.
From being King tobacco over 50 years ago, cigarette companies are more regulated and daily tobacco smoking is down from 45% of adults to less than 15% of adults. But now there is vaping. Deadly asbestos is out of most products.
Solar energy and wind power are growing, even though energy company propaganda smeared them as science fiction more than 50 years ago.
Nuclear power plants are closing and no new ones are under construction, except for the massive Georgia boondoggle projects costing taxpayers and ratepayers billions of dollars in cost overruns. Heating, lighting and air-conditioning technology is more efficient, but nowhere near what it could be.
Clothing is cheaper due to production being taken to horrific polluting sweatshops abroad, leaving empty factories here.
Now look at the dark side. Housing is less affordable and homelessness is greater. Hunger is still a shameful plague in a land of plenty, with some 15 million children going to bed hungry. Nutritional, organic and ethnic foods are more widely available. We have pandemics instead of epidemics. Highway congestion and the paucity of mass transit is probably comparatively worse, despite some new investments in public transit since the ’60s.
The profit-driven opioid pandemic taking more than 100,000 American lives a year didn’t exist in the 1960s. Drug prices are sky high, even with large government subsidies and free research and development from the National Institute of Health.
Corporate crime escaping accountability is more diverse, brazen and massive. Big time corporate crime pays. More than $350 billion is lost in computer billing fraud every year just in the health care industry. There are very few prosecutions. Since computer use has grown, it has been much easier for corporations to cheat, fine, penalize and overcharge consumers and commit automated billing fraud.
Fine-print contracts keep reaching new levels of coercion unheard of in the 1960s. This is due to the endless opportunities created by the incarcerating credit card economy, which has taken away consumers’ control over their own money.
It is hard to exaggerate the massive controls over consumers which come from losing their freedom of contract and being coerced by companies with threats to worsen consumer credit scores and credit ratings, especially if they dare to persistently complain about a lemon car or a callous landlord.
Working only three days a week when they are not in extended recesses, Congress holds fewer investigative public hearings on issues affecting consumers such as monopolies or oligopolies that plague one industry after another. There are far fewer full-time consumer reporters at newspapers and radio/TV stations. Wells Fargo Bank creates fictitious credit card accounts, auto insurance, and other sales for millions of their non-requesting customers for years and then when caught escapes any jail time for the top bosses.
What would have been incredible in the ’60s is the relentless drive by companies such as Amazon, rental car giants, and others to get rid of purchasing by cash or check. Many companies want everybody to be coerced into the credit/debit penitentiary so they can charge your account for their dictatorial fees and other abuses.
Companies can charge you an outrageous fee or so-called penalty. They control your money through access to your credit card and deduct their bilk.
Finally, the marketing to children is out of control. Companies are circumventing parental authority selling directly to kids, harmful junk food, junk drink, and violent programs and games. These avaricious corporations are electronic child molesters. Direct marketing to kids and pushing to hook them with credit cards at an early age is pulling them into the addiction industries and creating intense family turmoil — especially with children’s omnipresent iPhone as the delivery vehicle.
Now comes Facebook’s “metaverse” that sucks in these youngsters far beyond the cruel seductions of today’s internet, further distancing this generation from the realities of life.
We need hundreds of new consumer protection organizations from the local to the national and international levels making tough demands on lawmakers and pushing for wider access to justice for aggrieved people.
Big corporations have meticulous strategic plans for humans, including robotic replacement of workers and human-to-human contact. It is time for a new consumer revolution and new consumer rules for a just, safe and consumer-sovereign economy.
Alexa can’t help you with this portentous mission. | https://www.albanyherald.com/opinion/ralph-nader-consumer-protection-progress-regress-from-the-60s-to-now/article_ebc1dc84-bd8b-11ec-9be3-1fa6c5d83196.html | 2022-04-17T01:04:32Z |
LAS VEGAS, Aug. 19, 2022 /PRNewswire/ -- International organization, GoTopless, proudly celebrates its 15th annual GoTopless day on Sunday, August 21, 2022 with events in the US, Canada, and Europe. According to GoTopless, achieving topless equality will actually change the world.
"By defending women's right to go topless, we are fighting against wars, we are fighting against poverty, we are fighting against child starvation, we are changing the world. It's not by changing big things that we fight revolutions, but by changing everyday details. If men can go topless anywhere they want, women can do the same.[...] A peaceful future is a future led by women," stated Maitreya Rael—spiritual leader & GoTopless founder.
"During the upcoming GoTopless Day (or any day for that matter), women are urged to take the lead and exercise their topless right wherever it is legal, e.g., Canada, UK, Germany, Spain, Holland, Colombia, South America, and several U.S. states including New York, which is celebrating its 30th anniversary of topless equality this year (People V. Santorelli, 1992)," said Nadine Gary—GoTopless President and Raelian Guide.
"In places where it is still illegal, women must work up their courage to challenge topless gender discrimination. This Saturday in Lauzanne, Switzerland, for instance, Swiss GoTopless activists will stand up against a public pool ordinance that bars topless women from swimming or walking topless but that, oddly enough, tolerates it if they remain seated or lying down! And the rule does not apply to men!" added Gary.
In the US, over the past decade, both GoTopless and Free The Nipple advocates have been actively fighting topless gender discrimination through the courts with varying degrees of success.
"Sometimes, District Court judges outrageously rule that "the people's sensibility" overrides gender equality (the same argument was once used to legally defend racism) but in one instance the ruling was pronounced in favor of topless equality and 6 western states suddenly embraced topless equality. So far, none of the cases were heard by the U.S. Supreme Court," said Gary.
According to Ms. Gary, in Europe and other places around the world, the last two decades have seen a trendy wind of repression influencing the younger generation of women who have unconsciously begun imitating the American puritanical culture portrayed in popular movie networks and on social media, and GoTopless constantly strives to educate women of their right.
"All women who want no discrimination against their gender, who want to see women with the same power as men, need to promote the right to go topless, not as a shy little wish, but as an act of revolution. Women, look the men in the eye and say 'I have the same right as you, and no one will stop me. I go topless because I want to change the world," concluded Maitreya Rael.
View original content:
SOURCE GoTopless | https://www.wibw.com/prnewswire/2022/08/19/gotopless-day-2022-support-equal-gender-topless-equality-change-world/ | 2022-08-19T13:06:35Z |
BEIJING, May 26, 2022 /PRNewswire/ -- Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888) ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced its unaudited financial results for the first quarter ended March 31, 2022.
"Baidu delivered solid first quarter results, especially with regard to our cloud and intelligent driving businesses. Baidu AI Cloud reported another quarter of strong revenue growth and Apollo Go was granted the first permit in China to provide driverless ride-hailing services on public roads in Beijing," said Robin Li, Co-founder and CEO of Baidu. "Since mid-March, our business has been negatively impacted by the recent COVID-19 resurgence in China. Although challenges related to the virus continue to pressure our near term business operations, we remain confident that our new AI businesses will boost the long-term growth of Baidu and contribute to China's innovation-driven economy and sustainable development."
"Revenues from Baidu Core remained healthy with non-ad revenues increasing by 35% year over year, driven by Baidu AI Cloud, which grew 45% year over year in the quarter," said Rong Luo, CFO of Baidu. "Looking ahead, we remain committed to quality revenue growth and an enduring business model. In addition, we will further enhance our overall operational efficiency to drive long-term growth."
First Quarter 2022 Financial Highlights[1]
Operational Highlights
Corporate
- Baidu released its annual ESG Report in May 2022, which details Baidu's ESG policies and sustainability initiatives (http://esg.baidu.com/en/esg_download.html).
AI Cloud
- PaddlePaddle developer community has grown to 4.77 million and has served 180,000 businesses and created 560,000 models, as of May 20, 2022.
- Baidu ACE smart transportation has been adopted by 41 cities, up from 16 cities a year ago, based on contract value of over RMB10 million, as of the end of the first quarter of 2022.
Intelligent Driving
- Baidu received a nomination letter from Dongfeng Motor, a Top 3 domestic automaker, in April 2022, indicating that Dongfeng Motor intends to adopt Apollo Self Driving (ANP, AVP, HD Map) in one of its popular models. This followed the nomination letter from BYD earlier this year.
- On April 28th 2022, Apollo Go was granted the permits to provide driverless ride hailing services on public roads of the Yizhuang region of Beijing. Apollo also received the first permits in Chongqing to conduct driverless testing on May 20th, 2022.
- Apollo Go provided 196K rides in the first quarter of 2022.
- Apollo Go is now available in ten cities, including Beijing, Shanghai, Guangzhou, Shenzhen, Chongqing, Changsha, Cangzhou, Yangquan, Wuzhen Water Town in Jiaxing and Wuhan. Apollo Go expanded into Wuzhen Water Town in Jiaxing on March 26, 2022 and Wuhan on May 10, 2022.
Other Growth Initiatives
- Xiaodu again ranked No.1 in smart display shipments globally for 2021, according to Strategy Analytics and Canalys. Xiaodu continues to be ranked No.1 in smart speaker shipments in China for 2021, according to Strategy Analytics, IDC and Canalys.
Mobile Ecosystem
- In March, Baidu App's MAUs reached 632 million, up 13% year over year, and daily logged in users reached 83%.
- In March, Baidu Smart Mini Program ("SMPs") MAUs reached 508 million, up 22% year over year, and the number of SMPs grew by 26% year over year.
- Revenue from Managed Page grew by 31% and reached 47% of Baidu Core's online marketing revenue in the first quarter of 2022.
iQIYI
- iQIYI's average daily number of total subscribing members for the quarter was 101 million, compared to 105 million for the first quarter of 2021 and 97 million for the fourth quarter of 2021.
First Quarter 2022 Financial Results
Total revenues were RMB 28.4 billion ($4.48 billion), increasing 1% year over year.
- Revenue from Baidu Core was RMB 21.4 billion ($3.37 billion), increasing 4% year over year; online marketing revenue was RMB 15.7 billion ($2.47 billion), decreasing 4% year over year, and non-online marketing revenue was RMB 5.7 billion ($903 million), up 35% year over year, driven by cloud and other AI-powered businesses.
- Revenue from iQIYI was RMB 7.3 billion ($1.15 billion), decreasing 9% year over year.
Cost of revenues was RMB 15.5 billion ($2.45 billion), increasing 4% year over year, primarily due to an increase in cost of goods sold, traffic acquisition costs, bandwidth costs, and other costs related to new AI business, offset by a decrease in content costs.
Selling, general and administrative expenses were RMB 4.7 billion ($735 million), decreasing 11% year over year, primarily due to a decrease in channel spending, promotional marketing and expected credit losses.
Research and development expense was RMB 5.6 billion ($885 million), increasing 10% year over year, primarily due to an increase in personnel related expense.
Operating income was RMB 2.6 billion ($410 million). Baidu Core operating income was RMB 2.5 billion ($398 million), and Baidu Core operating margin was 12%. Non-GAAP operating income was RMB 4.0 billion ($630 million). Non-GAAP Baidu Core operating income was RMB 3.7 billion ($581 million), and non-GAAP Baidu Core operating margin was 17%.
Total other loss, net was RMB 3.0 billion ($466 million), which mainly included a fair value loss of RMB 3.0 billion from long-term investments. A significant portion of long-term investments, including but not limited to investments in equity securities of public and private companies, private equity funds and digital assets, is subject to quarterly fair value adjustments, which may contribute to net income volatility in future periods.
Income tax expense was RMB 391 million ($62 million), decreasing 75% year over year, primarily due to a decrease in profit before tax and an increase in deduction on certain expenses that were previously considered non-deductible.
Net loss attributable to Baidu was RMB 885 million ($140 million), and diluted loss per ADS was RMB 2.87 ($0.45). Net loss attributable to Baidu Core was RMB 963 million ($152 million). Non-GAAP net income attributable to Baidu was RMB 3.9 billion ($612 million). Non-GAAP diluted earnings per ADS was RMB 11.22 ($1.77). Non-GAAP net income attributable to Baidu Core was RMB 3.8 billion ($600 million), and non-GAAP net margin for Baidu Core was 18%.
Adjusted EBITDA was RMB 5.5 billion ($867 million) and adjusted EBITDA margin was 19%. Adjusted EBITDA for Baidu Core was RMB 5.1 billion ($805 million) and adjusted EBITDA margin for Baidu Core was 24%.
As of March 31, 2022, cash, cash equivalents, restricted cash and short-term investments were RMB 191.0 billion ($30.13 billion), and cash, cash equivalents, restricted cash and short-term investments excluding iQIYI were RMB 185.8 billion ($29.31 billion). Free cash flow was negative RMB 107 million ($17 million), and free cash flow excluding iQIYI was RMB 1.1 billion ($175 million).
Conference Call Information
Baidu's management will hold an earnings conference call at 8.00AM on May 26, 2022, U.S. Eastern Time (8.00PM on May 26, 2022, Beijing Time).
Please register in advance of the conference call using the link provided below. Upon registering, you will be provided with participant dial-in numbers, Direct Event passcode and unique registrant ID by email.
For pre-registration, please click
It will automatically direct you to the registration page of "Baidu Q1 2022 Earnings Conference Call", where you may fill in your details for RSVP. If it requires you to enter a participant conference ID, please enter " 3917105".
In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), Direct Event passcode and unique registrant ID) provided in the confirmation email that you have received following your pre-registration.
Additionally, a live and archived webcast of this conference call will be available at http://ir.baidu.com.
About Baidu
Founded in 2000, Baidu's mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on NASDAQ under "BIDU" and HKEX under "9888". One Baidu ADS represents eight Class A ordinary shares.
Contacts
Investors Relations, Baidu, Inc.
Tel: +86-10-5992-8888
Email: ir@baidu.com Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, Baidu's and other parties' strategic and operational plans, contain forward-looking statements. Baidu may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in announcements made on the website of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Baidu's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Baidu's growth strategies; its future business development, including development of new products and services; its ability to attract and retain users and customers; competition in the Chinese Internet search and newsfeed market; competition for online marketing customers; changes in the Company's revenues and certain cost or expense items as a percentage of its revenues; the outcome of ongoing, or any future, litigation or arbitration, including those relating to intellectual property rights; the expected growth of the Chinese-language Internet search and newsfeed market and the number of Internet and broadband users in China; Chinese governmental policies relating to the Internet and Internet search providers, and general economic conditions in China and elsewhere. Further information regarding these and other risks is included in the Company's annual report on Form 20-F and other documents filed with the Securities and Exchange Commission, and announcements on the website of the Hong Kong Stock Exchange. Baidu does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of the press release, and Baidu undertakes no duty to update such information, except as required under applicable law.
Non-GAAP Financial Measures
To supplement Baidu's consolidated financial results presented in accordance with GAAP, Baidu uses the following non-GAAP financial measures: non-GAAP operating income (loss), non-GAAP operating margin, non-GAAP net income (loss) attributable to Baidu, non-GAAP net margin, non-GAAP diluted earnings per ADS, adjusted EBITDA, adjusted EBITDA margin and free cash flow. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.
Baidu believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity by excluding certain items that may not be indicative of its recurring core business operating results, such as operating performance excluding non-cash charges or non-operating in nature. The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to Baidu's historical performance and liquidity. The Company believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using these non-GAAP financial measures is that these non-GAAP measures exclude certain items that have been and will continue to be for the foreseeable future a significant component in the Company's results of operations. These non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to the Company's data.
Non-GAAP operating income represents operating income excluding share-based compensation expenses, amortization and impairment of intangible assets resulting from business combinations and contingent loss pertaining to legal proceeding in relation to former advertising agencies and iQIYI's non-recurring employee severance costs.
Non-GAAP net income attributable to Baidu represents net income attributable to Baidu excluding share-based compensation expenses, amortization and impairment of intangible assets resulting from business combinations, contingent loss pertaining to legal proceeding in relation to former advertising agencies, iQIYI's non-recurring employee severance costs, disposal gain or loss, impairment of long-term investments, fair value change of long-term investments, charitable donation from Baidu, adjusted for related income tax effects. Baidu's share of equity method investments for these non-GAAP reconciling items, amortization and impairment of intangible assets not on the investees' books, accretion of their redeemable non-controlling interests, and the gain or loss associated with the issuance of shares by the investees at a price higher or lower than the carrying value per shares, adjusted for related income tax effects, are also excluded.
Non-GAAP diluted earnings per ADS represents diluted earnings per ADS calculated by dividing non-GAAP net income attributable to Baidu, by the weighted average number of ordinary shares expressed in ADS. Adjusted EBITDA represents operating income excluding depreciation, amortization and impairment of intangible assets resulting from business combinations, contingent loss pertaining to legal proceeding in relation to former advertising agencies, iQIYI's non-recurring employee severance costs, and share-based compensation expenses.
For more information on non-GAAP financial measures, please see the tables captioned "Reconciliations of non-GAAP financial measures to the nearest comparable GAAP measure.
View original content:
SOURCE Baidu, Inc. | https://www.mysuncoast.com/prnewswire/2022/05/26/baidu-announces-first-quarter-2022-results/ | 2022-05-26T10:20:13Z |
TIRANA, Albania (AP) — The Albanian Parliament on Monday failed to elect the country’s next president after no candidates were nominated for the first round of voting.
Neither the governing left-wing Socialist Party, nor the opposition, or any independent candidate could be nominated. The parliament’s legal commission said that the vote was, nevertheless, considered formally as done.
The next round should be held in the next seven days.
Candidates are proposed by a group of at least 20 lawmakers in the 140-seat parliament. The parliament may hold five rounds to elect the president. In the first three rounds, the winner must secure at least three-fifths of the vote, or 84 lawmakers, which the ruling Socialists do not have. In the last two rounds, only the majority of the vote, or 71 lawmakers, is needed.
Edi Rama, the prime minister and leader of the governing Socialists, said they will patiently wait for the fourth round to elect the next president. Socialists have 74 votes.
The five-year presidency has a largely ceremonial role, generally understood to be apolitical. It carries some authority over the judiciary and the armed forces and is limited to two terms. | https://cw33.com/news/international/ap-international/albanian-parliament-fails-to-elect-a-president-in-1st-vote/ | 2022-05-17T14:28:04Z |
ROME (AP) — The Ocean Viking rescue ship brought 294 migrants rescued over the last 10 days in the central Mediterranean to a port in Sicily on Monday, as the number of migrant arrivals surges by one-third over last year’s levels.
The SOS Mediterranee charity criticized Italy for the long wait for a port, noting that many of those rescued were showing signs of trauma from the perilous journey and were in need of immediate assistance.
“The wait of over a week for a port to disembark these people was senseless,” said Candida Lobes, communications officer on the Ocean Viking.
The migrants were rescued in several operations off the coast of Libya starting on May 19, including 49 children, some as young as 3 years old.
Italy has seen a surge in migrant arrivals in recent weeks with warmer weather. The Interior Ministry said 18,841 migrants have arrived in Italy by sea so far this year, up by 31% over last year.
Authorities are increasingly concerned that a growing food crisis exacerbated by the blockade of grain stores in Ukraine could provoke a fresh migrant crisis out of North Africa.
Italian Interior Minister Luciana Lamorgese will host counterparts from five European countries this week in Venice to discuss the migrant situation.
“The problem hits our countries at first, but is a question facing the whole continent,” she added.
___
Follow all AP stories on global migration at https://apnews.com/hub/migration. | https://cw33.com/news/international/ap-international/italy-opens-sicilian-port-to-nearly-300-rescued-migrants/ | 2022-05-31T08:00:00Z |
VALHALLA, N.Y. (WPIX) — A baby girl who was shot in the face in New York City more than three months ago was released from the hospital Friday.
At just 11 months old, the little girl was hit on her left cheek by a stray bullet while sitting inside a parked car with her mother, Miraide Gomez, when a gunman fired shots in The Bronx on Jan. 19, according to police. She was taken to a hospital. Police initially described her condition as critical.
Two days after the shooting, she spent her first birthday in the hospital. A vigil was held at the location of the shooting to honor her. A GoFundMe page was set up by a woman claiming to be the child’s aunt to assist the baby’s family with medical expenses.
After more than three months of medical treatment, the baby was released from Blythedale Children’s Hospital in Valhalla. Gomez said her daughter’s recovery has been a “miracle medical journey.”
“Here we are and she’s walking, which is something that they told us might not happen,” Gomez said.
Police have not made an arrest in the shooting. The New York Police Department offered a $10,000 reward for information that leads to an arrest.
The suspect, described as a man with a medium build, was last seen wearing a face mask, a dark-colored hooded sweatshirt with a white Nike logo on the front, gray sweatpants and black and white sneakers. He fled in a gray car, police said.
Anyone with information can submit tips by calling Crime Stoppers at (800) 577-TIPS (8477), visiting crimestoppers.nypdonline.org, downloading the NYPD Crime Stoppers mobile app, or texting 274637 (CRIMES) then entering TIP577. Spanish-speaking callers are asked to dial (888) 57-PISTA (74782). | https://cw33.com/news/national/nexstar-media-wire/baby-girl-shot-in-face-in-nyc-released-from-hospital-months-later-miracle-medical-journey/ | 2022-05-14T20:05:32Z |
Hiker comes face to face with cougar
MILL CREEK, UTAH (KUTV) - A Utah man had a terrifying confrontation with a cougar Monday while hiking a trail, and he captured it all on camera.
“I saw it off about 10 feet in the bushes,” hiker Garrett Foster said. “It just jumped out at me.”
Foster said the cougar was about two feet from him.
“She jumped. Not jumped towards me, but like hurled herself towards me and was like ‘roar!’’” he said.
Foster said it was “surreal.”
“You’re by yourself in a canyon with a mountain lion. They can run up to like 50 miles an hour,” he said.
Just three days before this incident, Foster had spotted a cougar for the first time in his life. It did not come close, but it made him a little more prepared this time around.
“I picked up a rock, and I had a knife out just in case something happened. But I roared back twice, and it just took off, ran up the trail,” he said.
After two sightings in just three days, Foster said he might avoid Mill Creek Canyon for a bit, but he will be back. For now, he has some advice for anyone going out for a hike.
“Just being alert, knowing that you’re out there with some kind of wildlife at any given time even if you don’t see it, so yeah. Just be alert,” he said.
The Utah Division of Wildlife has some more advice.
If you encounter a cougar, do not run from it because it could trigger their instincts to chase. Instead, try and make yourself bigger by raising your arms and talking firmly in a loud voice while backing away slowly.
Copyright 2022 KUTV via CNN Newsource. All rights reserved. | https://www.kxii.com/2022/07/06/hiker-comes-face-face-with-cougar/ | 2022-07-06T13:26:57Z |
HORNELL, N.Y. (WETM) — Carol Hover, from Hornell, New York, received multiple pieces of mail that were written decades ago.
“They shouldn’t have gotten to me,” said Hover.
In early April, Hover received a postcard in the mail. While this is not unusual, the fact that it was dated August 30, 1960, was peculiar.
“The first thing I noticed was my mother’s handwriting,” said Hover. “She passed away back in 2014. I found that it was postmarked from Canada in August of 1960. So, they would have been on their honeymoon.”
Maybe it was just a strange accident? That is what Carol thought at first. However, that was not the only mail she received.
“So, the next day, I took it over to the post office just to have a laugh,” said Hover. “They said, ‘Oh you had a substitute delivery person. We are sorry. Do you know Jim and Peg, the people that sent it?’ I’m like those were my parents. She goes, “Oh my gosh! We have two more in the back.”
And more letters kept coming. Her cousin, Karen Kohnke, also received a letter at her former family home in Minnesota.
“Nobody seems to know, including the post office, how they are getting to us and why,” said Hover.
Regardless of the reason, Hover is enjoying the mystery mail. She especially enjoys the notes written by her family.
“It was just really nice to see my mother’s handwriting on a recent piece of mail, or my father’s [handwriting],” said Hover. “That was nice. So whether it gets explained or not, I am okay with that.” | https://cw33.com/news/nexstar-media-wire/mysterious-mail-woman-receives-mail-written-decades-ago/ | 2022-05-19T05:31:24Z |
JEDDAH, Saudi Arabia, July 5, 2022 /PRNewswire/ -- Saudia Cargo, one of the largest middle eastern airlines, has partnered with Revenue Technology Services (RTS) in the cargo division.
The partnership entails the implementation of a Revenue Planning solution, Foresight, pricing solution, Accelerate, as well as revenue management solution, Velocity.
The three-pronged solution will be hosted in RTS private cloud environment.
- Foresight helps airlines to determine the value of cargo in a schedule, set revenue and sales targets and track them.
- Accelerate helps airlines to negotiate optimal contract, spot, and tariff rates along with generating rate sheets and offers real time rating.
- Velocity forecasts short-term and long-term capacity and demand and evaluates each booking for profitability.
Sound Machine learning and AI (Artificial Intelligence) based algorithms are the base for all three solutions. With this, Saudia Cargo joins the growing cargo community at RTS.
Raja Kasilingam, President of RTS commented, "We are quite excited about this partnership as we begin implementing all three of our cargo solutions at Saudia Cargo. RTS is proud to be part of Saudia Cargo's strategy to provide the best products to their customers while maintaining sustainability on all fronts."
This partnership demonstrates the leadership and drive shown by both companies to challenge the industry norm and their aim to make significant improvements to how air cargo is handled. This incentivizes RTS in its pursuit to being the cargo solution of choice in the airline industry, by integrating advanced forecasting and optimization algorithms, as well as cutting edge features required for enhanced pricing, revenue management and revenue planning.
Mansour Alasmi, Executive Director of Network & Revenue Management at Saudia Cargo commented: "In a continuous effort to be at the forefront of innovation, it's essential for us to utilize the latest technology and embrace digitization, this can uplift the quality of our services significantly allowing us to reach new heights."
Mukundh Parthasarathy, Senior Vice President for Revenue Technology Services added, "I am super thrilled to have Saudia Cargo, a coveted brand, in my customer portfolio and the fact that they picked multiple solutions from our suite speaks volumes about the solution suite capabilities and benefits"
About RTS: Revenue Technology Services (RTS) offers solutions and services that help their customers to increase margins, improve customer experience, enhance productivity of their employees, and support their growth. RTS solutions are aimed at travel and transportation verticals to provide analytics, software solutions, consulting and education services, operations research capabilities, technology services and IT development support. RTS is headquartered in Dallas, Texas with offices in London- UK (United Kingdom), Cape Town -South Africa and Pune, Chennai, Hyderabad, Bengaluru, Chandigarh- India. To learn more about RTS, please visit www.rtscorp.com
About Saudia Cargo:
Saudia Cargo serves an extensive global network spanning four continents, 225 international destinations, and 26 domestic destinations, operates a dedicated freighter fleet and offers ample cargo capacity on its passenger flights across Asia, Africa, Europe, and the USA.
Contact:
Patrick Mashegwana
p.mashegwana@mcgroup.com
Phone: +49(0)3065000435
View original content:
SOURCE Saudia Cargo | https://www.kxii.com/prnewswire/2022/07/05/saudia-cargo-selects-rts-cargo-suite-revenue-management-velocity-pricing-accelerate-revenue-planning-foresight-solutions/ | 2022-07-05T10:02:52Z |
As natural gas expands in Gulf, residents fear rising damage
LAKE CHARLES, Louisiana (AP) — The front lawn of Lydia Larce’s home is strewn with debris: Remnants of cabinets and chunks of pink shower marble lie between dumpsters. She lives in a FEMA trailer out back, her home in shambles more than a year after Hurricane Laura tore through Lake Charles.
Larce, like many in Southwest Louisiana, has what she calls “storm PTSD.” Tornado warnings trigger anxiety. She fidgets and struggles to sleep.
“The fear and the unknown — it has me on an edge,” Larce said. “I’m scared.”
A string of devastating hurricanes has torn through this region in recent years. Nationally, too, there have been more Category 4 and 5 hurricane landfalls in the past five years than in the previous 50 years combined. Larce and her neighbors know they are on the front lines of climate change.
Her region is now the epicenter of a trend that she fears will make those disasters even more destructive.
Developers plan to build a series of liquefied natural gas export facilities across Southwest Louisiana, already the heart of the industry. Even in a state with a heavy industrial base, these facilities are among the largest emitters of greenhouse gases in Louisiana.
“They’re an absolute powerhouse for greenhouse gas emissions,” said Naomi Yoder, a staff scientist at Healthy Gulf, a nonprofit that advocates for clean energy. That’s because these export facilities tend to burn off, or flare, natural gas.
Greenhouse gases are raising global temperatures and fueling extreme weather, from wildfires to violent storms like the ones that have pummeled Larce’s hometown.
“We all are living in chaos,” Larce said.
For a while, it looked as though an era of steadily expanding fossil fuel facilities might be ending. Last year, after taking office, President Joseph Biden announced his intention to fight climate change by eliminating fossil fuels from electricity generation by 2035 and by sharply reducing emissions from the rest of the economy.
Yet since Biden became president, the U.S. has become the world’s largest exporter of liquefied natural gas as demand for the fuel, known as LNG, has escalated.
Russia’s invasion of Ukraine suddenly intensified the push. It heightened demand for natural gas, especially for countries in Europe that relied on Russian energy but now need to cut those ties.
Seizing the opportunity, the natural gas industry promoted U.S.-produced LNG as a way to fill the gaps, and prices for the fuel have skyrocketed. American terminals are now exporting gas at full capacity, which is why the expansion of the terminals has accelerated.
It is along the Gulf Coast, in a line from Louisiana to Texas, where the new and proposed export terminals are clustered. Talk to some locals and government officials and you’ll hear unqualified support for the facilities in this battered region.
“It’s a significant boon to our economy, because it provides good, high-paying jobs,” said Eric Tarver, a member of the Calcasieu Parish School Board and chief financial officer of Lake Charles Toyota. “More than that, it’s a tremendous amount of tax revenue that just dwarfs what we’ve had from any other industry.”
But some long-time residents — often the ones who’ve lost the most to the storms — dispute those claims, saying that few of those coveted jobs end up going to people who grew up in the region.
REGION IN DISTRESS
Scattered across the neighborhoods of Lake Charles, blue tarps cover dozens of dilapidated roofs. Bungalows, pockmarked by gaping holes, are marred by broken siding and boarded-up windows — evidence of the damage inflicted by Hurricanes Laura and Delta more than a year ago. Yet with few other options, some residents are living here under the tarps.
“I feel Southwest Louisiana has been made a sacrificial lamb,” said Roishetta Ozane, a single mother of six and an organizer for Healthy Gulf.
An outspoken critic of the expansion of LNG facilities, Ozane warns her neighbors that the emissions worsen global warming and violent storms and impair their community’s air quality. She has raised money, organized food drives and helped neighbors navigate government agencies to obtain relief after disasters hit.
“Now is the time to get people’s attention, to open their eyes that climate change is real,” Ozane said. “They’re going to continue to bring these facilities here. We’ve already had these major hurricanes here. Where are we going to live?”
As she drives around a predominantly Black area of Lake Charles, past shuttered businesses and crumbling homes, Ozane’s phone buzzes with requests for help.
“Are you living in a FEMA trailer?” she asks one caller. “Text me what you need.”
There are other helpers here. Cindy Robertson is one of them. In her front yard bursting with daisies and ferns, she refills a pantry box that she stocks each morning to help feed homeless neighbors. By mid-afternoon, it’s nearly empty.
Her neighborhood has endured seven federally declared disasters in two years, and she’s grown increasingly concerned, even though her family worked in coal mining. Robertson, 62, runs a nonprofit to help vulnerable people recover.
From her house, with its seascape paintings and tapestries, she provides water, sleeping bags and tents. With a succession of LNG terminals opening around her, she worries that her region hasn’t yet seen the worst.
“The more we have more pollution from greenhouse gases,” she fears, “the worse our storms are going to get.”
A few miles away, Cameron LNG began exporting LNG in 2019. Further south, Venture Global Calcasieu Pass is shipping its first loads.
Still another LNG company, Driftwood, recently broke ground to build an export facility. That’s on top of more than a dozen oil, gas and chemical processing plants surrounding her community.
Robertson would much prefer increased investment in renewable energy, in line with Biden’s stated priorities when he took office.
“Instead of focusing on LNG, expanding what they already have... we need to take all that brainpower and all that money and put it into expanding our renewable resources,” Robertson said.
EXPORTS SURGING
The use of wind, solar and other renewable energy has grown as prices of solar components and wind turbines have plunged. But so has the world’s thirst for natural gas. In February, the U.S. exported 317 billion cubic feet of liquefied natural gas — six times times the amount five years earlier.
Investment in LNG terminals catapulted from nothing in 2011, before the U.S. export industry existed, to $63 billion over the next decade, according to Rystad Energy. The firm projects that investment could swell an additional $100 billion over the next two decades.
That’s despite warnings from the United Nations Intergovernmental Panel on Climate Change that emissions from existing fossil fuel infrastructure alone would cause global warming to exceed 1.5 degrees Celsius (2.7 Fahrenheit) — a level that scientists say would bring dangerous consequences.
Of the eight terminals now exporting LNG, five lie on the coast of Louisiana and Texas. At least 16 more plus four expansions are proposed or under construction, nearly all along that same stretch of Gulf coastline.
The projects are backed by Exxon Mobil, Qatar Energy, Total Energies and numerous other global energy giants. Financing for several proposed plants comes from BlackRock, Vanguard and Mitsubishi, according to Global Energy Monitor.
At Cameron LNG in Hackberry, Louisiana, storage tanks loom over the wetlands next to rows of intersecting pipes. There, gas is treated to remove impurities. Then it’s cooled to a liquid at minus 260 degrees Fahrenheit to flow onto ships. In a narrow channel, a huge French vessel called LNG Endeavor, escorted by tug boats, heads for the facility, dwarfing the homes it passes.
“We’re delivering a cleaner, more environmentally friendly fuel,” said Charlie Riedl, executive director of the Center for LNG, the industry’s lobbying group. “The U.S. can use that to help defuse some of the geopolitical issues around the world by delivering a reliable fuel source.”
Initially, Biden’s administration held off on approving requests that would expand the LNG industry. But after the war in Ukraine began, the Energy Department allowed some facilities to upgrade, increasing how much they could produce.
“The U.S. is exporting every molecule of liquefied natural gas that we can to alleviate supply issues in Europe,” Energy Secretary Jennifer Granholm said in March, urging the oil and gas industry to ramp up production.
Asked whether boosting fossil fuel exports contradicts Biden’s climate goals, Granholm told The Associated Press “we have got to do both.” She said she believes the United States can help its allies, reduce the cost of fuel and transition to more sustainable options.
Since the war increased the need for alternatives to Russian gas, some European LNG import projects that had stalled are being revived, said Emily McClain, a vice president at Rystad.
“It’s really showing we’re not quite ready to table gas and move to cleaner or greener energies,” McClain said.
Riedl said he would like the administration to do even more, by approving any of the proposed LNG export terminals.
Louisiana offers a property tax break of up to 10 years to companies that build LNG terminals. Even with those tax breaks, the increased property tax income provides a windfall for the area, said Tarver, the school board member.
With Driftwood LNG beginning construction of a facility, the expected jobs are a “shot in the arm after a devastating series of disasters,” Tarver said. That the world is looking to the Gulf Coast as an energy supplier is, he said, a source of pride.
“That’s a very powerful thing to us locally, just because we’re big Pro-America, proud American people here,” Tarver said.
Others, like Ozane, argue that the tax breaks give away too much.
“We have a big homelessness problem,” Ozane said. “Our schools look horrible. If LNG is doing so much for the state, why is it like that?”
CLEANER THAN COAL?
Down the road from Cameron LNG, a new export terminal has opened about a mile from John Allaire’s beachfront home. His property, where he’s lived in an RV for 17 years since Hurricane Rita washed away his bunk house, is a refuge for spawning shrimp and diving sea birds. When his children were young, Allaire brought them fishing and hunting there.
At sunrise, the dark sky begins to crack into shades of orange and gray. A bright orb on the horizon looks like the rising sun. It’s not. It’s a flare from Venture Global’s Calcasieu Pass LNG, the latest export terminal to open. The flare, a mixture of flames and smoke that pours out when the facility burns natural gas, had been burning non-stop for a week, Allaire said.
“That’s pure profit and pollution going up the stack,” he said.
Allaire, 66, a retired environmental engineer for an oil company, doesn’t oppose oil and gas use. His property sits on a former oilfield.
But he fears the destruction of the wetlands he loves: The soft waving cordgrass where black rails hide, the pelicans diving down over the lapping water to catch fish.
Commonwealth LNG has proposed another export terminal, sandwiched between Allaire’s yard and the LNG terminal that just opened. It would cover about half the ponds that are packed with blue crabs and mud minnows.
“I’m glad there’s still places like this left — I really don’t want to see it paved over,” Allaire said.
The wetlands he loves play a beneficial role for climate, too. They absorb carbon dioxide. And they provide a buffer from storm surges.
Together, the four LNG export terminals on the Gulf Coast emitted nearly 10 million metric tons of carbon dioxide equivalent in 2020 — comparable to all of Costa Rica, according to the Global Carbon Project.
The LNG plants are tied to climate change in another way, too. Along the whole pathway to export, from the wells where companies drill to the ships getting loaded with LNG, methane — the powerful greenhouse gas that’s the primary ingredient of natural gas — can escape.
And it does, from leaky wells, pipelines, compressors and storage tanks. In the Permian Basin, one of the world’s richest oil and gas fields, well heads and pipelines are leaking far more methane than previously thought, according to a study that concluded that 9% of the gas produced in New Mexico’s side of the basin is leaking.
“That’s a shocking leakage estimate,” Rob Jackson, a professor of earth system science at Stanford University and chairman of the Global Carbon Project, an international research group, said about natural gas.
At that that rate, he said, the leaking methane alone is warming the climate more than the carbon dioxide that would be released if all the produced natural gas were burned.
Natural gas proponents say it’s better for the climate than burning coal, because it releases fewer emissions when burned. But gas isn’t substituting for coal in most places, Jackson noted. Instead, as energy demand grows globally, natural gas is being used in addition to coal and other sources.
According to projections by the Energy Information Administration, natural gas use will drive an overall increase in greenhouse gas emissions in the U.S. from 2037 to 2050 as the nation’s population and its reliance on gas grow.
To show it’s trying to limit its environmental impact, Cameron LNG reduced its emissions by 10% from 2020 to 2021. It’s also built 500 acres of tidal marsh, using material it digs up when dredging the canal.
But residents who are enduring the trauma of relentless storms know any facility that adds emissions to the atmosphere magnifies the likelihood of destruction in vulnerable communities.
“In building more LNG export terminals,” Jackson said, “we’re locking in emissions for decades to come.”
______
Associated Press journalists Janet McConnaughey in New Orleans and Rhonda Shafner in New York contributed to this report.
Associated Press climate and environmental coverage receives support from several private foundations. See more about AP’s climate initiative here. The AP is solely responsible for all content.
Copyright 2022 The Associated Press. All rights reserved. | https://www.kxii.com/2022/06/02/natural-gas-expands-gulf-residents-fear-rising-damage/ | 2022-06-02T12:53:04Z |
Quest Diagnostics Reports First Quarter 2022 Financial Results; Raises Guidance for Full Year 2022
Published: Apr. 21, 2022 at 5:45 AM CDT|Updated: 28 minutes ago
First quarter revenues of $2.61 billion, down 4.0% from 2021
First quarter reported diluted earnings per share ("EPS") of $2.92, down 15.6% from 2021; and adjusted diluted EPS of $3.22, down 14.4% from 2021
Base business revenues of $2.01 billion, up 6.3% from 2021
Full year 2022 reported diluted EPS now expected to be between $7.88 and $8.38; and adjusted diluted EPS expected to be between $9.00 and $9.50
SECAUCUS, N.J., April 21, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 2022.
"We're off to a good start in 2022, as we drove strong year-over-year growth in our base business, which excludes COVID-19 testing," said Steve Rusckowski, Chairman, CEO and President. "COVID-19 volumes remained strong early in the quarter and decreased in February and March, in line with the market. We continue to make investments to further accelerate growth in the base business, while our efforts to improve productivity are helping us to offset inflationary pressures. Based on our strong performance in the quarter and our expectations for the remainder of 2022 we have raised our full year guidance."
Updated Guidance for Full Year 2022
The company raises its Full Year 2022 guidance as follows:
Note on Non-GAAP Financial Measures
As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, certain financial impacts resulting from the COVID-19 pandemic, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, costs associated with donations, contributions, and other financial support through Quest for Health Equity (our initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities), gains and losses associated with changes in the carrying value of our strategic investments, and other items.
Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.
Conference Call Information
Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call.
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on April 21, 2022 until midnight Eastern Time on May 5, 2022, by phone at 800-583-8095 for domestic callers or 203-369-3815 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
Forward Looking Statements
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, impacts of the COVID-19 pandemic and measures taken in response, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.
This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.
The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc. | https://www.wibw.com/prnewswire/2022/04/21/quest-diagnostics-reports-first-quarter-2022-financial-results-raises-guidance-full-year-2022/ | 2022-04-21T11:13:02Z |
Lung Association educates adults living with chronic lung disease about the importance of pertussis vaccination
CHICAGO, Aug. 24, 2022 /PRNewswire/ -- Pertussis, commonly referred to as whooping cough, is a serious and highly contagious respiratory illness. There is a vaccine available for whooping cough, however only 30% of adults in the U.S. received it in the past 10 years. The American Lung Association, in collaboration with Sanofi, are working to educate adults living with asthma and chronic obstructive pulmonary disease (COPD) about the potential dangers of pertussis and the importance of vaccination.
"Here in the U.S., there are approximately 21.1 million adults living with asthma and 12.5 million adults living with COPD. For these people, whooping cough can lead to severe, sometimes life-threatening health challenges including exacerbation of their chronic medical conditions," said Harold Wimmer, National President and CEO for the American Lung Association. "Thankfully, there is a vaccine available, Tdap, which is specifically developed for adults and helps protect against tetanus, diphtheria and pertussis."
Vaccination is the best way to help protect against pertussis. Preventing pertussis helps reduce the risk of hospitalization and severe outcomes for high-risk individuals.
The Lung Association's Pertussis Educational Campaign includes online resources with key facts about pertussis, an online assessment and targeted outreach to raise awareness about the disease to high-risk individuals.
If you are living with COPD or asthma, visit Lung.org/Pertussis to learn more and speak with your healthcare provider about getting a vaccination to help protect against pertussis.
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about the American Lung Association, which has a 4-star rating from Charity Navigator and is a Gold-Level GuideStar Member, or to support the work it does, call 1-800-LUNGUSA (1-800-586-4872) or visit: Lung.org.
American Lung Association • 55 W. Wacker Drive, Suite 1150 • Chicago, IL 60601
1331 Pennsylvania Ave. NW, Ste. 1425 North • Washington, D.C. 20004
1-800-LUNGUSA (1-800-586-4872) Lung.org
CONTACT: Jill Dale | American Lung Association
P: 312-940-7001 C:720-438-8289 E: Jill.Dale@Lung.org
View original content to download multimedia:
SOURCE American Lung Association | https://www.wibw.com/prnewswire/2022/08/24/only-30-adults-have-received-whooping-cough-vaccination-more-needed-protect-people-highest-risk/ | 2022-08-24T11:05:56Z |
WASHINGTON (AP) — The FBI searched Donald Trump’s Mar-a-Lago estate as part of an investigation into whether he took classified records from the White House to his Florida residence, people familiar with the matter said, a dramatic and unprecedented escalation of law enforcement scrutiny of the former president.
Trump, disclosing the search in a lengthy statement, asserted that agents had opened a safe at his home and described their work as an “unannounced raid” that he likened to “prosecutorial misconduct.” He was in New York, planning to meet later Tuesday at his Bedminster, New Jersey, club with members of the Republican Study Committee, a group headed by Rep. Jim Banks of Indiana that says it is committed to putting forth his priorities in Congress.
Monday’s search intensified the months-long probe into how classified documents ended up in boxes of White House records located at Mar-a-Lago earlier this year. A separate grand jury is investigating efforts to overturn the results of the 2020 presidential election, and it all adds to potential legal peril for Trump as he lays the groundwork for another run.
About two dozen Trump supporters stood in protest at midmorning Tuesday in the Florida summer heat and sporadic light rain on a bridge near the former president’s residence. One held a sign reading “Democrats are Fascists” while others carried flags saying “2020 Was Rigged,” “Trump 2024″ and Biden’s name with an obscenity. Some cars honked in support as they passed.
Familiar battle lines, forged during a a four-year presidency shadowed by investigations, quickly took shape again. Trump and his allies sought to cast the search as a weaponization of the criminal justice system and a Democratic-driven effort to keep him from winning another term in 2024 — though the Biden White House said it had no prior knowledge and current FBI Director Christopher Wray was appointed by Trump five years ago.
Trump’s Vice President Mike Pence, a potential 2024 rival, tweeted on Tuesday: “Yesterday’s action undermines public confidence in our system of justice and Attorney General Garland must give a full accounting to the American people as to why this action was taken and he must do so immediately”
Trump wrote Monday night, “These are dark times for our Nation, as my beautiful home, Mar-A-Lago in Palm Beach, Florida, is currently under siege, raided, and occupied by a large group of FBI agents,” Trump wrote. “Nothing like this has ever happened to a President of the United States before.”
“After working and cooperating with the relevant Government agencies, this unannounced raid on my home was not necessary or appropriate,” Trump said.
Justice Department spokesperson Dena Iverson declined to comment on the search, including whether Attorney General Merrick Garland had personally authorized it.
The FBI reached out to the Secret Service shortly before serving a warrant, a third person familiar with the matter told The Associated Press. Secret Service agents contacted the Justice Department and were able to validate the warrant before facilitating access to the estate, the person said.
The Justice Department has been investigating the potential mishandling of classified information since the National Archives and Records Administration said it had received from Mar-a-Lago 15 boxes of White House records, including documents containing classified information, earlier this year. The National Archives said Trump should have turned over that material upon leaving office, and it asked the Justice Department to investigate.
There are multiple federal laws governing the handling of classified records and sensitive government documents, including statutes that make it a crime to remove such material and retain it at an unauthorized location. Though a search warrant does not necessarily mean criminal charges are near or even expected, federal officials looking to obtain one must first demonstrate to a judge that they have probable cause that a crime occurred.
Two people familiar with the matter, speaking on condition of anonymity to discuss an ongoing investigation, said the search on Monday was related to the records probe. Agents were also looking to see if Trump had additional presidential records or any classified documents at the estate.
Trump has previously maintained that presidential records were turned over “in an ordinary and routine process.” His son Eric said on Fox News on Monday night that he had spent the day with his father and that the search happened because “the National Archives wanted to corroborate whether or not Donald Trump had any documents in his possession.”
Asked how the documents ended up at Mar-a-Lago, Eric Trump said the boxes were among items that got moved out of the White House during “six hours” on Inauguration Day, as the Bidens prepared to move into the building.
“My father always kept press clippings,” Eric Trump said. “He had boxes, when he moved out of the White House.”
Trump made no mention of the search during a Monday evening tele-town hall on behalf of Leora Levy, the Connecticut Republican he has endorsed in Tuesday’s U.S. Senate primary.
But in a social media post Monday night, he called it a “weaponization of the Justice System, and an attack by Radical Left Democrats who desperately don’t want me to run for President in 2024.”
Other Republicans echoed that message.
Florida Gov. Ron DeSantis, a Republican who is considered a potential 2024 presidential candidate, said on Twitter that it was “an escalation in the weaponization” of U.S. government agencies. Kevin McCarthy, the House minority leader, said in a tweet that if Republicans win control of the U.S. House, they will investigate the Justice Department.
Trump took a different stance during the 2016 presidential campaign, frequently pointing to an FBI investigation into his Democratic opponent, Hillary Clinton, over whether she mishandled classified information via a private email server she used as secretary of state. Then-FBI Director James Comey concluded that Clinton had sent and received classified information, but the FBI did not recommend criminal charges.
Trump lambasted that decision and then stepped up his criticism of the FBI as agents began investigating whether his campaign had colluded with Russia to tip the 2016 election. He fired Comey during that probe, and though he appointed Wray months later, he repeatedly criticized him, too, as president.
Thomas Schwartz, a Vanderbilt University history professor who studies and writes about the presidency, said there is no precedent for a former president facing an FBI raid — even going back to Watergate. President Richard Nixon wasn’t allowed to take tapes or other materials from the White House when he resigned in 1974, Schwartz noted, and many of his papers remained in Washington for years before being transferred to his presidential library in California.
The probe is hardly the only legal headache confronting Trump. A separate investigation related to efforts by him and his allies to undo the results of the 2020 presidential election — which led to the Jan. 6, 2021, riot at the U.S. Capitol — has also been intensifying in Washington. Several former White House officials have received grand jury subpoenas.
And a district attorney in Fulton County, Georgia, is investigating whether Trump and his close associates sought to interfere in that state’s election, which was won by Democrat Joe Biden.
___
Associated Press writers Terry Spencer, Meg Kinnard, Michelle L. Price and Will Weissert contributed to this report. | https://cw33.com/news/politics/ap-politics/fbi-searches-trumps-florida-estate-for-classified-records/ | 2022-08-09T18:01:58Z |
ST. PAUL, Minn., July 6, 2022 /PRNewswire/ -- Today, the Flemish Government and 3M Belgium announced plans for 3M Belgium to invest a total of more than €571 million to benefit the People of Flanders and also carry out certain previously agreed-upon PFAS-related remedial actions. This agreement cooperatively resolves ongoing disagreements between the Flemish Government and 3M Belgium.
"For the Flemish government, the health of our citizens and the protection of the environment comes first," says Flemish Minister of Environment Zuhal Demir. "We expect that every entrepreneur and company takes their responsibility to act upon that. This Agreement is the result of an intense process during months in which 3M Belgium took action and financial responsibility towards our community. It is no secret that Flanders was counting on that as a clear signal towards the Flemish People and as a sign of respect. As a result of this Agreement, we will be able to get things done in the best interest of the People of Zwijndrecht, our local farmers and our prosperity and wellbeing in general. Not only in direct proximity of the plant, but also within the city community of Zwijndrecht and the construction site of the Oosterweel project, without ever letting the health of our citizens be a stake during negotiations. Flanders has the solid ambition of being a region where entrepreneurship goes hand in hand with care and love for the community and our environment."
"This agreement is a major step forward for the People of Flanders, as well as for our operations in Zwijndrecht and our ability to serve our customers. It also reflects 3M's ongoing stewardship journey as a responsible manufacturer and our willingness to engage with communities where we live and work to chart a positive course for the future," said John Banovetz, Executive Vice President, Chief Technology Officer and Environmental Responsibility, 3M Company. "We greatly appreciate the Ministry's collaboration in reaching this agreement, which builds on the commitments we have previously made and will fully uphold to carry out PFAS-related remediation and provide other support to the Flanders region. We have already taken significant actions to reduce PFAS discharges and emissions. These actions have enabled us to restart operations at the site. Through this agreement, we will address priorities identified by the government to provide for the citizens of Zwijndrecht, build the foundation for future certainty in 3M Belgium's operations, and address future potential liabilities."
3M Belgium's total commitment of €571 million incorporates previous and new commitments, as outlined below:
As noted, under the terms negotiated by the Flemish Government and 3M Belgium, 3M Belgium will commit €250 million for priority remedial actions identified by the government for the benefit of Zwijndrecht's residents, including:
- Remediation of contaminated soil in residential areas (gardens) in proximity to 3M Belgium's Zwijndrecht facility and the functional restoration of the gardens,
- Reduction of flow of contaminated groundwater into the Palingbeek,
- Prevention of future wind dispersion of potentially PFAS-containing soil or dust through a comprehensive dust control plan, and
- Remediation of agricultural and recreational lands in proximity to the facility.
The agreement calls for 3M Belgium to pay €100 million to the Flemish Government to be used in the government's sole discretion in connection with any PFAS released from the 3M Belgium facility. These funds may be used to benefit governmental entities beyond those that are parties to the agreement.
3M Belgium will provide €50 million in financial support and up to €50 million in support services to assist Lantis and facilitate the Oosterweel Project.
The 3M commitments are based on truthful estimates of experts of the OVAM. In addition, under the agreement 3M Belgium agreed to support additional actions to the extent required under the Flemish Soil Decree, if necessary.
3M Belgium will be required to take additional actions to transparently share information with the public about its operations and how the company is fully upholding its responsibilities under the agreement. These include:
- Enhancing and upgrading its publicly accessible websites to help people learn more about its operations in Zwijndrecht and around the globe, the science of PFAS and more, all in consultation with the Flemish Government. 3M Belgium will provide updates on ongoing Descriptive Soil Investigations, Remedial Action Plans and other reports related to management of PFAS from legacy manufacturing.
- Hosting regular public meetings in the municipality of Zwijndrecht to provide citizens of the region updates on remedial actions and answer their questions on a broad range of issues. These will be held at least quarterly for the first year and provide a helpful opportunity for individual citizens to learn how 3M Belgium is fulfilling its commitments.
- These information sharing requirements will continue for at least 10 years and may be extended upon agreement by the parties.
The agreement also contains certain provisions ending current litigation and provides certain releases of liability for 3M while recognizing that the Government retains its authority to act in the future to protect the citizenry.
3M expects to record a charge in the second quarter of 2022 associated with these actions and to reflect it as an adjustment in arriving at results, adjusted for special items.
This news release contains forward-looking information about 3M's financial results and estimates and business prospects that involve substantial risks and uncertainties. You can identify these statements by the use of words such as "anticipate," "estimate," "expect," "aim," "project," "intend," "plan," "believe," "will," "should," "could," "target," "forecast" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, regulatory, capital markets and other external conditions and other factors beyond the Company's control, including natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) risks related to public health crises such as the global pandemic associated with the coronavirus (COVID-19); (3) foreign currency exchange rates and fluctuations in those rates; (4) liabilities related to certain fluorochemicals, including lawsuits concerning various PFAS-related products and chemistries, and claims and governmental regulatory proceedings and inquiries related to PFAS in a variety of jurisdictions; (5) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and any subsequent quarterly reports on Form 10-Q (the "Reports"); (6) competitive conditions and customer preferences; (7) the timing and market acceptance of new product offerings; (8) the availability and cost of purchased components, compounds, raw materials, labor, and energy (including oil and natural gas and their derivatives) due to shortages, increased demand and wages, logistics, manufacturing site disruptions or supply chain interruptions (including those caused by natural and other disasters and other events); (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) the impact of acquisitions, strategic alliances, divestitures and other unusual events resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (11) operational execution, including scenarios where the Company generates fewer productivity improvements than estimated; (12) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; (13) the Company's credit ratings and its cost of capital; and (14) tax-related external conditions, including changes in tax rates, laws or regulations. Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located in the Reports under "Cautionary Note Concerning Factors That May Affect Future Results" and "Risk Factors" in Part I, Items 1 and 1A (Annual Report) and in Part I, Item 2 and Part II, Item 1A (Quarterly Reports), as updated by applicable Current Reports on Form 8-K. The information contained in this news release is as of the date indicated. The Company assumes no obligation to update any forward-looking statements contained in this news release as a result of new information or future events or developments.
View original content:
SOURCE 3M | https://www.wibw.com/prnewswire/2022/07/06/agreement-reached-between-flemish-government-3m-belgium-support-people-flanders/ | 2022-07-06T12:01:50Z |
Thousands of Cyclists will Ride Up to 211 Miles across Massachusetts This Weekend
BOSTON, Aug. 6, 2022 /PRNewswire/ -- On Saturday, August 6 and Sunday, August 7, the Pan-Mass Challenge (PMC) will bring together more than 6,300 registered riders from around the globe for its 43rd ride with the goal of raising a record-breaking $66 million for cancer research and patient care at the world-renowned Dana-Farber Cancer Institute in Boston, Massachusetts.
"We are excited to bring together our dedicated riders, volunteers, donors and sponsors this weekend for our first traditional PMC since 2019 as we raise the fundraising bar for Dana-Farber once again," said Billy Starr, founder and executive director of the PMC. "Our PMC community has demonstrated their unwavering commitment to our mission by raising $114 million over the last two years, and we are collectively focused on achieving another record-breaking gift in 2022."
For the 16th consecutive year, the PMC will donate 100% of every rider-raised dollar to Dana-Farber as its largest single contributor, accounting for 55% of the Jimmy Fund's annual revenue. If the PMC achieves its goal of raising $66 million this year, it will bring its total contributions to more than $897 million since 1980. Since the start of the global pandemic in early 2020, the PMC has raised more than $114 million for Dana-Farber, making a 42-year contribution to Dana-Farber of $831 million.
"As our largest single contributor, we are incredibly grateful for the PMC and its dedicated community that continues to remain steadfast in its commitment to fundraising for critical cancer research and treatment at Dana-Farber," said Laurie H. Glimcher, MD, President and Chief Executive Officer of Dana-Farber. "Cancer doesn't stop for anything, so we are especially inspired by the perseverance the PMC community has continued to show over the last two challenging years."
PMC 2022 includes 16 one and two-day routes ranging from 25 to 211 miles that are designed to cater to all levels of cycling and fundraising ability. Cyclists from 8 countries and 43 states will participate in this year's ride, many in honor of a family member or friend fighting cancer. At the cornerstone of the PMC community are the more than 950 riders and volunteers are cancer survivors or current patients, considered Living Proof® of the PMC's mission. More than 140 Dana-Farber employees are committed to the PMC as riders and volunteers as well, in some cases helping to fund their own cancer research.
The PMC is presented by the Red Sox Foundation® and M&T Bank. To learn more or to make a financial contribution to the cause, visit www.pmc.org, or call (800) WE-CYCLE. Connect with #PMC2022 on Facebook, Twitter, Instagram and LinkedIn.
About the Pan-Mass Challenge
The Pan-Mass Challenge (PMC) is a bikeathon that today raises more money for charity than any other single athletic fundraising event in the world. The PMC was founded in 1980 by Billy Starr, who remains the event's executive director, an annual cyclist and a fundraiser. The PMC has since raised $831 million for adult and pediatric patient care and cancer research at Dana-Farber Cancer Institute through the Jimmy Fund. The event donates 100 percent of every rider-raised dollar directly to the cause, generating 55 percent of the Jimmy Fund's annual revenue as Dana-Farber's single largest contributor. The PMC has successfully melded support from committed cyclists, volunteers, corporate sponsors and individual contributors, all of which are essential to the PMC's goal and model: to attain maximum fundraising efficiency while increasing its annual gift. The PMC's hope and aspiration is to provide Dana-Farber's doctors and researchers with the necessary resources to discover cures for all cancers. The PMC is presented by the Red Sox Foundation® and M&T Bank. For more information on the Pan-Mass Challenge, visit www.pmc.org.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. Dana-Farber's mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School. We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care. As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.
Contact:
Taylor Sheehan, Pan-Mass Challenge
taylor.sheehan@porternovelli.com
View original content to download multimedia:
SOURCE Pan-Mass Challenge | https://www.wibw.com/prnewswire/2022/08/06/worlds-most-successful-bike-a-thon-pan-mass-challenge-kicks-off-2022-ride-raise-record-breaking-66-million-cancer-research/ | 2022-08-06T14:19:02Z |
NEW YORK, Aug. 9, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Hyzon Motors Inc. ("Hyzon" or the "Company") (NASDAQ: HYZN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Hyzon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On August 4, 2022, in a filing with the U.S. Securities and Exchange Commission, Hyzon disclosed, among other items, that the Company's board had appointed a committee of independent directors to investigate issues regarding revenue recognition timing and internal controls/procedures, which were primarily related to its China operations, as a result of which the Company would be unable to timely file its quarterly report for the second quarter of 2022.
On this news, Hyzon's stock price fell $1.71 per share, or 38.08%, to close at $2.78 per share on August 5, 2022.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content:
SOURCE Pomerantz LLP | https://www.wibw.com/prnewswire/2022/08/09/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-hyzon-motors-inc-hyzn/ | 2022-08-09T08:09:11Z |
New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose groups in the Phase 2 GALAXI 1 study
Other data presented demonstrate the long-term safety profile of STELARA® (ustekinumab) in bio-naïve and bio-failure patients living with inflammatory bowel disease
SPRING HOUSE, Penn., May 24, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn's disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Diego, California on May 21-24, 2022.
The GALAXI 1 data showed study participants with an inadequate response or intolerance to conventional therapies and/or biologics treated with TREMFYA achieved high levels of clinical-biomarker responsea (47.5-66.7 percent), endoscopic responseb (44.3-46 percent), and clinical remissionc with C-reactive protein (CRP) ≤3 mg/L or fecal calprotectin ≤250 μg/g (39.3-66.7 percent) at 48 weeks across dose groups.1 TREMFYA is not approved to treat adult patients with CD or UC in the U.S.5
The STELARA pooled analyses of long-term safety data in bio-naïve and bio-failure CD/UC patients treated with STELARA demonstrated a favorable safety profile consistent with analyses in the overall inflammatory bowel disease (IBD) population and the established safety profile across approved indications.2,3 In addition, a STELARA pooled safety analysis from 13 total studies across all approved indications (including data up to one year in psoriatic arthritis [PsA], two in UC, and five in CD and plaque psoriasis [PsO]), showed no increased incidence (adjusted for duration of follow up) of malignancy with STELARA treatment compared to placebo.4
"These new data from the GALAXI 1 study are encouraging as we continue to investigate long-term treatment solutions to address the unmet needs for our patients who live with the burden of moderately to severely active Crohn's disease," said GALAXI 1 presenting study author Remo Panaccione, M.D., Professor of Medicine and Director of the Inflammatory Bowel Disease Unit at the University of Calgary, Alberta, Canada.d "The clinical-biomarker response and endoscopic response data from the Phase 2 GALAXI 1 clinical trial build upon the study's clinical remission outcomes and give us insight into the potential that TREMFYA may provide sustained remission."
- Clinical-biomarker response:a The proportions of patients treated with TREMFYA across dose groupse (n=185) who achieved clinical-biomarker response at week 48 ranged from 47.5-66.7 percent.f,g
- Endoscopic response:b The proportions of patients treated with TREMFYA achieving endoscopic response ranged from 44.3-46 percent across dose groupse (n=185) at week 48.f
- Clinical remission and achieving CRP or fecal calprotectin normalization:c The proportions of patients treated with TREMFYA achieving clinical remission and CRP ≤3 mg/L or fecal calprotectin ≤250 μg/g ranged from 39.3-66.7 percent across dose groups (n=185).e,f,h
- Safety: Safety results were consistent with the known safety profile of TREMFYA in approved indications.
Janssen previously announced 48-week clinical remission and corticosteroid-free clinical remission results from the GALAXI 1 Phase 2 study.6 Phase 3 clinical trials evaluating TREMFYA for the treatment of moderately to severely active CD are ongoing and actively enrolling participants. Learn more through the Janssen Global Trial Finder.
- Safety profile similar to placebo in bio-naïve patients: In a pooled long-term safety analysis of four Phase 2/3 IBD studies, 771 bio-naïve patientsi received STELARA with 1511 patient-years of follow up and 425 bio-naïve patients received placebo with 376 patient-years of follow up.3 Event rates adjusted per 100 patient-years for adverse events (AEs), serious AEs, infections, serious infections, major adverse cardiac events (MACE), and malignancies were similar between STELARA and placebo through up to one year.3 Rates per 100 patient-years (adjusted for duration of follow up) for AEs, serious AEs, infections, serious infections, and MACE were similar and/or numerically lower for STELARA versus placebo through up to five years in bio-naïve patients with CD and up to two years in bio-naïve patients with UC (Poster #Tu1440).3
- Safety profile similar to placebo in bio-failure patients: In a pooled long-term safety analysis of five Phase 2/3 IBD studies, 1596 bio-failurej patients with 1970 patient-years of follow up received STELARA and 847 bio-failure patients with 473 patient-years of follow up received placebo.2 Event rates per 100 patient-years (adjusted for duration of follow up) for AEs, serious AEs, infections, serious infections, MACE, and malignancies were similar between STELARA and placebo through up to five years in bio-failure patients with CD and up to two years in bio-failure patients with UC.2 The safety profile of STELARA was consistent with the established safety profile in IBD and across approved indications (Poster #Tu1438).2
- Malignancy risk comparable to placebo: In an analysis of pooled long-term safety data from 13 studies across approved indications, including CD and UC, in 2501 placebo-treated patients with 1244 patient-years of follow up and 6710 STELARA-treated patients with 13807 patient-years of follow up, STELARA showed no increased incidence (adjusted for duration of follow up) of malignancy compared to placebo through up to five years of STELARA follow up.4 Comparisons between the number of malignancies observed for patients treated with STELARA compared to expected malignancies based on the National Institutes of Health Surveillance, Epidemiology, and End Results database (SEER),7,k which does not include nonmelanoma skin cancer (NMSC) and cervical cancer in situ,8 resulted in a standard incidence ratio (SIR)l of 0.85 (95 percent confidence intervals:m 0.65, 1.09) for STELARA across approved indications, suggesting no increased malignancy risk with STELARA treatment. (Oral presentation #14).4
"These data provide validation and underscore our commitment to continuing to innovate for patients with disease where considerable need remains," said Jan Wehkamp, M.D., Ph.D., Vice President, Gastroenterology Disease Area Leader, Janssen Research & Development, LLC. "Drawing from a two-decade legacy of immunology innovation, we continue to generate new evidence for STELARA and are investing deeply in our pipeline to usher in a new era of treatment, leveraging the continued research of pathway science aiming to establish TREMFYA as a trusted therapeutic option for healthcare professionals and people who are living with inflammatory bowel disease."
a. Clinical-biomarker response is defined as clinical response and ≥50 percent reduction from baseline in CRP or fecal calprotectin.1
b. Endoscopic response is defined as ≥50 percent improvement from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) or SES-CD ≤2.1 SES-CD score at week 48 was based on all observed segments scored at week 48. Subjects who had insufficient data to calculate the total SES-CD score at week 48 were considered not to be in endoscopic response.1
c. Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score of <150.1
d. Dr. Panaccione is a paid consultant for Janssen. He has not been compensated for any media work.
e. The GALAXI 1 48-week analyses report the results of 248 patients randomized to TREMFYA or STELARA: patients receiving TREMFYA 200 mg intravenous (IV) were shifted to TREMFYA 100 mg subcutaneous (SC) dose every eight weeks (q8w); patients receiving TREMFYA at 600 or 1200 mg IV changed to TREMFYA 200 mg SC every four weeks (q4w).1 Please see the 'About GALAXI 1' section below for further details regarding dose and study design.
f. Patients who had a prohibited change in concomitant CD medication, a CD-related surgery, or discontinued study agent due to lack of efficacy, or an AE of worsening CD prior to the designated analysis timepoint were considered not to be in clinical remission, clinical response, clinical-biomarker response, endoscopic response, or clinical remission and CRP concentration ≤3 mg/L or fecal calprotectin concentration ≤250 μg/g from that timepoint onwards. Patients who had discontinued the study agent due to any other reasons prior to the designated analysis timepoint had their observed data used, if available, to determine responder and non-responder status from that timepoint onwards.1
g. Patients who had a missing CDAI score or who were missing both CRP and fecal calprotectin values at the designated analysis timepoint were considered not to be in clinical-biomarker response at that timepoint.1
h. Patients who had missing CDAI score or who were missing both CRP and fecal calprotectin values at the designated analysis timepoint were considered not to be in clinical remission and CRP concentration ≤3 mg/L or fecal calprotectin concentration ≤250 μg/g at that timepoint.1
i. All patients who received ≥1 dose of STELARA and were never treated with a biologic were included in the analysis.3
j. All patients who received ≥1 dose of STELARA and were identified as having a history of prior biologic failure were included in the analysis.2
k. The expected number of patients with malignancies is based on the SEER Database (year 2016), adjusted for age, gender, and race. Only patients with race belonging to White, Black or African American, Asian, American Indian/Alaska Native, Native Hawaiian, or other Pacific Islander were included since SEER only contains incidence rates for these populations.8
l. Standard incidence ratio is the observed number of patients with malignancy divided by the expected number of patients with malignancy.9
m. Confidence intervals are based on an exact method assuming that the observed number of events follows a Poisson distribution.4
GALAXI 1 is a double-blind, placebo-controlled, active-reference arm, global, multicenter, treat-through, Phase 2 dose-ranging study evaluating the efficacy and safety of TREMFYA in adult participants with moderately to severely active CD with inadequate response/intolerance to conventional therapies (corticosteroids, immunosuppressives) and/or biologics (tumor necrosis factor [TNF] antagonists, vedolizumab).
Participants were randomized equally into five treatment arms, including treatment with TREMFYA dosed at 200, 600, or 1200 mg IV at weeks 0, 4 and 8, respectively; or treatment with the reference product, STELARA, dosed at ~6 mg/kg IV at week 0 and then dosed at 90 mg SC at week 8; or IV placebo. The study was not powered to evaluate differences between treatment groups after the primary endpoint at week 12.
The primary endpoint of the Phase 2 GALAXI 1 study is change from baseline in CDAI scores at week 12.12 All three induction doses of TREMFYA significantly improved CDAI scores from baseline as compared to placebo, with placebo- subtracted Least Squares Mean reductions of 124.2 (p<0.001), 102.7 (p<0.001), and 108.7 (p<0.001) for the 200 mg IV, 600 mg IV, and 1200 mg IV groups, respectively. Additional key outcomes evaluated at week 12 include clinical remission (CDAI<150), clinical response (decrease from baseline in CDAI ≥100 or CDAI<150), PRO-2 remission (abdominal pain mean daily score ≤1 and mean daily stool frequency score ≤3 and no worsening from baseline), clinical-biomarker response (clinical response and ≥50 percent reduction from baseline in CRP or fecal calprotectin), endoscopic response (≥50 percent improvement from baseline in the SES-CD or SES-CD≤2), and safety in participants treated with TREMFYA compared with placebo.12 Participants may receive treatment through five years.10
The 48-week analyses report the results of the 248 patients randomized to TREMFYA or STELARA.13 After completing 12 weeks of IV induction therapy, patients transitioned to their long-term maintenance treatments as follows: patients receiving TREMFYA 200 mg IV were shifted to TREMFYA 100 mg SC dose q8w; patients receiving TREMFYA dosed at 600 mg IV or 1200 mg IV changed to TREMFYA 200 mg SC q4w; patients receiving STELARA continued with a 90 mg SC dose q8w; in addition to the 248 randomized patients, placebo non-responders began STELARA IV followed by STELARA SC q8w; and placebo responders continued on a placebo SC q4w.13
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and virtual meeting from May 21-24, 2022. The meeting showcases more than 5000 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology. More information can be found at www.ddw.org.
CD is one of the two main forms of IBD, which affects an estimated three million Americans.14 CD is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet or other environmental factors.15 Symptoms of CD can vary, but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss and fever.16 There is currently no cure for CD.17
In the United States, about one million people are affected by UC.18 UC is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucus.19 It is the result of an abnormal response by the body's immune system.19 Symptoms vary, but may include loose and more urgent bowel movements, persistent diarrhea, abdominal pain, bloody stool, loss of appetite, weight loss and fatigue.20
Developed by Janssen, TREMFYA is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor.5,21 IL-23 is an important driver of the pathogenesis of inflammatory diseases such as moderate to severe plaque PsO and active PsA. TREMFYA is approved in the U.S., Canada, Japan, and a number of other countries for the treatment of adults with moderate to severe plaque PsO who are candidates for injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light), and for the treatment of adult patients with active PsA.5,22,23 It is also approved in the EU for the treatment of moderate to severe plaque PsO in adults who are candidates for systemic therapy and for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug therapy.24
The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to TREMFYA®.
What is the most important information I should know about TREMFYA®?
TREMFYA® is a prescription medicine that may cause serious side effects, including:
- Serious Allergic Reactions. Stop using TREMFYA® and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
- Infections. TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA® and may treat you for TB before you begin treatment with TREMFYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA®.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
Do not take TREMFYA® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA®.
Before using TREMFYA®, tell your healthcare provider about all of your medical conditions, including if you:
- have any of the conditions or symptoms listed in the section "What is the most important information I should know about TREMFYA®?"
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA®.
- are pregnant or plan to become pregnant. It is not known if TREMFYA® can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if TREMFYA® passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of TREMFYA®?
TREMFYA® may cause serious side effects. See "What is the most important information I should know about TREMFYA®?"
The most common side effects of TREMFYA® include: upper respiratory infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, and bronchitis.
These are not all the possible side effects of TREMFYA®. Call your doctor for medical advice about side effects.
Use TREMFYA® exactly as your healthcare provider tells you to use it.
Please read the full Prescribing Information, including Medication Guide for TREMFYA®, and discuss any questions that you have with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
cp-82626v3
STELARA is a fully human monoclonal antibody and is the first biologic treatment to selectively inhibit the IL-12 and IL-23 pathways.25,26 Janssen commercializes STELARA in the U.S., EU, and in countries around the world. STELARA is approved in the U.S. for the treatment of: 1) adults and children six years and older with moderate to severe plaque PsO who are candidates for phototherapy or systemic therapy; 2) adult patients (18 years or older) with active PsA, used alone or in combination with methotrexate (MTX); 3) adult patients (18 years and older) with moderately to severely active CD; 4) adult patients (18 years and older) with moderately to severely active UC.
The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to STELARA®.
STELARA® (ustekinumab) is a prescription medicine that affects your immune system. STELARA® can increase your chance of having serious side effects including:
Serious Infections
STELARA® may lower your ability to fight infections and may increase your risk of infections. While taking STELARA®, some people have serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.
- Your doctor should check you for TB before starting STELARA® and watch you closely for signs and symptoms of TB during treatment with STELARA®.
- If your doctor feels that you are at risk for TB, you may be treated for TB before and during treatment with STELARA®.
You should not start taking STELARA® if you have any kind of infection unless your doctor says it is okay.
- think you have an infection or have symptoms of an infection such as:
- are being treated for an infection or have any open cuts.
- get a lot of infections or have infections that keep coming back.
- have TB, or have been in close contact with someone with TB.
After starting STELARA®, call your doctor right away if you have any symptoms of an infection (see above). These may be signs of infections such as chest infections, or skin infections or shingles that could have serious complications. STELARA® can make you more likely to get infections or make an infection that you have worse. People who have a genetic problem where the body does not make any of the proteins interleukin 12 (IL-12) and interleukin 23 (IL-23) are at a higher risk for certain serious infections that can spread throughout the body and cause death. People who take STELARA® may also be more likely to get these infections.
Cancers
STELARA® may decrease the activity of your immune system and increase your risk for certain types of cancer. Tell your doctor if you have ever had any type of cancer. Some people who had risk factors for skin cancer developed certain types of skin cancers while receiving STELARA®. Tell your doctor if you have any new skin growths.
Posterior Reversible Encephalopathy Syndrome (PRES)
PRES is a rare condition that affects the brain and can cause death. The cause of PRES is not known. If PRES is found early and treated, most people recover. Tell your doctor right away if you have any new or worsening medical problems including: headache, seizures, confusion, and vision problems.
Serious Allergic Reactions
Serious allergic reactions can occur. Stop using STELARA® and get medical help right away if you have any symptoms of a serious allergic reaction such as: feeling faint, swelling of your face, eyelids, tongue, or throat, chest tightness, or skin rash.
Lung Inflammation
Cases of lung inflammation have happened in some people who receive STELARA® and may be serious. These lung problems may need to be treated in a hospital. Tell your doctor right away if you develop shortness of breath or a cough that doesn't go away during treatment with STELARA®.
Before receiving STELARA®, tell your doctor about all of your medical conditions, including if you:
- have any of the conditions or symptoms listed above for serious infections, cancers, or PRES.
- ever had an allergic reaction to STELARA® or any of its ingredients. Ask your doctor if you are not sure.
- are allergic to latex. The needle cover on the prefilled syringe contains latex.
- have recently received or are scheduled to receive an immunization (vaccine). People who take STELARA® should not receive live vaccines. Tell your doctor if anyone in your house needs a live vaccine. The viruses used in some types of live vaccines can spread to people with a weakened immune system, and can cause serious problems. You should not receive the BCG vaccine during the one year before receiving STELARA® or one year after you stop receiving STELARA®.
- have any new or changing lesions within psoriasis areas or on normal skin.
- are receiving or have received allergy shots, especially for serious allergic reactions.
- receive or have received phototherapy for your psoriasis.
- are pregnant or plan to become pregnant. It is not known if STELARA® can harm your unborn baby. You and your doctor should decide if you will receive STELARA®.
- are breastfeeding or plan to breastfeed. It is thought that STELARA® passes into your breast milk.
- talk to your doctor about the best way to feed your baby if you receive STELARA®.
Tell your doctor about all the medicines you take, including prescription and over‐the‐counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
- Use STELARA® exactly as your doctor tells you to.
- STELARA® is intended for use under the guidance and supervision of your doctor. In children 6 years and older, it is recommended that STELARA® be administered by a healthcare provider. If your doctor decides that you or a caregiver may give your injections of STELARA® at home, you should receive training on the right way to prepare and inject STELARA®. Your doctor will determine the right dose of STELARA® for you, the amount for each injection, and how often you should receive it. Do not try to inject STELARA® yourself until you or your caregiver have been shown how to inject STELARA® by your doctor or nurse.
Common side effects of STELARA® include: nasal congestion, sore throat, and runny nose, upper respiratory infections, fever, headache, tiredness, itching, nausea and vomiting, redness at the injection site, vaginal yeast infections, urinary tract infections, sinus infection, bronchitis, diarrhea, stomach pain, and joint pain. These are not all of the possible side effects with STELARA®. Tell your doctor about any side effect that you experience. Ask your doctor or pharmacist for more information.
Please click to read the full Prescribing Information and Medication Guide for STELARA® and discuss any questions you have with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
cp-124932v3
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal.
Janssen Research & Development, LLC is a part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding TREMFYA® (guselkumab) and STELARA® (ustekinumab) product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
- Panaccione, R. et al. Efficacy and Safety of Guselkumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: Week 48 Analyses from the Phase 2 GALAXI 1 Study. Presented at DDW 2022, May 21-24.
- Loftus, EV. et al. Long-term Safety of Ustekinumab in IBD Patients with a History of Biologic Failure: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 2 Years in Ulcerative Colitis. Presented at DDW 2022, May 21-24.
- Sands, BE. et al. Long-term Cumulative Safety of Ustekinumab in Bio-naïve Patients with Crohn's Disease and Ulcerative Colitis. Presented at DDW 2022, May 21-24.
- Long, M. et al. Malignancies in Patients Treated with Ustekinumab: Long-term Pooled Safety Analysis in Crohn's Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis Through Up To 5 Years. Presented at DDW 2022, May 21-24.
- Food and Drug Administration. TREMFYA® Prescribing Information. Horsham, PA. 2017. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf. Accessed May 2022.
- Janssen. The Majority of Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA® (guselkumab). Available at: https://www.janssen.com/us/sites/www_janssen_com_usa/files/the_majority_of_adults_with_moderately_to_severely_active_crohns_disease_in_a_phase_2_study_achieved_clinical_remission_and_corticosteroid-free_remission_through_48_weeks_with_tremfya.pdf. Accessed May 2022.
- National Cancer Institute Surveillance, Epidemiology, and End Results Program database. Available at: https://seer.cancer.gov/resources. Accessed May 2022.
- National Cancer Institute Surveillance, Epidemiology, and End Results Program database. Technical Notes to the SEER Cancer Statistics Review, 1975-2016. Available at https://seer.cancer.gov/archive/csr/1975_2016/results_figure/sect_01_intro2_25pgs.pdf Accessed May 2022.
- National Cancer Institute Surveillance, Epidemiology, and End Results Program database. Standardized Incidence Ratio and Confidence Limits. Available at: https://seer.cancer.gov/seerstat/WebHelp/Standardized_Incidence_Ratio_and_Confidence_Limits.htm. Accessed May 2022.
- Clinicaltrials.gov. A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI). Identifier: NCT03466411. Available at: https://clinicaltrials.gov/ct2/show/record/NCT03466411. Accessed May 2022.
- EU Clinical Trials Register. 2017-002195-13. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002195-13/ES. Accessed May 2022.
- Sandborn, WJ. et al. (2022). Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study. Gastroenterology. https://www.gastrojournal.org/article/S0016-5085(22)00102-0/fulltext. Accessed May 2022.
- Danese, S. et al. Clinical Efficacy and Safety of Guselkumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: Week 48 Analyses from the Phase 2 GALAXI 1 Study (OP24). Presented at the 2022 ECCO Congress, February 16-19, 2022.
- Crohn's & Colitis Foundation. Overview of Crohn's disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed May 2022.
- Crohn's & Colitis Foundation. What is Crohn's disease? Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/causes. Accessed May 2022.
- Crohn's & Colitis Foundation. Signs and Symptoms of Crohn's Disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/symptoms. Accessed May 2022.
- Mayo Clinic. Crohn's disease. Available at: https://www.mayoclinic.org/diseases- conditions/crohns-disease/symptoms-causes/syc-20353304. Accessed May 2022.
- Garland, CF. et al. Incidence rates of ulcerative colitis and Crohn's disease in 15 areas of the United States. Gastroenterology. 1981 Dec; 81(6):1115-24.
- Crohn's & Colitis Foundation. What is Ulcerative Colitis? Available at: https://www.crohnscolitisfoundation.org/what-is-ulcerative-colitis. Accessed May 2022.
- Crohn's & Colitis Foundation. Signs and Symptoms of Ulcerative Colitis. Available at: https://www.crohnscolitisfoundation.org/what-is-ulcerative-colitis/symptoms. Accessed May 2022.
- McInnes, IB. et al. Long‐term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through 2 Years: Results from a Phase 3, Randomized, Double‐blind, Placebo‐controlled Study Conducted in Biologic‐naïve Patients with Active Psoriatic Arthritis. Arthritis & Rheumatology (2021).
- The Canadian Agency for Drugs & Technologies in Health. TREMFYA Prescribing Information. Available at: https://pdf.hres.ca/dpd_pm/00042101.PDF. Accessed May 2022.
- Japan Pharmaceuticals and Medical Devices Agency. Tremfya Report on the Deliberation Results. Available at: https://www.pmda.go.jp/files/000234741.pdf. Accessed May 2022.
- European Medicines Agency. TREMFYA Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf. Accessed May 2022.
- Food and Drug Administration. STELARA® Prescribing Information. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf. Accessed May 2022.
- Benson, JM. et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. Vol. 3. No. 6. Taylor & Francis, 2011.
Media Contact:
Bridget Kimmel
Mobile: (215) 688-6033
Investor Contact:
Raychel Kruper
Office: (732) 524-6164
Email: rkruper@its.jnj.com
View original content to download multimedia:
SOURCE Janssen Pharmaceutical Companies of Johnson & Johnson | https://www.mysuncoast.com/prnewswire/2022/05/24/janssen-presents-study-results-showing-clinical-efficacy-tremfya-guselkumab-long-term-safety-profile-stelara-ustekinumab-patients-living-with-inflammatory-bowel-disease-digestive-disease-week-2022/ | 2022-05-24T21:54:33Z |
PITTSBURGH, May 24, 2022 /PRNewswire/ -- "I'm a truck driver and I wanted to create a simple way to urinate without leaving the truck cab," said an inventor, from Dallas, Texas, "so I invented the TRUCKER'S PORTABLE URINAL. My design eliminates the need to continually pull off the highway to locate and use a public restroom."
The patent-pending invention provides an effective way for truck drivers to urinate without stopping. In doing so, it offers an alternative to finding a public restroom. As a result, it saves time and effort and it eliminates hassles, discomfort and delays. The invention features a practical design that is easy to use so it is ideal for truck drivers, professional drivers, travelers, etc. Additionally, it is producible in design variations and a prototype is available.
The original design was submitted to the Dallas sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 20-DAL-133, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.
View original content to download multimedia:
SOURCE InventHelp | https://www.mysuncoast.com/prnewswire/2022/05/24/inventhelp-inventor-develops-portable-urinal-truck-drivers-dal-133/ | 2022-05-24T18:51:58Z |
NEW YORK, July 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, XELA, BHC, FLNC, and EVFM.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
- TBLT: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=TBLT&prnumber=072920221
- XELA: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=XELA&prnumber=072920221
- BHC: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=BHC&prnumber=072920221
- FLNC: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=FLNC&prnumber=072920221
- EVFM: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=EVFM&prnumber=072920221
(Note: You may have to copy this link into your browser then press the [ENTER] key.)
InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
View original content to download multimedia:
SOURCE InvestorsObserver | https://www.kxii.com/prnewswire/2022/07/29/thinking-about-buying-stock-toughbuilt-industries-exela-technologies-bausch-health-fluence-energy-or-evofem-biosciences/ | 2022-07-29T13:26:16Z |
Ashish Prasad and Warren Kruse also listed as leading eDiscovery litigation support professionals
for multiple years
WASHINGTON, June 30, 2022 /PRNewswire/ -- Chambers USA has recognized HaystackID, a specialized eDiscovery services firm supporting law firms and corporate legal departments, and two of its team members for their eDiscovery litigation expertise in its 2022 Chambers Litigation Support Guide.
Chambers notes, "They really help their clients to think about cyber as a program and build a program that is put in place to mitigate risk and help manage incidents when they come." Chosen as one of only 19 U.S. eDiscovery litigation support providers recognized and ranked in the guide, the company received a Band 3 rating.
Chambers USA also recognized Vice President and General Counsel Ashish Prasad (Band 2) and Vice President of Forensics and Consulting Warren Kruse (Band 3) as top eDiscovery litigation support experts. Prasad and Kruse are two of only 12 U.S. professionals ranked in the guide as leading eDiscovery practitioners.
"Our firm is honored to be recognized by Chambers USA as a premier litigation support provider for the fourth consecutive year," HaystackID CEO Hal Brooks said. "We also congratulate Ashish and Warren on this well-deserved recognition, which is a testament to their deep knowledge of the nuances of eDiscovery and their commitment to excellence in client service."
Prasad said, "I am thrilled to have again received this coveted recognition from Chambers USA as a leading eDiscovery litigation support lawyer." Prasad has been Chambers ranked for his expertise for the past five years. According to Chambers, a source stated, "Clients value him because he has that deep perspective of not only what tech can do, but as an attorney, what the lawyers need to resolve their problems. He brings that mixture of perspectives."
"I am appreciative of this recognition and of the continued support from clients, partners and peers," said Kruse, who has also been ranked by Chambers for five years. A source told Chambers, "If I call Warren, I know he is going to lead me in the right direction from a technical and investigatory perspective." Kruse added, "We look forward to continued company success as we broaden our cyber and legal discovery offerings."
The Chambers Litigation Support Guide is a comprehensive guide to the leading professional services providers in key markets worldwide. Compiled by researchers and supported by hundreds of in-depth interviews with senior market leaders, the guide rates organizations and lawyers in key areas, including:
+ Technical Legal Ability
+ Professional Conduct
+ Client Service
+ Commercial Astuteness
+ Diligence
+ Commitment
+ Additional Qualities as Highlighted by Clients
The rating system for the litigation support guide consists of banded rankings for organizations and lawyers. These banded rankings are based on surveys and significant achievements, with an aggregate rating band assigned by Chambers to those recognized as worthy of inclusion in the guide. The bands range from Band 1 (highest) through Band 6 (lowest).
About HaystackID®
HaystackID is a specialized eDiscovery services firm that helps corporations and law firms securely find, understand, and learn from data when facing complex, data-intensive investigations and litigation. HaystackID mobilizes industry-leading cyber discovery services, enterprise solutions, and legal discovery offerings to serve more than 500 of the world's leading corporations and law firms in North America and Europe. Serving nearly half of the Fortune 100, HaystackID is an alternative cyber and legal services provider that combines expertise and technical excellence with a culture of white-glove customer service. In addition to consistently being ranked by Chambers USA, the company was recently named a worldwide leader in eDiscovery Services by IDC MarketScape, a representative vendor in the Gartner Market Guide for E-Discovery Solutions, and a Legal Technology Trailblazer by The National Law Journal. Further, HaystackID has achieved SOC 2 Type II attestation in the five trust service areas of security, availability, processing integrity, confidentiality, and privacy. For more information about its suite of services, including programs and solutions for unique legal enterprise needs, go to HaystackID.com.
HaystackID Media Contacts:
Jaime Wittner
jwittner@baretzbrunelle.com
973-407-9196
Rob Robinson
pr@HaystackID.com
512-934-7531
HaystackID on Social Media
+ Twitter (@HaystackID)
+ LinkedIn
View original content to download multimedia:
SOURCE HaystackID | https://www.wibw.com/prnewswire/2022/06/30/chambers-usa-ranks-haystackid-its-litigation-support-guide-fourth-year/ | 2022-06-30T17:05:53Z |
Experience the Kia EV6 in the Metro-New York City Area at Nassau Coliseum, August 27-28
- Electrify Expo series highlight new electric vehicles, sustainability, energy, infrastructure, and EV legislation
IRVINE, Calif., Aug. 26, 2022 /PRNewswire/ -- Kia America joins cutting-edge mobility companies for Electrify Expo, a series of five local events where leaders in electrification come together to discuss the key challenges, insights, available research, and trends facing the mobility sector as it moves toward an all-electric future. After events earlier this summer in Long Beach, CA and Seattle, the series continues August 27-28, in the metro New York City area at Nassau Coliseum, where attendees will have the opportunity to experience the all-new Kia EV6 first-hand.
"Electrify Expo brings together the top companies and executives in electrification to share knowledge and discuss how we'll make the transition to all-electrified vehicles as seamlessly as possible," said Eric Watson, vice president, sales operations, Kia America. "The impact that the Electrify Expo events will have on us all cannot be overestimated. Kia is one of the best-selling manufacturers of EV vehicles in the U.S. thus far in 2022 and we are proud to collaborate with our industry colleagues to chart the best path forward and help shape the future of the automotive industry."
A wide variety of topics are set for discussion and include legislation affecting the EV industry, range anxiety, battery materials and sustainability, charging infrastructure, the future of autonomous driving applications and supply chain barriers. A full list of sessions and presenters can be found by visiting www.electrifyexpo.com.
Electrify Expo expanded its industry-facing events, and education programs, with a full day of programming, industry leadership, and breakout sessions for the Auto and Micromobility categories. The series will close in Austin, Texas, at Circuit of the Americas on November 11, 2022. The upcoming schedule of Electrify Expo events is as follows (*indicates Industry Day):
Kia America - about us
Headquartered in Irvine, California, Kia America continues to top automotive quality surveys and is recognized as one of the 100 Best Global Brands. Kia serves as the "Official Automotive Partner" of the NBA and offers a range of gasoline, hybrid, plug-in hybrid, and electrified vehicles sold through a network of more than 750 dealers in the U.S., including several cars and SUVs proudly assembled in America.
For media information, including photography, visit www.kiamedia.com. To receive custom email notifications for press releases the moment they are published, subscribe at www.kiamedia.com/us/en/newsalert.
About Electrify Expo
Electrify Expo is North America's largest outdoor electric vehicle festival showcasing the latest e-mobility products, including EVs, e-motorcycles, e-bikes, e-scooters, e-skateboards, e-boats, e-surfboards, and more from top brands around the world. The festival addresses one of the most challenging barriers to mass adoption of electric vehicles with meaningful hands-on experiences, demonstrations, and test rides. Electrify Expo meets the soaring demand for companies to share new technologies, new modes of mobility and put products in the hands of consumers in a meaningful way. Electrify Expo will feature more than 1M+ square feet of exhibit space in Los Angeles County, Seattle, New York, Miami, and Austin.
View original content to download multimedia:
SOURCE Kia America | https://www.wibw.com/prnewswire/2022/08/26/kia-america-plugs-into-electrify-expo-2022/ | 2022-08-26T20:00:29Z |
TULSA, Okla., July 20, 2022 /PRNewswire/ -- The board of directors of ONEOK, Inc. (NYSE: OKE) today declared a quarterly dividend of 93.5 cents per share, unchanged from the previous quarter, resulting in an annualized dividend of $3.74 per share.
The dividend is payable Aug. 15, 2022, to shareholders of record at the close of business Aug. 1, 2022.
ONEOK, Inc. (pronounced ONE-OAK) (NYSE: OKE) is a leading midstream service provider and owner of one of the nation's premier natural gas liquids (NGL) systems, connecting NGL supply in the Rocky Mountain, Mid-Continent and Permian regions with key market centers and an extensive network of natural gas gathering, processing, storage and transportation assets.
ONEOK is a FORTUNE 500 company and is included in the S&P 500.
For the latest news about ONEOK, find us at www.oneok.com or on LinkedIn, Facebook, Twitter and Instagram.
Some of the statements contained and incorporated in this news release are forward-looking statements as defined under federal securities laws. The forward-looking statements relate to our anticipated financial performance (including projected levels of quarterly and annual dividends), liquidity, market conditions and other matters. We make these forward-looking statements in reliance on the safe harbor protections provided under federal securities laws and other applicable laws.
Forward-looking statements include the items identified in the preceding paragraph, the information concerning possible or assumed future results of our operations and other statements contained or incorporated in this news release identified by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "intend," "may," "might," "plan," "potential," "project," "scheduled," "should," "will," "would" and other words and terms of similar meaning.
One should not place undue reliance on forward-looking statements. Known and unknown risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. Those factors may affect our operations, markets, products, services and prices. These and other risks are described in greater detail in Item 1A, Risk Factors, in our most recent Annual Report on Form 10-K and in the other filings that we make with the Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Any such forward-looking statement speaks only as of the date on which such statement is made, and, other than as required under securities laws, we undertake no obligation to update publicly any forward-looking statement whether as a result of new information, subsequent events or change in circumstances, expectations or otherwise.
View original content:
SOURCE ONEOK, Inc. | https://www.kxii.com/prnewswire/2022/07/20/oneok-declares-quarterly-dividend/ | 2022-07-20T21:41:06Z |
NEW ORLEANS, May 20, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 27, 2022 to file lead plaintiff applications in a securities class action lawsuit against Natera, Inc. (NasdaqGS: NTRA), if they purchased the Company's shares between February 26, 2020 and April 19, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Texas.
Get Help
Natera investors should visit us at https://claimsfiler.com/cases/nasdaq-ntra-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Natera and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 14, 2022, a jury found that the Company intentionally and willfully misled the public through its false advertisements to market Prospera, a screening test for kidney transplant failure, in violation of the federal Lanham Act, the Delaware Deceptive Trade Practices Act, and Delaware common law, including that the Company's marketing falsely claimed that Prospera was more accurate than the competing kidney transplant testing offered by CareDx, Inc. Ultimately, the jury awarded CareDx $44.9 million in monetary damages. On this news, shares of Natera fell $8.81, or 22.5% to close at $30.32 per share on March 15, 2022.
Then, on April 19, 2022, the United States Food and Drug Administration ("FDA") issued a safety communication "to educate patients and health care providers and to help reduce the inappropriate use of [NIPTs]," a non-invasive prenatal test like the Company's product, Panorama, and cautioned that statements about NIPTs' reliability and accuracy "may not be supported with sound scientific evidence." On this news, shares of Natera fell as much as $1.53 per share, or approximately 3.9%, to close at $38.10 per share on April 20, 2022.
The case is John Harvey Schneider v. Natera, Inc., et al., No. 1:22-cv-00398.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
View original content:
SOURCE ClaimsFiler | https://www.kxii.com/prnewswire/2022/05/21/natera-shareholder-alert-claimsfiler-reminds-investors-with-losses-excess-100000-lead-plaintiff-deadline-class-action-lawsuit-against-natera-inc-ntra/ | 2022-05-21T04:13:26Z |
LAS VEGAS, April 18, 2022 /PRNewswire/ -- OPTX, the Las Vegas-based software company focused on analyzing complex player data to provide real-time insights and recommendations to casino operators, is proud to welcome Washington's Swinomish Casino & Lodge to its rapidly increasing portfolio.
OPTX is bringing its full suite of player development, slots, and artificial intelligence products to Swinomish Casino & Lodge. "We are fortunate to have a growing team and expanding player base, but we needed software that can keep up," said Jumada Schwinden, Director of Marketing for Swinomish Casino and Lodge. "OPTX is able to improve the ability of our team to cultivate customers and provide an unparalleled customer experience, while also providing our executive team with insights that help the entire property. OPTX is exactly what we have been searching for."
"Our advanced machine learning and AI algorithms identify countless insights for departments across the property. We are thrilled to welcome Swinomish Casino & Lodge to the future of player development and slots," said OPTX co-CEO, Brooke Fiumara.
OPTX provides an end-to-end solution focused on slots, marketing and campaigns, player development, and artificial intelligence. Available via desktop and mobile applications, the data intelligence used by OPTX creates actionable recommendations for casino operators, provides real-time individualized insights to ensure that no actionable player is missed, and empowers teams to spend less time compiling the data and more time implementing strategies that increase guest visitation, revenue, and profitability.
For more information about OPTX or to schedule a demo, go to www.OPTX.com.
ABOUT OPTX:
OPTX was founded in mid-2019 by former casino executives that believe only through the union of operations, people and technology can impactful results be achieved. The OPTX solution is designed from the ground up to simplify complex processes and improve operational efficiency. As an enterprise technology solution for casino operators, OPTX gathers the meaningful player data from multiple source systems, cleanses it and then presents it in an understandably clear way. For more information about OPTX go to www.OPTX.com.
View original content to download multimedia:
SOURCE OPTX | https://www.wibw.com/prnewswire/2022/04/18/optx-casino-data-platform-coming-swinomish-casino-amp-lodge/ | 2022-04-18T18:24:16Z |
- Mengiste has been instrumental in leading the Genesis Motor America Sales Operations team to 19 consecutive months of record sales growth
FOUNTAIN VALLEY, Calif., July 28, 2022 /PRNewswire/ -- Today Genesis Motor North America announced the promotion of Tedros Mengiste to Vice President, Sales Operations effective Aug. 1. Mengiste will continue to be responsible for Genesis sales, production, distribution, incentives, and field operations in the United States.
"Ted is a hard-working, dedicated leader who continues to achieve exceptional results for our business," said Claudia Marquez, chief operating officer of Genesis Motor North America. "Under Ted's stewardship, Genesis has made significant gains in both sales volume and market share, and I look forward to further success as we continue to make our mark here in the United States."
Mengiste joined Genesis Motor America in March 2020 as executive director of sales operations. Under his leadership of the team, the brand has achieved record sales results and market growth. In 2021, Genesis Motor America saw a 203% year-over-year sales volume increase, selling more than 49,000 units annually for the first time. In 2022, Genesis achieved its best-ever first half, selling 25,668 units resulting in 19 consecutive months of year-over-year sales growth as of July 1, 2022.
"Building the Genesis brand in the U.S. market has been one of the highlights of my career," said Mengiste. "I appreciate the support and confidence of Jose, Claudia, and the entire GMA team. I look forward to continuing this journey with them in my new capacity."
Mengiste has 26 years of extensive experience in the automotive industry, having previously served in executive positions at Nissan Motor America and Infiniti Motor Company. Before that, he spent 13 years with the Ford Motor Company and three years in retail.
During his tenures, Mengiste cultivated leadership experience in a variety of roles, including national and regional sales strategy, market representation, and product and consumer marketing.
He has a Bachelor of Science in Business Marketing from Indiana University and an MBA from the University of Michigan, Ross School of Business. Additionally, he completed the Global Executive Program at the University of Pennsylvania Wharton School of Business.
Genesis Motor North America
At Genesis, we put the customer at the center of every decision we make. Genesis is a global automotive brand that delivers the highest standards of performance, design, safety, and innovation while looking towards a more sustainable future. Genesis designs customer experiences that go beyond products, embodying audacious, forward-thinking, and distinctly Korean characteristics within its unique Athletic Elegance design identity. With a growing range of award-winning models — including G70, G80, and G90 sedans, along with GV60, GV70, and GV80 SUVs — Genesis aims to lead the age of electrification, starting with its Electrified G80 and GV60 electric models. Genesis has stated its commitment to becoming an all-electric vehicle brand by 2030 and to pursuing carbon neutrality by 2035.
Please visit our media site for the latest news at www.genesisnewsusa.com (United States) and www.genesisnews.ca (Canada).
View original content to download multimedia:
SOURCE Genesis Motor America | https://www.mysuncoast.com/prnewswire/2022/07/28/tedros-mengiste-promoted-vice-president-sales-operations/ | 2022-07-28T18:45:48Z |
LOS ANGELES, Aug. 5, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ: APYX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between May 12, 2021 and March 11, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before August 5, 2022.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Apyx's Advanced Energy products were frequently used for off-label indications, representing a significant portion of its sales. These off-label uses led to an increase in the number of adverse event reports filed by the Company. This was likely to lead to regulatory scrutiny. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Apyx, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:
SOURCE The Schall Law Firm | https://www.kxii.com/prnewswire/2022/08/05/final-deadline-alert-schall-law-firm-encourages-investors-apyx-medical-corporation-with-losses-100000-contact-firm/ | 2022-08-05T16:01:41Z |
WASHINGTON, Sept. 7, 2022 /PRNewswire/ -- In an effort to reduce the risk of children and teens experiencing serious, even life-threatening injuries from swallowing dangerous, small high-powered magnets, the U.S. Consumer Product Safety Commission (CPSC) voted to approve a new federal safety standard for magnets on September 7, 2022.
When high-powered magnets are swallowed, they can attract to each other, or to other material that attracts to magnets, through internal body tissue. This can result in perforations, twisting and/or blockage of the intestines, infection, blood poisoning and death. These injuries can occur when children and teens access and ingest the magnets, including, for example, when teens use the magnets to mimic mouth piercings and swallow them inadvertently.
The new mandatory federal standard requires loose or separable magnets in certain magnet products to be either too large to swallow, or weak enough to reduce the risk of internal injuries when swallowed; specifically, if the magnets fit in a small parts cylinder, then they must have a flux index of less than 50 kG2 mm2.
In 2014, CPSC established a mandatory federal standard for magnet sets, which have been the most concerning subset of the products subject to the new standard. However, the U.S. Court of Appeals for the Tenth Circuit overturned the mandatory standard in 2016. After the court's ruling allowed the continued sale of magnet sets, magnet ingestions and injuries rose.
CPSC estimates 26,600 magnet ingestions were treated in hospital ERs from 2010 through 2021, and cases have been rising annually since 2018. CPSC is aware of seven deaths involving the ingestion of hazardous magnets (including two outside of the United States), the majority of these incidents likely involved magnet sets.
The new rule applies to consumer products that are designed, marketed, or intended to be used for entertainment, jewelry (including children's jewelry), mental stimulation, stress relief, or a combination of these purposes, and that contains one or more loose or separable magnets. It does not include products sold and/or distributed solely to school educators, researchers, professionals, and/or commercial or industrial users exclusively for educational, research, professional, commercial, and/or industrial purposes.
The new rule does not apply to toys for children under 14 years old, because the CPSC's mandatory toy standard (16 CFR part 1250) already covers such products.
The products subject to the rule present an unreasonable risk of injury, and less stringent measures, such as safety messaging, have historically been ineffective in attempting to persuade children, teens and caregivers to avoid the hazard.
The Commission voted 5 to 0 to approve the mandatory standard. The rule goes into effect 30 days after publication in the Federal Register for magnet products manufactured after that date.
NOTE: CPSC urges anyone who may own these magnets and magnet sets to discard them to protect children who may come into contact with them and unintentionally ingest them.
CPSC Chair & Commissioner Statements:
Chair Alex D. Hoehn-Saric Statement
Commissioner Richard Trumka Statement
About the U.S. CPSC
The U.S. Consumer Product Safety Commission (CPSC) is charged with protecting the public from unreasonable risk of injury or death associated with the use of thousands of types of consumer products. Deaths, injuries, and property damage from consumer product-related incidents cost the nation more than $1 trillion annually. CPSC's work to ensure the safety of consumer products has contributed to a decline in the rate of injuries associated with consumer products over the past 50 years.
Federal law prohibits any person from selling products subject to a Commission ordered recall or a voluntary recall undertaken in consultation with the CPSC.
For lifesaving information:
- Visit CPSC.gov.
- Sign up to receive our e-mail alerts.
- Follow us on Facebook, Instagram @USCPSC and Twitter @USCPSC.
- Report a dangerous product or a product-related injury on www.SaferProducts.gov.
- Call CPSC's Hotline at 800-638-2772 (TTY 301-595-7054).
- Contact a media specialist.
Release Number: 22-219
View original content to download multimedia:
SOURCE U.S. Consumer Product Safety Commission | https://www.kxii.com/prnewswire/2022/09/07/cpsc-approves-new-federal-safety-standard-magnets-prevent-deaths-serious-injuries-high-powered-magnet-ingestion/ | 2022-09-07T17:54:24Z |
AG honors Kansans for outstanding service to victims of crime
TOPEKA, Kan. (WIBW) - Five Kansans have been honored by the Attorney General for their outstanding service to victims of crime in the Sunflower State.
Kansas Attorney General Derek Schmidt says on Wednesday, April 6, he recognized five Kansans for their outstanding service to crime victims.
In a video presentation as part of 2022′s virtual Crime Victims’ Rights Conference, AG Schmidt announced Danielle Thompson, of the Kansas Department of Corrections, as the recipient of the Outstanding System-Based Advocate Award.
At KDOC, Schmidt said Thompson started the very first facility-based BIP group in Kansas and now supervises one of the largest in the state. In managing the KDOC Batterer Intervention Program, he said Thompson directly enhances safety for both the victims and the greater community because of her commitment to victim safety and offender accountability within the work.
“[Thompson] works collaboratively within the correctional system to ensure policies and programming are reflective of victims’ needs and overall safety. By helping to reduce recidivism in those who cause harm, Danielle is ensuring a safer future for existing victims of domestic violence and preventing potential harm for countless more,” colleague Mary Stafford said.
Schmidt also announced the Ford County Attorney Victims Services Unit was honored with the Outstanding Victim Service Organization Award. Staff includes Tiffanie Askew, director, and victim service assistants Idania Muniz, Gretchen Webster, Marissa Ruiz and Maria Cruz.
The AG noted the victim started to provide victim services to victims at court in Ford Co., however, the unit has grown to meet the needs of victims in Western Kansas now serving victims in Ford, Meade, Kiowa, Clark and Comanche counties. A unit is also dedicated to help those at the Dodge City Police Department and Ford Co. Sheriff’s Office.
“I have witnessed the lengths to which each advocate goes to ensure not only that the victim is afforded their constitutional rights, but to ensure that each victim is treated with respect, dignity, and professionalism,” Meade Co. Attorney Clay Kuhns said. “These advocates dedicate countless hours, at all hours of the day, providing services for victims.”
Schmidt said Detective Steven Meyer of the Wichita Police Department was also honored as the recipient of the Outstanding Criminal Justice Service Award for Law Enforcement. He said Det. Meyer has served WPD for 26 years. He spent the first 22 as a patrol officer, field training officer and school resource officer, then was promoted to the rank of detective.
As a detective, the AG said Meyer has served as the task force officer for the FBI Human Trafficking Task Force where he has worked with multiple agencies and successfully charged cases at both the state and federal levels as lead investigator. He said Meyer is currently assigned to the Exploited and Missing Child Unit where he investigates child physical and sexual abuse cases.
“Steve supports all aspects of the CAC and will lend a hand when his fellow detectives or the advocates need his help - day or night. He is always the one you know will answer the phone and be there,” Toni Baker of the Child Advocacy Center of Sedgwick County said. “His heart is huge and he deserves some recognition for all the hard work and sacrifices he makes each and every day.”
Locally, Schmidt said he honored Abilene native and current member of the Sunflower CASA of Manhattan Jennifer Anguiano with the Outstanding Community Based Advocate Award. He said she has been at Sunflower CASA of Manhattan for nearly two decades and has described the highlight of her career as being able to advocate for incredibly brave children during some of the most difficult moments in their lives.
Carson Kober, executive director of the Sunflower CASA project, said during Anguiano’s time, she has served as interim executive director for the organization three times as she carried her own caseload as a CASA and supervised over 1,000 cases.
“She has been a rock for the organization–never losing focus of what matters–being an advocate for child victims in our community,” Kober said.
Last, but not least, the AG honored Connie Cahoone of SOS, Inc., in Emporia, with the Community Champion Award. He said Cahoone has been executive director of SOS, Inc., since June 2012. She came to SOS after a career in banking but decided to give back to the Emporia community and put her talents and efforts toward creating change. She led a capital campaign to raise over $4 million for SOS, which allowed it to purchase and renovate a building to better meet the needs of crime victims.
“Beyond statistics, Connie is an outstanding leader and mentor who gives 110% devotion. It takes an exceptional, devoted and driven individual to have a vision this immense and successful,” colleague Tara Schnakenberg said. “The vision becomes a full reality under Connie’s leadership. We are so grateful for Connie’s leadership and accomplishments which will have a lasting impact in our community for victims of domestic violence, sexual assault, child abuse and neglect, and child witnesses of domestic violence/assault.”
The annual recognition happened during the 24th Annual Crime Victims’ Rights Conference, hosted virtually this week by Governor Laura Kelly and the AG.
Copyright 2022 WIBW. All rights reserved. | https://www.wibw.com/2022/04/06/ag-honors-kansans-outstanding-service-victims-crime/ | 2022-04-06T18:39:35Z |
CHARLESTON, S.C., Aug. 22, 2022 /PRNewswire/ -- First Capital Bancshares, Inc. ("First Capital"), parent company of First Capital Bank (the "Bank"), announced today the completion of a private placement of shares of its common and non-voting preferred stock to accredited individual and institutional investors. Due to the high level of interest in the offering, the First Capital Bancshares board of directors elected to modify the original offering from $10 Million to $15.1 Million.
The private placement resulted in gross proceeds to the company of $15.1 million before deducting expenses. First Capital intends to use the proceeds from the private placement to support growth of the franchise in its South Carolina and North Carolina markets and for general corporate purposes.
Commenting on the capital raise, Harvey L. Glick, Chairman and CEO, said, "We are so pleased with the level of interest the community showed in our offering. Our team of talented bankers is ready to put the new capital to work knowing it will enhance our client services and shareholder value."
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. The securities offered and sold in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration under the Securities Act and applicable state securities laws.
About First Capital Bancshares, Inc.
First Capital Bancshares, Inc. is a bank holding company headquartered in Charleston, South Carolina with assets of approximately $458 million as of June 30, 2022. Its principal activity is the ownership and operation of First Capital bank, a state-chartered community bank that operates four branches and one loan production office in South Carolina and North Carolina. For more information, please visit www.bankwithfirstcapital.com.
Forward-Looking Statements
Certain statements in this news release contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future plans and expectations, and are thus prospective. Such forward-looking statements are identified by words such as "believe," "expect," "anticipate," "estimate," "intend," "plan," "target," and "project," as well as similar expressions. Such statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Although we believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove to be inaccurate. Therefore, we can give no assurance that the results contemplated in the forward-looking statements will be realized. The inclusion of this forward-looking information should not be construed as a representation by our company or any person that the future events, plans, or expectations contemplated by our company will be achieved.
The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: (1) competitive pressures among depository and other financial institutions may increase significantly and have an effect on pricing, spending, third-party relationships and revenues; (2) the strength of the United States economy in general and the strength of the local economies in which the company conducts operations may be different than expected, including, but not limited to, due to the negative impacts and disruptions resulting from the national political turmoil as well as continuing impact of the novel coronavirus, or COVID-19, on the economies and communities the company serves, which may have an adverse impact on the company's business, operations and performance, and could have a negative impact on the company's credit portfolio, share price, borrowers, and on the economy as a whole, both domestically and globally; (3) the rate of delinquencies and amounts of charge-offs, the level of allowance for loan loss, the rates of loan growth, or adverse changes in asset quality in our loan portfolio, which may result in increased credit risk related losses and expenses; (4) changes in legislation, regulation, policies, or administrative practices, whether by judicial, governmental, or legislative action, including, but not limited to, changes affecting oversight of the financial services industry or consumer protection; (5) adverse conditions in the stock market, the public debt market and other capital markets (including changes in interest rate conditions) could have a negative impact on the company; (6) changes in interest rates, which may affect the company's net income, prepayment penalty income, mortgage banking income, and other future cash flows, or the market value of the company's assets, including its investment securities; and (7) changes in accounting principles, policies, practices, or guidelines. All subsequent written and oral forward-looking statements concerning the company or any person acting on its behalf is expressly qualified in its entirety by the cautionary statements above. We do not undertake any obligation to update any forward-looking statement to reflect circumstances or events that occur after the date the forward-looking statements are made, except as required by law.
View original content:
SOURCE First Capital Bancshares | https://www.kxii.com/prnewswire/2022/08/22/first-capital-bancshares-announces-completion-151-million-private-placement/ | 2022-08-22T13:21:43Z |
NEW YORK, July 13, 2022 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spero Therapeutics, Inc. (NASDAQ: SPRO) between October 28, 2021 and May 2, 2022, both dates inclusive (the "Class Period"), of the important than July 25, 2022 lead plaintiff deadline.
SO WHAT: If you purchased Spero Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 25, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the data submitted in support of the New Drug Application ("NDA") of Tebipenem HBr, an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults, were insufficient to obtain U.S. Food and Drug Administration ("FDA") approval; (2) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (3) the foregoing would necessitate a significant workforce reduction and restructuring of Spero Therapeutics's operations; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com
View original content to download multimedia:
SOURCE Rosen Law Firm, P.A. | https://www.kxii.com/prnewswire/2022/07/13/rosen-skilled-investor-counsel-encourages-spero-therapeutics-inc-investors-secure-counsel-before-important-deadline-securities-class-action-spro/ | 2022-07-13T23:40:42Z |
DUBAI, United Arab Emirates (AP) — Iran said Tuesday it submitted a “written response” to what has been described as a final roadmap to restore its tattered nuclear deal with world powers.
Iran’s state-run IRNA news agency offered no details on the substance of its response, but suggested that Tehran still wouldn’t take the European Union-mediated proposal, despite warnings there would be no more negotiations.
“The differences are on three issues, in which the United States has expressed its verbal flexibility in two cases, but it should be included in the text,” the IRNA report said. “The third issue is related to guaranteeing the continuation of (the deal), which depends on the realism of the United States.”
Tehran under hard-line President Ebrahim Raisi has repeatedly tried to blame Washington for the delay in reaching an accord. Monday was reported to have been a deadline for Iran’s response.
Nabila Massrali, a spokesperson for the EU on foreign affairs and security policy, told The Associated Press that the EU received Iran’s response on Monday night.
“We are studying it and are consulting with the other JCPOA participants and the U.S. on the way ahead,” she said, using an acronym for the formal name for the nuclear deal, the Joint Comprehensive Plan of Action.
The EU has been the go-between in the indirect talks as Iran refused to negotiate directly with America since then-President Donald Trump unilaterally withdrew the U.S. from the accord in 2018.
From Washington, State Department spokesman Ned Price said the U.S. would share its own response to the EU.
“We do agree, however, with (the EU’s) fundamental point, and that is that what could be negotiated has been negotiated,” Price said.
He added that Iran had been making “unacceptable demands” going beyond the text of the 2015 nuclear deal, which saw Iran drastically limit its enrichment of uranium in exchange for the lifting of economic sanctions.
“If Iran wants these sanctions lifted, they will need to alter their underlying conduct,” Price said. “They will need to change the dangerous activities that gave rise to these sanctions in the first place.”
As of the last public count, Iran has a stockpile of some 3,800 kilograms (8,370 pounds) of enriched uranium. Under the deal, Tehran could enrich uranium to 3.67% purity, while maintaining a stockpile of uranium of 300 kilograms (660 pounds) under constant scrutiny of surveillance cameras and international inspectors.
Iran now enriches uranium up to 60% purity — a level it never reached before and one that is a short, technical step away from 90%. Nonproliferation experts warn Iran now has enough 60%-enriched uranium to reprocess into fuel for at least one nuclear bomb. Meanwhile, the surveillance cameras have been turned off and other footage has been seized by Iran.
However, Iran still would need to design a bomb and a delivery system for it, likely a monthslong project. Tehran insists its program is peaceful, though the West and the International Atomic Energy Agency say Iran had an organized military nuclear program until 2003.
___
Follow Jon Gambrell on Twitter at www.twitter.com/jongambrellAP. | https://cw33.com/news/international/ap-international/iran-submits-a-written-response-in-nuclear-deal-talks/ | 2022-08-17T00:46:11Z |
SAN DIEGO, May 25, 2022 /PRNewswire/ -- Raving and Quick Custom Intelligence (QCI) announced that QCI will be the Title Sponsor of the Casino Marketing & Technology Conference and the Host Player Development Conference. The conference will be held at the South Point Casino Hotel & Spa in Las Vegas, July 12th -14th 2022. The conference is the longest running event dedicated to casino marketing and the technology that drives the gaming industry.
Deana Scott, CEO of Raving, said, "Not only are we thrilled to be bringing back an industry event that has informed and motivated thousands of operators since 2003, we are pleased to welcome the market-leading data solutions company Quick Custom Intelligence as the Title Sponsor of the Casino Marketing & Technology Conference. Attendees that have been to a Raving conference expect valuable and candid conversations around the industry's toughest issues. They want current data and tools in a format that sparks conversation and sharing. We're back and we will deliver as promised this July."
Andrew Cardno, CTO & Co-Founder of QCI said, "The Casino Marketing & Technology Conference is an industry leading event where thought leaders from across the industry are able to collaborate, develop ideas and share best practices. The learnings shared at the CMTC provide an invaluable toolset for developing effective marketing plans in this volatile marketplace."
ABOUT RAVING
Raving was founded in 1998 and is a Native-owned, women-managed organization. For over two decades, Raving has partnered with over 152 Tribal Nations and enterprises and 71 commercial properties along with First Nations throughout Canada and internationally in Europe and Asia. From years on the casino floor, we understand all aspects of your gaming and resort operations and the challenges and sticky situations gaming executives face. We pride ourselves on building custom programs tailored to your needs, utilizing evidence-based methodologies to identify the root cause and create lasting solutions.
Our team of over 20 strategic partners, all experienced gaming and hospitality professionals, support Tribal organizations and commercial casinos worldwide in strategically improving their overall operations. Raving produces several events and publications including Raving Host and Player Development Conference; Raving NEXT: Indian Gaming Analytics and Marketing Conference; Casino Marketing and Technology Conference; Tribal Gaming & Hospitality Magazine. Visit www.betravingknows.com to subscribe to our publications or contact Daniel Wood daniel@betravingknows.com, 775-329-7864 to find out more about Raving's products and services.
ABOUT QCI
The QCI Platform aligns player development, marketing and gaming with powerful real-time operational tools developed for the gaming and hospitality industries. QCI has installed their ground-breaking, highly configured software in 55 casino resorts in North America and in over 3,000 sites worldwide. QCI products provide tooling for gaming operators managing over $10 billion in annual gross gaming revenue, these products are built on the QCI Platform, a best-in-class on-premise, hybrid or cloud-based technology that enables fully coordinated activities across gaming or hospitality operations. This data-driven software allows for quick, informed decisions in the ever-changing world of the casino industry and assists casinos in their efforts to optimize resources and profits, manage marketing campaigns and increase customer loyalty. QCI was founded by Dr. Ralph Thomas and Mr. Andrew Cardno. Based in San Diego, QCI also has offices in Las Vegas, St. Louis, Dallas & Phoenix.
View original content to download multimedia:
SOURCE Quick Custom Intelligence | https://www.mysuncoast.com/prnewswire/2022/05/25/deana-scott-ceo-raving-pleased-welcome-market-leading-data-solutions-company-quick-custom-intelligence-title-sponsor-casino-marketing-amp-technology-conference/ | 2022-05-25T19:08:33Z |
ALBANY – When family members pinned on badges and chevrons for eight new Albany Police Department officers during a Thursday-night recognition ceremony, those recent academy graduates were prepared to take their place on the streets.
The ceremony, held at the Albany Municipal Auditorium, also included the announcement of promotions for an additional 18 officers. Eight officers were promoted to corporal, seven to sergeant and three to lieutenant.
Kiwanis Manson, who was promoted to corporal, has been with the department for four years and was excited about her new rank.
“I enjoy serving this community,” the Dawson native said. “At the department, we get a lot of great training. It’s just a great department to be in.”
The importance of family was stressed repeatedly during the event, including speaker Maj. Gen. Joseph Shrader, commanding general of Marine Corps Logistics Command, who is wrapping up a career of more than four decades in a few days.
“You couldn’t do it without (family),” he said.
The military and police serve similar roles in their various uniforms, the general said, sprinkling his speech with experiences from his time in the military and in southwest Georgia.
“We share a love of service, service to this country, our community, to the good order and discipline of the state," he said. "In the community, people depend on police officers to enforce that order and discipline.
“I want to thank you for your service.”
Shrader also gave his audience an overview of leadership qualities he learned during his long military career as both a subordinate and a commander.
His remarks on humility were illustrated by a story from his first days in southwest Georgia. Topping a hill in Pelham and driving 65 miles per hour in a 45 zone, he spotted a police car and was quickly pulled over by the officer.
Shrader handed the officer his license – and his military identification card – and mentioned he was a new officer in command in Albany, confident that he would escape without a citation. The officer returned the ID card and took his license to the police car.
When he returned he had a ticket and a suggestion that Shrader slow down so he would be around to command his Marines for a long time to come. The experience cost him more than $200.
“Leadership is a difficult thing to talk about, because it is an art and a science,” he said. “You have to be a good communicator. I know you’ve all heard that to be a good communicator, you have to be a good listener.
“You must be humble. You have got to have humility. A leader must be present. You can’t lead from behind a desk.”
Among the special recognitions for the evening, Police Chief Michael Persley called out Lt. Victor Camp and Assistant Chief Derrell Smith, who are both departing.
Camp, a veteran of 32 years, is retiring, and Smith is leaving to take on the role of chief at a college campus in Florida.
Persley recounted his first encounter with Vick. As a young man, Persley said he was leaving a restaurant in the early morning hours and Camp followed him for a while. Feeling nervous, Persley turned on his right blinker and made a left, and then he saw blue lights.
He got away without a ticket that night, he said.
“Vick, it’s 32 years and six days,” the chief said of Camp's time in uniform. “From me and the department to you, we want to wish you the best in your future endeavors. I also wanted to take the opportunity to recognize Derrell Smith for 35 1/2 years.”
Officer of the year Christopher Oakes, and civilians of the year Fontashia Thurmond, who was not present, and Deandra Francis, who were given their awards earlier in the year at an Albany City Commission meeting, also were recognized. | https://www.albanyherald.com/news/albany-police-department-welcomes-new-officers-promotes-18-during-ceremony/article_b6ca46b0-ffa8-11ec-a70c-e399babf8aae.html | 2022-07-09T19:23:06Z |
MIAMI, Aug. 29, 2022 /PRNewswire/ -- As a part of their mission to revolutionize America's broken healthcare system, ChenMed's CEO Dr. Chris Chen and CMO Dr. Gordon Chen have released their first book, The Calling: A Memoir of Family, Faith, and the Future of Healthcare [Forefront Books, August 16, 2022], shining a light on how the healthcare system works for itself, not for its suffering patients.
The Calling tells the story of how the Chens created ChenMed, a physician-led, mission-driven company that puts patients from forgotten and underserved communities first. The company recently opened its 100th center.
"Our family knows what it means to struggle, to be poor, to know the battles people wage for quality care within the healthcare system. Now we're leading the charge in a healthcare revolution. Our system delivers improved health for less money and rectifies inequities at the same time. Through our book, we hope to continue to inspire change and transform communities left behind by America's current transaction-driven healthcare system." – Chris and Gordon Chen
Chris and Gordon Chen will initially provide a complimentary copy of The Calling to Primary Care Physicians (PCPs) in New York, Texas, and Florida as they look to recruit doctors to help the organization grow to more needy communities. Eventually, their goal is to get the book in the hands of every PCP across the US.
ChenMed, headquartered in Miami, is a privately owned medical, management and technology company that delivers the high-touch and personalized primary care Medicare-eligible seniors need to enjoy better health. The company operates 100 senior medical centers in 15 states. Named one of Fortune 2020 "Change the World" companies, a "Most Loved Workplace" by Newsweek Magazine, and a certified Great Place to Work® by the Great Place to Work Institute, ChenMed brings concierge-style medicine and better health outcomes to the neediest populations. ChenMed brands include Chen Senior Medical Center, Dedicated Senior Medical Center, JenCare Senior Medical Center and IntuneHealth™. Thanks to its leading healthcare technology organization, CurityTM, ChenMed was recently named a "Best Place to Work in IT" by IDG's Insider Pro and ComputerWorld.
ChenMed's unique physician-led primary care model, proprietary technological capabilities, and impressive results have earned the company recognition by the White House, the Department of Health and Human Services, and the U.K. National Health System. ChenMed has also been featured in publications such as Modern Healthcare, Health Affairs, Forbes, The Economist, The Wall Street Journal, The New England Journal of Medicine, The Guardian, and Medical Economics, which named ChenMed, "Best Primary Care System in the U.S."
For more information:
Ashlee White
Smith Publicity, Inc.
ashlee.white@smithpublicity.com
View original content to download multimedia:
SOURCE ChenMed | https://www.wibw.com/prnewswire/2022/08/29/chenmed-model-transforms-healthcare-provides-much-needed-support-seniors/ | 2022-08-29T15:18:52Z |
TORONTO and VANCOUVER, BC, Aug. 18, 2022 /PRNewswire/ - GCM Mining Corp. (GCM Mining) (TSX: GCM) (OTCQX: TPRFF) and Aris Gold Corporation (Aris Gold) (TSX: ARIS) (OTCQX: ALLXF) announce they have filed the joint management information circular and related meeting materials in connection with their respective special meetings of shareholders to be held on September 19, 2022. The purpose of the meetings is to approve the proposed business combination of GCM Mining and Aris Gold announced on July 25, 2022. The combined entity will continue under the name Aris Mining Corporation and will be a gold producer with increased scale, increased diversification of operating and project development risk, have an improved capital markets profile, and reduced overhead costs.
Pursuant to the transaction, Aris Gold shareholders will receive 0.5 of one GCM Mining share for each Aris Gold share held. At closing, based on the respective share values at the date of announcement of the transaction, GCM Mining and Aris Gold shareholders (excluding the 44% of Aris Gold shares held by GCM Mining) will own approximately 74% and 26% of the combined entity, respectively, on a diluted in-the-money basis.
The Board of Directors of GCM Mining and the Board of Directors of Aris Gold have unanimously approved the transaction and recommend that shareholders vote in favour of the transaction at their respective meetings.
On August 16, 2022, Aris Gold obtained an interim order from the Supreme Court of British Columbia authorizing the holding of the Aris Gold special meeting of its shareholders and matters relating to the conduct of the Aris Gold Meeting. Mailing of the joint management information circular and related meeting materials will begin soon and shareholders of both GCM Mining and Aris Gold should receive them shortly. All of the meeting materials are available on GCM Mining's website at www.gcm-mining.com and on Aris Gold's website at www.arisgold.com, as well as on each company's profile on SEDAR at www.sedar.com. GCM Mining and Aris Gold shareholders should carefully review all of the meeting materials as they contain important information concerning the transaction and the rights and entitlements of the shareholders thereunder.
Completion of the transaction is subject to customary conditions, including GCM Mining shareholder approval, Aris Gold shareholder approval, final approval from the Toronto Stock Exchange, and other regulatory approvals. The transaction is expected to close before the end of September 2022.
GCM Mining is a mid-tier gold producer with a proven track record of mine building and operating in Latin America. In Colombia, the Company is the leading high-grade underground gold and silver producer with several mines in operation at its Segovia Operations. Segovia produced 206,389 ounces of gold in 2021. In Guyana, the Company is advancing its fully funded Toroparu Project, one of the largest undeveloped gold/copper projects in the Americas, which is expected to commence production of more than 200,000 ounces of gold annually in 2024. GCM Mining has equity interests in Aris Gold Corporation (~44%; TSX: ARIS; Colombia – Marmato, Soto Norte; Canada – Juby), Denarius Metals Corp. (~32%; TSX-V: DSLV; Spain – Lomero-Poyatos and Colombia – Guia Antigua, Zancudo) and Western Atlas Resources Inc. (~26%; TSX-V: WA: Nunavut – Meadowbank).
Additional information on GCM Mining can be found at www.gcm-mining.com and www.sedar.com.
Aris Gold is a Canadian mining company listed on the TSX under the symbol ARIS and on the OTCQX under the symbol ALLXF. The Company is led by an executive team with a demonstrated track record of creating value through building globally relevant gold mining companies. In Colombia, Aris Gold operates the 100%-owned Marmato mine, where a modernization and expansion program is under way, and as of April 12, 2022, operates the Soto Norte joint venture, where environmental licensing is advancing to develop a new gold mine. Aris Gold also owns the Juby project, an advanced exploration stage gold project in the Abitibi greenstone belt of Ontario, Canada. Aris Gold plans to pursue acquisition and other growth opportunities to unlock value creation from scale and diversification.
Additional information on Aris Gold can be found at www.arisgold.com and www.sedar.com.
Forward-looking Information
This news release contains "forward-looking information" or forward-looking statements" within the meaning of Canadian securities legislation. All statements included herein are forward-looking, other than statements of historical fact, including without limitation statements relating to: approval by the GCM Mining and Aris Gold shareholders; the satisfaction of the conditions precedent to the transaction, and timing, receipt and anticipated effects of court, regulatory and other consents and approvals. Generally, the forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", "will continue" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Statements concerning mineral resource estimates may also be deemed to constitute forward-looking information to the extent that they involve estimates of the mineralization that will be encountered. The material factors or assumptions used to develop forward-looking information or statements are disclosed throughout this news release.
Forward-looking information and forward-looking statements, while based on management's best estimates and assumptions, are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of GCM Mining, Aris Gold and the resulting entity to be materially different from those expressed or implied by such forward-looking information or forward-looking statement
Although GCM Mining and Aris Gold have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information and forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information or statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information or statements. The forward-looking statements and forward-looking information are made as of the date hereof and each of GCM Mining and Aris Gold disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results. Accordingly, readers should not place undue reliance on forward-looking statements and information.
View original content:
SOURCE Aris Gold Corporation | https://www.kxii.com/prnewswire/2022/08/19/aris-gold-gcm-mining-file-joint-circular-special-meetings-shareholders-approve-business-combination/ | 2022-08-19T01:30:39Z |
Medicare Health Plan in Arizona specifically designed for Medicare beneficiaries living with Diabetes, Heart Failure, Cardiovascular Disease and End Stage Kidney Disease
SCOTTSDALE, Ariz., Sept. 15, 2022 /PRNewswire/ -- Gold Kidney of Arizona, Inc., a subsidiary of Gold Kidney Health Plan has contracted with the Centers of Medicare and Medicaid (CMS) and is launching a Medicare Advantage Chronic-Care Special Needs Plan effective January 1, 2023. Gold Kidney of Arizona will offer the same coverage as Medicare with additional benefits, designed for patients with Chronic Kidney Disease that lead to and include Kidney Failure.
The plan will be available to Arizona residents who have chronic conditions including diabetes, heart failure, cardiovascular and end stage renal disease and are Medicare eligible. Gold Kidney of Arizona will begin enrolling members in its new Medicare Advantage plan beginning October 15, 2022. Our service area includes the counties of Gila, Maricopa, Pima and Pinal in Arizona.
"We are really pleased to offer the Medicare Health Plan in Arizona Intended for Medicare beneficiaries living with chronic conditions that lead to and include kidney failure," said Dave Firdaus, CEO of Gold Kidney Health Plan. "Currently Medicare beneficiaries who live in Arizona with chronic diseases especially ESRD have limited choice of Medicare Advantage coverage. For example, there is no ESRD Medicare C-SNP plan in Maricopa County today."
Under Gold Kidney Health Plan's model of care, a team of experts, including primary care physicians and nephrologists, will collaborate more closely to develop individualized care plans which address each member's unique health care needs. The member will choose a primary care physician, a nephrologist, and be provided a nurse care manager knowledgeable in the patients' chronic conditions to help them understand their coverage and answer questions.
"Our goal is to improve our members' health and delay their disease progression, and if they must start dialysis, we will be with them and their significant others to help them understand and facilitate their choices for receiving either a kidney transplant, starting on dialysis, and/or continuing to live the quality of life they desire" said Kirsten Sorensen, VP of Clinical Services for Gold Kidney Health Plan. "That's why we have partnered with trusted primary care physicians, nephrologists, hospitals, pharmacies, and other providers — to make sure Gold Kidney Health Plan members get the right care at the right time with the right resources. Our mission is to improve our members' health outcomes through empowering our members and providers with improved access to health care, less prior authorizations, lower out of pocket costs, and benefits designed specifically with their daily health care needs in mind."
Gold Kidney of Arizona is a Medicare Advantage Chronic Condition Special Needs Plan with a Medicare contract to offer coverage to individuals diagnosed with Diabetes, Heart Failure, Cardiovascular Disease and End Stage Renal Disease (ESRD).
Press or Provider Contact: Sandra.Howe@GoldKidney.Com
View original content:
SOURCE Gold Kidney Health Plan | https://www.kxii.com/prnewswire/2022/09/15/gold-kidney-health-plan-launches-arizona/ | 2022-09-15T20:57:54Z |
BOSTON (AP) — Red Sox manager Alex Cora said Boston expects to be without multiple unvaccinated players for an upcoming series at Toronto.
Starting pitcher Tanner Houck told the Boston Globe on Sunday that he is not vaccinated against COVID-19 and won’t pitch during the four-game series beginning Monday, April 25. He would have been in line to start the second game.
To enter Canada, the Canadian government requires a person must have received a second COVID-19 vaccine dose — or one dose of Johnson & Johnson — at least 14 days prior to entry.
“I’m bummed that I won’t be able to make that start,” Houck said.
Cora was asked after an 8-1 win over Minnesota on Sunday if he expected to be missing other players.
“Yeah,” Cora said. He was not asked a follow-up question and then ended the press conference.
Asked earlier about Houck, Cora said: “We knew it beforehand, so we’ll plan accordingly.”
Players sidelined by COVID-19 vaccine issues are not paid and do not accrue major league service time while on the restricted list.
Oakland placed catcher Austin Allen and left-handers A.J. Puk and Kirby Snead on the restricted list for the Athletics’ series in Toronto this weekend.
“I think it’s a personal choice for everyone whether they get it or not,” Houck told The Globe.
___
More AP MLB: https://apnews.com/hub/MLB and https://twitter.com/AP_Sports | https://cw33.com/sports/ap-sports/cora-sox-to-miss-multiple-unvaccinated-players-at-toronto/ | 2022-04-18T20:27:36Z |
COLUMBIA, Mo., June 7, 2022 /PRNewswire/ -- American Outdoor Brands, Inc. (NASDAQ Global Select: AOUT), an industry leading provider of products and accessories for rugged outdoor enthusiasts, today announced that Luis G. Marconi, 55, has joined the company's Board of Directors as an independent director. Most recently as Group Vice President of Grocery Products at Hormel Foods Corporation, Marconi is an accomplished P&L leader, Fortune 500 corporate officer, and board member with over 34 years of leadership experience in the food and beverage industry in the United States and Latin America, with depth in strategy, M&A, joint ventures, and board governance.
Barry M. Monheit, Chairman of the Board of American Outdoor Brands, said, "Luis' experience and expertise are a tremendous fit with our strategic objectives, which include growing our diverse consumer outdoor brand portfolio, both organically and through potential acquisitions. In addition, his experience in leading and growing consumer brands globally in international markets at both Hormel Foods Corporation and The Quaker Oats Company will allow him to make meaningful contributions toward our efforts to grow our business in both domestic and international markets."
Marconi began his career with The Quaker Oats Company, where he served for nearly ten years as Group Product Manager for the company's Andean Region. He then joined Hormel Foods, a $12 billion global branded food company based in Austin, Minnesota, where he built an accomplished 22-year career, initially as the Sales & Marketing Manager of Latin America, and most recently as Group Vice President of the $3+ billion Grocery Products division, the second largest of the company. He also led a Hormel Foods/Rica Rondo Joint Venture in Colombia in the late 1990's.
Marie Wadecki, Chair of the Nominations and Corporate Governance Committee, said, "We are pleased that our recent search has resulted in the appointment of Luis to our board. His experience and skill set demonstrate our commitment to ensuring that our board composition can best address the evolving needs of our business. With this appointment, our board now comprises six directors, half of whom represent diverse communities: female, Latino."
Marconi graduated from Pontifical Xaverian University in Colombia with a Bachelor of Science degree in Industrial Engineering and received his MBA from Icesi University. He is also a graduate of the University of Minnesota Carlson School of Management Executive Program in Minneapolis, Minnesota.
American Outdoor Brands, Inc. (NASDAQ Global Select: AOUT) is an industry leading provider of outdoor products and accessories, including hunting, fishing, camping, shooting, and personal security and defense products, for rugged outdoor enthusiasts. The company produces innovative, top quality products under its brands Caldwell®; Wheeler®; Tipton®; Frankford Arsenal®; Hooyman®; BOG®; MEAT!; Grilla Grills®; Uncle Henry®; Old Timer®; Imperial®; Crimson Trace®; LaserLyte®; Lockdown®; ust®; BUBBA®; and Schrade®. For more information about all the brands and products from American Outdoor Brands, Inc., visit www.aob.com.
Contact:
Liz Sharp, VP, Investor Relations
lsharp@aob.com
(573) 303-4620
View original content to download multimedia:
SOURCE American Outdoor Brands, Inc. | https://www.mysuncoast.com/prnewswire/2022/06/07/luis-g-marconi-joins-board-american-outdoor-brands/ | 2022-06-07T11:37:20Z |
3 in 10 Earning Over $250,000 Continue to Live Paycheck to Paycheck
Nearly 40% of Those Earning Over $250,000 Cite Paying for a Family Members' Expenses as a Driver of Financial Distress
SAN FRANCISCO, June 27, 2022 /PRNewswire/ -- LendingClub Corporation (NYSE: LC), the parent company of LendingClub Bank, America's leading digital marketplace bank, today released findings from the 11th edition of the Reality Check: Paycheck-To-Paycheck research series, conducted in partnership with PYMNTS.com. The Financial Distress Factors Edition examines the financial lifestyle of U.S. consumers who live paycheck to paycheck, the factors that cause financial distress – life-cycle events or life-altering events – and the impact of these financial stressors on their lives.
Key Takeaways: 65% of paycheck-to-paycheck consumers have experienced a financially stressful event in the past three years, with sudden income disruptions such as losing a job being the most common. Moreover, half of paycheck-to-paycheck consumers say their salary only covers basic expenses and is one reason behind their financial distress.
"Consumers have experienced a tough last couple of years as different factors have affected their financial lifestyle and there seems to be little relief in sight," said Anuj Nayar, LendingClub's Financial Health Officer. "While the specific nature of the event that causes financial distress may vary, it's clear we all need to plan for the unexpected. It's simply a matter of time before something will come up to knock even the best laid financial plans askew."
Living paycheck to paycheck means devoting all of one's salary to expenses with little to nothing left over at the end of the month, yet many of these consumers remain credit-worthy, actively managing their cash flows in real time. Paycheck-to-paycheck consumers fall into two categories: those who can pay their monthly bills easily and those who struggle to do so.
The Impact of Major Life Events on Living Paycheck To Paycheck
To understand the drivers of financial distress, this report surveyed consumers about life-cycle events such as getting married or divorced, birth of a child, moving residences and retirement, and financially life-altering events such as a job loss, serious illness, disability, or major unexpected expenses such as a natural disaster or lawsuit.
According to the data, more than half of U.S. consumers have faced either a life-cycle event or a life-altering event in the last three years. Life-cycle events, such as marriage or having a child, are the most common events, with 38% of consumers overall having experienced these situations in the last three years. The share jumps to 51% among millennials but drops to 30% among baby boomers and seniors. Life-altering events such as losing a job or facing serious illness in the household occurred to 33% of all consumers in the last three years.
While low income is cited as a cause of financial distress, paycheck-to-paycheck consumers from high-income brackets and large households cite paying for a family member's expenses as a driver of financial distress. In fact, nearly 40% of paycheck-to-paycheck consumers earning more than $250,000 say this is a factor driving their financial struggles.
How Paycheck-To-Paycheck Consumers Save
One in five consumers living paycheck to paycheck have spent more than what they have earned in the last six months, with those struggling to pay bills seeing their savings cut in half over the past year. Close to half of all paycheck-to-paycheck consumers say their salary only covers basic expenses and is a reason behind their financial distress. While many consumers leverage credit as a financial tool to manage expenses and cash flow during financially distressing events, high-income consumers tend to use it more.
"Setting an automatic transfer to a savings account, even if it's a small amount, can help you weather the next storm because it's not if you'll need the cash, but when. Credit can also be an effective tool to help with expenses during financially distressing events, but those struggling financially should exercise caution," continued Nayar. "Credit card interest rates are rising, and, if you don't intend to pay your bills in full monthly, you could potentially get into a steep revolving debt trap. For those looking for relief, consider refinancing high-interest debt into a lower cost installment loan."
To view the full report, visit: https://www.pymnts.com/study/reality-check-paycheck-to-paycheck-financial-distress-consumer-savings-credit/
Methodology
New Reality Check: The Paycheck-To-Paycheck Report is based on a census-balanced survey of 3,708 U.S. consumers conducted from May 10 to May 23. The Paycheck-To-Paycheck series expands on existing data published by government agencies such as the Federal Reserve System and the Bureau of Labor Statistics to provide a deep look into the elements that lie at the backbone of the American consumer's financial wellness: income, savings, debt and spending choices. Our sample was balanced to match the U.S. adult population in a set of key demographic variables: 52% of respondents identified as female, 32% were college-educated and 36% declared incomes of over $100,000 per year.
About LendingClub
LendingClub Corporation (NYSE: LC) is the parent company of LendingClub Bank, National Association, Member FDIC. LendingClub Bank is the leading digital marketplace bank in the U.S., where members can access a broad range of financial products and services designed to help them pay less when borrowing and earn more when saving. Based on more than 150 billion cells of data and over $70 billion in loans, our advanced credit decisioning and machine-learning models are used across the customer lifecycle to expand seamless access to credit for our members, while generating compelling risk-adjusted returns for our loan investors. Since 2007, more than 4 million members have joined the Club to help reach their financial goals. For more information about LendingClub, visit https://www.lendingclub.com.
CONTACT:
For Investors: IR@lendingclub.com
Media Contact: Press@lendingclub.com
PYMNTS Contact: information@PYMNTS.com
View original content to download multimedia:
SOURCE LendingClub Corporation | https://www.wibw.com/prnewswire/2022/06/27/65-percent-paycheck-to-paycheck-consumers-experienced-financially-stressful-event-past-three-years/ | 2022-06-27T12:20:56Z |
The Dating App That Filters Potential Matches By Preferred Date Destinations Is On A Mission To Feature Local Businesses And Solve "Small Talk"
AUSTIN, Texas, Aug. 2, 2022 /PRNewswire/ -- Desti, the dating and social application designed to allow users to filter potential matches based on date destinations, announced today its official launch in Austin, Texas. Desti provides users a first-of-its-kind dating app experience unlike any other platforms on the market by not only saving users from the dreaded "small talk" of existing dating apps, but also by allowing potential matches to identify where and when they plan to meet up in their city.
"It's been about 10 years since dating apps like Tinder and Bumble emerged,'' said John Taylor, CEO of Desti. "In that time the landscape of social media has evolved but they haven't as much. We feel that Desti creates a new lane and is positioned for this generation of users."
Desti's innovative technology gives users control of their own experience by letting them filter who they see based on where they want to go, while simultaneously allowing users to discover hundreds of local businesses through engaging Desti videos. In an effort to drive people to start conversations with other users, Desti has removed the "send like'' feature. By removing the feature to only "like'' people and never start a conversation with them, Desti is on a mission to save users time and energy by avoiding the small talk and rather, starting a natural social conversation.
"When developing Desti, our goal was to create a distinctive user experience that offered at least 10 times more efficiency than competitors," said Nick Dominguez, COO and Lead Designer/Developer of Desti. "We decided to bet on short form video being the future and provide people a way to communicate with far less friction. If you take a look at any woman's dating app inbox it's not hard to see the issue. I looked to books I read like Zero to One by Peter Thiel for capitalizing on the last movers advantage."
Desti was created with single women's best interest in mind. Managing any current dating app is a full time job, and between drowning in small talk, boring dead-end conversations, terrible one-liners, and flakey matches that never go anywhere, Desti's founders saw there was clear friction in communication. Desti wants to bridge the gap between matching with someone and never conversing with them, and help foster real relationships.
"Desti's mission to shift online dating towards in-person dating is a change we can all get behind," said Julia Chesbrough, designer at Desti and former designer at Hinge. "When I heard that Desti wanted to bring people off of their phones and into the real world, pushing people to meet their matches in real life, I was really excited. Having worked in the dating app industry before, I knew just how difficult it was to motivate people to get outside their comfort zones and onto a date."
Desti launched on the App Store on July 31, 2022 for all smartphone users in the Austin area on iOS.
Desti is a first-of-its-kind dating and social app that gives users the control over their own experience by letting them filter who they see based on where they want to go. The goal is for (mainly women) to save time and energy to avoid the "Hey what's up" and start with the sushi place they love. In addition to offering a more ideal start to any conversation, it is important to Desti to allow users to discover exciting places in their city through in-house TikTok-style videos.
Please find additional assets HERE
View original content to download multimedia:
SOURCE Desti | https://www.mysuncoast.com/prnewswire/2022/08/02/first-of-its-kind-dating-app-desti-launches-austin-texas/ | 2022-08-02T15:52:11Z |
Supreme Court limits discrimination claims for emotional distress
WASHINGTON (AP) — The Supreme Court on Thursday upheld the dismissal of a discrimination lawsuit filed by a deaf, legally blind woman against a physical therapy business that wouldn’t provide an American Sign Language interpreter for her appointments.
In a 6-3 ruling with conservatives in the majority, Chief Justice John Roberts wrote that businesses that receive federal health care money can’t be sued for discrimination under the Affordable Care Act when the harm alleged is emotional, not financial.
Justice Stephen Breyer wrote in dissent that people who suffer discrimination often feel humiliation or embarrassment. “It is difficult to square the Court’s holding with the basic purposes that antidiscrimination laws seek to serve. One such purpose, as I have said, is to vindicate ‘human dignity and not mere economics,’” Breyer wrote, citing an opinion from his onetime boss, Justice Arthur Goldberg, in a key Civil Rights-era case.
Breyer noted in his opinion that some anti-bias laws, including against workplace discrimination, allow for damages for emotional distress.
The current case began when the woman, Jane Cummings, asked for an ASL interpreter for physical therapy appointments to treat chronic back pain with Premier Rehab Keller, in the Dallas-Fort Worth area.
Cummings communicates primarily in ASL. But Premier Rehab said Cummings could “communicate with the therapist using written notes, lip reading, or gesturing,” Roberts wrote.
She went elsewhere, but then sued the business, asking for a court order against Premier Rehab and damages for emotional distress. Lower courts dismissed the lawsuit.
Copyright 2022 The Associated Press. All rights reserved. | https://www.mysuncoast.com/2022/04/28/supreme-court-limits-discrimination-claims-emotional-distress/ | 2022-04-29T23:19:15Z |
Services for Jewell Mayes Thompson Slider, 71, of Temple will be 4 p.m. Friday at 2727 A S. 37th St. in Temple (behind Johnny’s Cleaners).
Mrs. Slider died Thursday, May 19.
She was born July 20, 1959, in Temple to Johnnie Mae Booker and Jewel Mayes. She was raised in Temple and attended Dunbar High School. She worked for the Four Seasons Nursing Home Country Club and Southland Villa Nursing Home. She married Willie Arthur Thompson in 1970 and later married Alvin Slider Sr. in 1986.
She was preceded in death by both of her husbands; and a daughter, Marshalle Evette Thompson Rector.
Survivors include a son, Rodrick Dewayne Thompson of Oklahoma City; a daughter, LaShaun Demetria Thompson of Temple; two brothers, Euell Booker and Bobby Ray Booker, both of Temple; a sister, Jerline Singleton; and seven grandchildren.
Don D. Summers Funeral Home in Temple is in charge of arrangements. | https://www.tdtnews.com/obituaries/article_ab3ea4cc-dc75-11ec-9709-5fffcdcc4298.html | 2022-05-26T08:57:09Z |
VERO BEACH, Fla., June 7, 2022 /PRNewswire/ -- Watercrest Myrtle Beach Assisted Living and Memory Care was officially welcomed to the community with a celebratory ribbon-cutting ceremony by the Myrtle Beach Area Chamber of Commerce. The ribbon-cutting ceremony coincided with the Cinco de Mayo holiday for a spirited fiesta for residents, families, and community partners celebrating the newly built community. The 98-unit, resort-style senior living community recently welcomed its first residents to their new home in the idyllic setting of Myrtle Beach, South Carolina.
"We are honored to be part of this spectacular community and thank the Myrtle Beach Area Chamber of Commerce and our community partners for their outstanding partnerships," said Hunter Weaver, Executive Director of Watercrest Myrtle Beach. "We look forward to growing relationships and welcoming seniors to our Watercrest family
Watercrest Myrtle Beach has already received widespread recognition as recent recipient of the 2022 Best of the Grand Strand for Assisted Living and the Outstanding Creative Landscape Design by the City of Myrtle Beach Community Appearance Board. The exterior landscaping of Watercrest Myrtle Beach boasts a PGA-worthy putting green with purposeful awnings for shade and individual gardening stations to appeal to horticulturists and nature lovers alike. The illuminated walking paths are surrounded by lush lawns and interwoven amongst rockscaped ponds and gorgeous arbors to create destinations and relaxing gathering spaces.
Ideally located at 6151 Colline Verdi Way, Watercrest Myrtle Beach is nestled amongst miles of uninterrupted shoreline and championship golf courses in a beautiful coastal community. For information, please contact the community at 843-483-6740.
With multiple senior living projects in development throughout the southeast, Watercrest Senior Living Group is setting new standards of quality for seniors and their families in the development of upscale senior living communities. Watercrest Macon is one of two senior living development projects partnered between Watercrest, Corecam Capital Partners, and Peninsula Alternative Real Estate. Their second project, Watercrest Macon Assisted Living and Memory Care recently opened in Macon, Georgia.
Watercrest Senior Living Group was founded to honor our mothers and fathers, aspiring to become a beacon for quality in senior living by surpassing standards of care, service and associate training. Watercrest senior living communities are recognized for their luxury aesthetic, exceptional amenities, world-class care, and innovative memory care programming offering unparalleled service to seniors living with Alzheimer's and dementia. A certified Great Place to Work, Watercrest specializes in the development and operations of assisted living and memory care communities and the growth of servant leaders. For information, visit www.watercrestseniorliving.com.
View original content to download multimedia:
SOURCE Watercrest Senior Living Group | https://www.wibw.com/prnewswire/2022/06/07/myrtle-beach-area-chamber-commerce-formally-welcomes-watercrest-myrtle-beach-assisted-living-memory-care/ | 2022-06-07T15:38:30Z |
- 2nd edition of the index for 2022 from BritishAmerican Business and Bain & Company examines the strength of the transatlantic trade, business and economic relationship
- American companies cite fractured UK-EU relations, rise in business tax and shortages of skilled workers in UK as key anxieties for future British investments and the business climate
- Report highlights importance of transatlantic business relationships and the transatlantic corridor as key source of strength amid rising geopolitical and economic tensions
LONDON, July 18, 2022 /PRNewswire/ -- US companies operating in the UK have seen their confidence in the British business environment dented by the ongoing impact of Brexit, along with anxieties over a rising corporate tax burden and increasing shortages of skilled labour, according to the latest Transatlantic Confidence Index issued today by BritishAmerican Business and Bain & Company.
The blow from Brexit to American businesses' view of the business and investment environment offered by the UK is the biggest change in the Confidence Index from the high levels shown by its launch edition last year.
The "progressive impact of the UK-EU split" is the predominant reason for a fall in sentiment seen among US firms in the index. US survey respondents cited this as one of the "most unattractive aspects of doing business in Britain", with persistent challenges over the UK-EU relationship having persisted, creating heightened political and regulatory uncertainty.
American businesses also singled out the prospect of a rising business tax burden and difficulties in attracting skilled workers as among their top concerns affecting their confidence for future investment in UK operations.
Today's report highlights that heightened concern over the UK business tax regime is likely to have been fuelled by the UK Government's controversial plan to increase the main rate of corporation tax next year from 19% to 25%.
The contentious corporation tax proposal has been thrust to the centre of political debate in the UK, with senior Conservative MPs and ministers who are vying to succeed Boris Johnson as the party's leader and the next UK Prime Minister, taking starkly opposing positions over the plan.
UK skills shortages emerged in the Confidence Index as the other key concern among US business operating in Britain. Despite the UK's post-Brexit efforts to relax its immigration framework to allow more workers to enter the country, a significant number of American firms reported ongoing labor shortages which they said cannot be met locally. The number of survey respondents with a negative view of the UK immigration and visa system outweighed those with a positive view by eight-to-one, making this the most negative overall factor in the UK business environment assessed by the Index.
However, despite these increased concerns over Brexit, taxation and skills, US businesses overall sentiment in the UK was only marginally lower than a year ago, with survey participants still reporting relatively high confidence. On a scale of 1 to 10, the average confidence rating reported fell to 7.3 for 2022, from 7.8 in 2021, while one in five respondents said their confidence in the UK is increasing. Although positive, this is fewer than in the previous edition of the Index. Last year, almost a quarter of companies expected their confidence in UK business conditions to increase over the next two to three years.
Today's report reveals that what US companies want to see from the UK is clear and that to ensure their future investments they want the British Government to look to repair its political and trade relationships with the European Union – an issue also at the forefront of the race to be the next UK Prime Minister.
Pursuing a US-UK Free Trade Agreement remains a high priority for US companies, although less notably than in the previous edition of the Index. The report finds this may reflect the current, unfavourable transatlantic political conditions for such a deal.
Instead, companies are more focused on solving the immediate problems in the transatlantic corridor without a full FTA. Specifically, companies are eager to improve business mobility and want to pursue joint initiatives around sustainability to forge new business opportunities. US companies also would like to see greater clarity around the UK's industrial strategy and support an expanded trade agenda with the rest of the world. However, the UK's "Levelling Up" agenda was not seen as a priority for attracting increased foreign direct investment from the US.
UK business confidence in the US continues to run at high levels
UK companies meanwhile have much higher confidence in the US as a place to conduct business than US companies have in the UK. One the same one-to-ten scale, UK respondents' average UK confidence rating was 8.0.
However, UK companies struggle with the US immigration system and practical barriers to business mobility. Problems associated with business mobility are seen as the most unattractive aspect of the US by UK companies, which also cited concerns over the US tax environment and political stability.
UK companies have a straightforward request from the US government: To attract future investment, they want the US to recommit to a clear trade agenda. An overwhelming majority of UK companies want the US to relaunch a comprehensive global trade agenda. They also want the US to take the lead on issues around sustainability. UK companies indicated moderated views of the Biden Administration's "worker-centric" trade policy with their detailed responses suggesting they respondents do not fully understand what the policy entails. At the same time, UK companies strongly favour US-UK trade talks continuing.
Transatlantic corridor a source of strength amid geopolitical and economic stress
Today's report emphasises the case for a strong transatlantic trade corridor between the US and UK as trusted partners, with the case for this being underlined at a time of rising geopolitical and economic stresses.
Duncan Edwards, CEO, BritishAmerican Business said: "The results from this survey illustrate that whilst overall confidence in the UK-US relationship remains very strong, transatlantic businesses operating in the United Kingdom are slightly less confident in it as a place to do business than last year. Concerns over the UK's post-Brexit relationship with the European Union, its future tax competitiveness, and perceived restrictions to labour mobility and access to talent are the driving force behind this slip in confidence.
"Addressing these concerns must be prioritised by the next Prime Minister and their Government if the UK is to stay as the leading place to do business for transatlantic investors. However, we are nonetheless encouraged to see how UK companies are taking advantage of the United States' business-friendly environment to accelerate growth and expand their business. The US government would do well to capitalize further on this high level of confidence in its market".
Jonathan Frick, partner at Bain & Company in London, said: "The business and economic partnership between Britain and America is a vital bulwark of stability. With economic stresses and recession fears rising, along with intensified geopolitical tensions, these relationships have rarely been more important. It's the importance of these connections to the UK and US, as an anchor for businesses in both countries, that led us to partner with BritishAmerican Business on this study.
"It's reassuring to see that transatlantic ties remain very strong. But the survey also highlights some important areas of concern – on both sides of the Atlantic – that both businesses and our governments should be thinking hard about, so that we can continue to bolster the transatlantic corridor to our mutual advantage."
Media contacts
For any questions or to arrange an interview, please contact:
Bain & Company: Gary Duncan (London) — Tel: +44 (0) 7788 163 791 Email: gary.duncan@bain.com
BritishAmerican Business: Mazar Ahmed (London) Tel: +44 (0)20 7290 9883 or +44 7366 300036 Email: mahmed@babinc.org
Notes to Editors
This is the second edition of the Transatlantic Confidence Index report issued by BritishAmerican Business and Bain & Company. The index survey measured the confidence of US companies that are active in the UK. This year, it also measured UK companies' confidence in the US. When appropriate, data from the inaugural survey are also referenced for comparison. Seventy-seven major companies responded to the survey (54 US companies and 23 from the UK). Together, they represent more than 4,000 years of activity and employ more than 288,000 people.
The respondents are based in all four nations and major regions across the UK and in all 50 US states. The respondents represent a range of sectors, including financial services, technology, healthcare, media, telecommunications, manufacturing, and others. While many factors influence confidence, our Transatlantic Confidence Index focused on overall confidence for investing and trading, short-term investment prospects, and the health of the US-UK relationship overall.
About BritishAmerican Business
BritishAmerican Business is the leading transatlantic trade association incorporating the British-American Chamber of Commerce in the US and the American Chamber of Commerce in the UK.
We are committed to strengthening the economic corridor between the United States and the United Kingdom by supporting policies and action that protect and enhance the environment for transatlantic trade and investment.
We convene and serve a growing network of companies and business leaders through networking opportunities, bespoke programming and marketing platforms.
About Bain & Company
Bain & Company is a global consultancy that helps the world's most ambitious change makers define the future.
Across 65 cities in 40 countries, we work alongside our clients as one team with a shared ambition to achieve extraordinary results, outperform the competition, and redefine industries. We complement our tailored, integrated expertise with a vibrant ecosystem of digital innovators to deliver better, faster, and more enduring outcomes. Our 10-year commitment to invest more than $1 billion in pro bono services brings our talent, expertise, and insight to organizations tackling today's urgent challenges in education, racial equity, social justice, economic development, and the environment. We earned a gold rating from EcoVadis, the leading platform for environmental, social, and ethical performance ratings for global supply chains, putting us in the top 2% of all companies. Since our founding in 1973, we have measured our success by the success of our clients, and we proudly maintain the highest level of client advocacy in the industry.
View original content to download multimedia:
SOURCE Bain & Company | https://www.kxii.com/prnewswire/2022/07/18/brexit-tax-skills-anxieties-dent-us-companies-sentiment-british-business-environment-despite-strong-overall-confidence-uk-transatlantic-confidence-index-finds/ | 2022-07-18T19:21:54Z |
Group seeking statewide vote on legal pot submits signatures
OKLAHOMA CITY (AP) — A group seeking a statewide vote on whether to fully legalize adult use of marijuana in Oklahoma submitted boxes of signatures on Tuesday with hopes of getting the question on the November ballot.
Oklahomans for Sensible Marijuana Laws submitted more than 164,000 signatures to the Office of the Secretary of State, far more than the roughly 95,000 they need to qualify State Question 820 for the ballot. They also beat the Aug. 1 deadline they had by nearly a month.
Campaign advisor Ryan Kiesel, an attorney and former Democratic state lawmaker, said the extra signatures and the additional time should ensure the question makes it on the November general election ballot.
“I think it’s very unlikely that there’s a credible challenge to our process that could delay this,” Kiesel said.
If approved by voters, the question would legalize the use of marijuana for any adult over the age of 21. Marijuana sales would be subjected to a 15% excise tax on top of the standard sales tax, and the revenue it generates would be used to help fund local municipalities, the court system, public schools, substance abuse treatment and the state’s general revenue fund.
The current 7% excise tax on medical marijuana sales generates about $5 million in state revenue each month, plus another roughly $6 million each month in state and local sales taxes, according to figures from the Oklahoma Tax Commission.
The proposal also outlines a judicial process for people to seek expungement or dismissal of prior marijuana-related convictions.
“We create a very simple, efficient, low-cost way for Oklahomans to be able to get those charges and convictions off their record,” Kiesel said.
Oklahoma already has one of the most robust medical marijuana programs in the country, with roughly 10% of the state’s residents having state-issued medical cards that allow them to purchase, grow and consume marijuana. Kiesel said full legalization would dovetail with the state’s existing medical marijuana program, but allow adults without a license, including those who visit from out of state, to purchase marijuana.
The Yes on 820 campaign raised about $70,000, all of it from two advocacy groups: New York-based Drug Policy Action, which advocates for sensible drug laws, and Washington, D.C.-based New Approach Advocacy Fund, which supports cannabis reform in states.
It’s also likely that a marijuana question on the ballot in November could increase voter turnout. About 892,000 voters cast ballots on the medical marijuana question in June 2018 midterm primary election. By comparison, only about 528,000 voters cast ballots in the governor’s race in last week’s midterm primary election.
A separate proposal that would legalize marijuana in Oklahoma through a constitutional amendment is still in the signature gathering phase.
___
Follow Sean Murphy at www.twitter.com/apseanmurphy
Copyright 2022 The Associated Press. All rights reserved. | https://www.kxii.com/2022/07/06/group-seeking-statewide-vote-legal-pot-submits-signatures/ | 2022-07-06T16:29:51Z |
NEW YORK, June 30, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Axsome investors who were adversely affected by alleged securities fraud between December 30, 2019 and April 22, 2022. Follow the link below to get more information and be contacted by a member of our team:
AXSM investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07, the Company's medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application ("NDA") on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration ("FDA") reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Axsome during the relevant time frame, you have until July 12, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
SOURCE Levi & Korsinsky, LLP | https://www.kxii.com/prnewswire/2022/06/30/axsm-lawsuit-alert-levi-amp-korsinsky-notifies-axsome-therapeutics-inc-investors-class-action-lawsuit-upcoming-deadline/ | 2022-06-30T11:09:11Z |
A 4-year-old girl in Baton Rouge, Louisiana, has died after her grandmother forced her to drink whiskey, police say.
The girl's blood alcohol content was 0.680%, a "lethal dosage," according to the arrest warrant. A level of .25% can cause alcohol poisoning, and anything higher than .40% can lead to a coma or death, according to a University of Notre Dame chart.
Roxanne Record, 53, and the girl's mother, Kadjah Record, 28, were booked into the East Baton Rouge Parish Prison for first-degree murder, according to inmate records.
It is unclear whether either woman has an attorney.
The two women became angry with the child on Thursday because she "may have drunk from a Canadian Mist bottle" that was on a counter, the warrants said.
The grandmother then forced the girl "to consume the remainder of the bottle which was possibly over half full while on her knees in the hallway," the warrants said.
The mother was present and didn't try to intervene, according to police, according to police.
Kadjah Record didn't seek medical help for her daughter until the girl stopped breathing, according to the warrants. First responders tried to perform lifesaving measures but were not successful.
Roxanne Record told police "that she messed up and that she wanted to take full responsibility for the death of the victim," the warrants stated.
"The defendant [Roxanne Record] stated that this went too far and that she ruined everyone's lives," but didn't elaborate, the warrants said.
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article. | https://www.albanyherald.com/news/4-year-old-dies-after-grandmother-forces-her-to-drink-whiskey-police-say/article_dcffebd0-4491-5f30-83e6-e071870e5262.html | 2022-04-23T21:05:31Z |
EXTON, Pa., June 13, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will unveil its new Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at BIO International Convention, taking place in San Diego, CA from June 13-16, 2022.
Daikyo Crystal Zenith® (CZ®) is a technologically advanced cyclic olefin polymer containment and delivery system that offers an alternative to glass, mitigating the risk of breakage and reducing the chance of particulates, contamination, and extractables.
The 2.25mL CZ Insert Needle Syringe System is an expansion upon the 1mL Insert Needle Syringe System offering. Until now, the syringe system has only been available in sizes up to 1mL, but the new 2.25mL size allows for larger volume injections. As market traction on larger dose injections grows, the new CZ syringe system size will help pharmaceutical companies to bring their product to patients in a safe and most user-centric model possible.
"By creating a larger fill volume in our high-quality CZ Insert Needle Syringe System, we're able to answer the needs of more patients with a safe and reliable containment solution," said Li Chen, VP and GM, Biologics at West. "Where patients previously may have needed multiple injections to achieve their dose, the 2.25mL Insert Needle Syringe System will allow for fewer or less frequent injections enabling an easier patient experience."
West has partnered with Daikyo in an exclusive distributor arrangement to provide the CZ Insert Needle Syringe Systems syringe globally.
To learn more about the Daikyo CZ 2.25mL Insert Needle Syringe System, visit https://www.westpharma.com/products/prefillable-systems/daikyo-syringe-systems/daikyo-crystal-zenith-insert-needle. For more about West products and services, visit www.westpharma.com.
Forward-Looking Statements
Certain forward-looking statements are included in this press release. They use words such as "mitigating," "answer," "allow," and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. Specifically, there is no certainty that the Crystal Zenith® 2.25mL syringe system will achieve any particular result. These forward-looking statements involve a number of risks and uncertainties. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: customers' changing inventory requirements and manufacturing plans; customer decisions to move forward with our new products and product categories; average profitability, or mix, of the products we sell; dependence on third-party suppliers and partners; interruptions or weaknesses in our supply chain; and the ability to meet development milestones with key customers. These important factors are not all inclusive. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2021. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year.
Headquartered in Exton, Pennsylvania, and in business for nearly a century, West in its fiscal year 2021 generated $2.83 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd. Crystal Zenith technology is licensed from Daikyo Seiko, Ltd
View original content to download multimedia:
SOURCE West Pharmaceutical Services, Inc. | https://www.mysuncoast.com/prnewswire/2022/06/13/west-introduces-daikyo-crystal-zenith-225ml-insert-needle-syringe-system-bio-international-convention/ | 2022-06-13T11:36:14Z |
LAGUNA HILLS, Calif. and SHANGHAI and BOCHUM, Germany, April 21, 2022 /PRNewswire/ -- Wallaby Medical ("Wallaby" or the "Company"), a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke, today announced that it has acquired phenox GmbH, including phenox's femtos GmbH ("femtos"), (together "phenox"), a German-based global innovation and technology leader in the neurovascular space, for a total consideration of approximately EUR 500 million including milestone payments. The acquisition is one of the largest cross-border transactions in the medical device industry globally in recent years and is driven by strong growth opportunities in both product portfolio and geographic coverage. It will enable the combined company to become a global leader in providing a wide range of neurovascular technologies and solutions to its customers and patients around the world, including in the U.S., China, Europe, Japan and other international markets.
The transaction has received all necessary regulatory approvals and has been completed. Michael Alper, CEO of Wallaby, will become CEO of the combined organization. Prof. Dr.-Ing. Hermann Monstadt, Founder of phenox, will assume the role of Managing Director of phenox. All current phenox product brands will be retained.
Wallaby, with its main offices in Laguna Hills, California and Shanghai, China achieves a significant portion of sales of its world-class and premier-quality products in the U.S. and other major developed markets. phenox, headquartered in Bochum, Germany, provides a broad portfolio of neurovascular devices to treat ischemic and hemorrhagic strokes that are sold in over 45 countries worldwide. The two companies have been strategic partners since 2019. phenox has been the exclusive distributor for Wallaby's Avenir® Coil System in the U.S. and European markets as well as for Wallaby's Esperance™ Aspiration Catheters in the U.S. market.
As part of the transaction, Wallaby also acquired femtos, which develops and manufactures next generation neurovascular devices for treating stroke, with special expertise in femto-second laser technology for the manufacturing of stents and other implantable devices. femtos serves as an incubator for next generation medical technologies and has already developed two CE approved products.
"The acquisition is a natural next step in the relationship of both companies and a transformational step in achieving our vision of saving the most lives affected by stroke", said Michael Alper. "The Wallaby-phenox combination will have deep roots in Europe and China, with a strong presence in the U.S., and a recent entrance into the Japan market. By combining the highly complementary product pipelines of the two companies, we will be able to offer a full spectrum of world-class interventional neurovascular products and solutions. The broadened product portfolio, enhanced R&D capability and expanded geographic coverage will provide Wallaby-phenox with an unparalleled competitive edge as we strive to become a global leader in the neurovascular market."
"I am very pleased to be joining Wallaby," said Hermann Monstadt. "Over the last 17 years we have built a company that is committed to delivering optimal solutions for our customers and patients. Through our past collaboration with Wallaby, I have come to deeply respect this organization and recognize our joint commitment to quality and innovation. This transaction will enable phenox's technology to be further developed with Wallaby's strong resources while also allowing phenox's products to reach new markets, and creating significant opportunities for the combined company."
Wallaby funded the acquisition of phenox from the proceeds of its Series D financing round supported by leading healthcare investors.
Media Contacts
Brunswick Group (U.S.)
Rachael Collins
wallaby@brunswickgroup.com
+1 (646) 464-4657
Brunswick Group (China)
Linjia Dai
wallaby@brunswickgroup.com
+86 15652702921
Brunswick Group (Germany)
Nina Jungcurt
wallaby@brunswickgroup.com
+49 1748812966
About Wallaby Medical
Wallaby Medical is a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke. Wallaby 's product portfolio includes the Avenir® Coil System, a technically differentiated neuro embolic coil system for treating intracranial aneurysms and other neurovascular abnormalities, the Esperance™ Aspiration Catheter, cleared in the U.S. and China for ischemic stroke treatment procedures, and the Esperance™ Distal Access Catheter, which was approved for delivery assistance in China. In addition, Wallaby has a full range of neurovascular products under development. Wallaby 's products are currently marketed in over 30 countries and regions. For more information, visit www.wallabymedical.com.
About phenox
Since its foundation in 2005, phenox has developed into a global innovation leader in neurovascular devices for the interventional treatment of strokes. The company has a broad product portfolio covering both ischemic and haemorrhagic stroke as well as Access & Support. The key product lines of phenox include the p64/p48 range of flow diverters for the treatment of intracranial aneurysms and the pRESET range of stent retrievers for the mechanical thrombectomy of ischemic strokes. Additionally, phenox has proprietary coating technologies for the enhancement of its permanent and short-term implants. The products of phenox are marketed in over 45 countries worldwide based on internationally leading clinical data. phenox has subsidiaries in Italy, the UK, Ireland and the U.S. For further information please visit https://phenox.net/international/
View original content:
SOURCE Wallaby Medical | https://www.wibw.com/prnewswire/2022/04/21/wallaby-acquires-german-neurovascular-leader-phenox-accelerate-global-expansion/ | 2022-04-21T09:32:06Z |
CYBEX and Evenflo Make Record High First Half Revenue Despite Facing Unprecedented Global Challenges
HONG KONG, Aug. 22, 2022 /PRNewswire/ -- Goodbaby International Holdings Limited ("Goodbaby International" or the "Company", HKEX stock code: 1086, together with its subsidiaries, the "Group"), a leading global parenting products company, announced today its interim results for the six months ended 30 June 2022 (the "Period"). During the Period, revenue of the Group amounted to approximately HK$4,372.8 million (1H 2021: HK$4,627.3 million) and profit for the period was HK$2.4 million (1H 2021: HK$101.2 million), amidst the challenges of protracted pandemic environment, massively increased global supply chain costs, continued global supply chain disruptions, and unfavorable foreign exchange rate movements in Europe.
Goodbaby International's CEO Mr. Martin Pos said, "Although the global economy remains ridden with uncertainties brought by COVID-19, and the global supply chain has been seriously disrupted and related costs have rocketed, plus there has been unfavorable exchange rate movements in Europe, we are prepared and ready to meet the challenges and seize opportunities. The Group initiated focused cost reduction measures in all business units to freeze unnecessary expenditures and implemented mitigation initiatives. Meanwhile, we continued to expand our own international distribution platforms and invest in innovation in a more prudent manner to maintain our competitive strength. In the future, we will continue to reinforce development of our one-dragon vertically integrated platform, invest in B2C platforms through our national distribution platforms and optimize supply chain strategies. We will be vigilant in guarding our business against impacts related to COVID-19 and will actively implement all necessary measures to ensure the Group delivers excellent performance."
CYBEX gains market share and reinforces global leadership
During the Period, CYBEX brand recorded growth of 0.9% (a 10.1% increase on a constant currency basis) with revenue reaching another first half high at approximately HK$1,631.8 million (1H 2021: HK$1,617.9 million). The growth momentum it enjoyed across all key global markets was primarily braced by its very strong brand position and disruptive and innovative product portfolio, introduction of new products – car seats, wheeled goods and home furniture, continuous efforts to expand and fortify its global omni-channel distribution network, in particular, and the successful roll-out of its own e-commerce platform in Europe also contributing to its positive growth performance.
gb continues to right-size and transforms commercial operations to cope with anti-epidemic measures and birth rate decline
Revenue of the gb brand amounted to approximately HK$791.7 million (1H 2021: HK$1,211.2 million). During the Period, the China market was hit hard by Omicron sub-variants and strict lockdowns as well as other anti-epidemic measures including forced closure of offline stores and warehouses, delivery logistics were seriously disrupted, as such, wholesale activities were stifled and consumer confidence weakened. gb brand consequently continued to right-size and transform its commercial operations to adapt to the new China market environment.
Evenflo demonstrates remarkable growth momentum with first half revenue climbing to record high
Evenflo brand recorded strong revenue growth of 31.2% (a 29.8% increase on a constant currency basis), with revenue amounting to approximately HK$1,229.7 million (1H 2021: HK$937.2 million) for the Period, primarily driven by the strong growth in digital channels and continued strong consumer acceptance of its innovative products, an elevated product portfolio and enhanced brand image, helping it gain business with retailers. As a result, its market share swelled in North America.
During the Period, Blue Chip business recorded revenue of approximately HK$560.6 million (1H 2021: HK$642.3 million). The revenue decrease was primarily due to fewer orders from customers with inventory piling up. Blue Chip continues to maintain very stable and healthy customer relationship.
Outlook
Looking ahead, the Group will continue its focused strategy on strategic brands of CYBEX, gb and Evenflo, and support the ongoing development of Blue Chip business.
It will continue the global growth strategy it has tailored for CYBEX across all key geographic regions, with the aim to help the brand gain market share with the support of an innovative product portfolio, new product launches, extended product categories, strengthened supply chain capabilities, new e-commerce platforms and expanded national distribution platforms in new geographic territories. Recently implemented price increases and cost reduction measures combined with the stabilization of key supply chain costs will significantly improve profitability.
gb will continue its brand upgrade, further develop its digital cloud retail system and social media-based own channels, and complete reforming its wholesale distribution channel as an effort to right-size and transform its business. Furthermore, by focusing on product innovation, technologies and new product launches, it will be able to cement the foundation for improving profitability.
As for Evenflo, it will press on with making strong revenue and growing market share with the support of perfecting digital channels and on its new innovative products gaining consumer reception. It expects profitability to improve from the competitive price increases implemented in the second quarter and the stabilization of supply chain costs.
For more details, please refer to the announcement:
About Goodbaby International Holdings Limited
Goodbaby International Holdings Ltd. (stock code: 1086) is a world-leading parenting products company. The Group serves millions of families around the world through design, research and development, manufacture, marketing and sales of children's car safety seats, strollers, apparel and home textile products, feeding, nursing and personal care products, cribs, bicycles and tricycles and other children's products.
View original content:
SOURCE Goodbaby International | https://www.kxii.com/prnewswire/2022/08/22/goodbaby-international-holdings-limited-announces-2022-interim-results/ | 2022-08-22T17:54:42Z |
Middle schooler commended for telling teacher about possible threat overheard at school
NAPLES, Fla. (Gray News) – A middle schooler in Florida was commended for reporting a threat he overheard to his teacher.
Jack Kelley, a seventh grader at Oakridge Middle School, overheard another student talking about a “possible school safety issue,” according to the Collier County Sheriff’s Office.
Jack then informed a teacher, who contacted a youth relations deputy at the school.
The sheriff’s office said Jack’s actions allowed their officers to investigate and prevent any possible threat.
“Jack is a terrific example of how we can all work together to keep our schools safe and protect our children,” Sheriff Kevin Rambosk said. “If you see something of concern, don’t spread it, report it. We applaud Jack for doing that.”
Jack earned the Do The Right Thing Award from the sheriff’s office for his actions, which was presented to him and his family during a celebration at his home on Wednesday.
Copyright 2022 Gray Media Group, Inc. All rights reserved. | https://www.wibw.com/2022/09/08/middle-schooler-commended-telling-teacher-about-possible-threat-overheard-school/ | 2022-09-08T23:54:58Z |
Milliman PPFI funded ratio at 74.0% as of June 30
SEATTLE, July 28, 2022 /PRNewswire/ -- Milliman, Inc., a premier global consulting and actuarial firm, today released the latest results of its Public Pension Funding Index (PPFI), which consists of the nation's 100 largest public defined benefit pension plans.
During June, the Milliman 100 public pension funded ratio dropped from 78.4% on May 31, 2022, to 74.0% as of June 30, 2022. The drop in funding was the result of poor investment performance, with PPFI plans experiencing investment losses of 5.13% in aggregate for the month and shedding approximately $240 billion in the market value of assets.
"Public pensions have seen their funding tumble during June 2022, thanks to the continuing turmoil in financial markets," said Becky Sielman, author of Milliman's PPFI. "Combined with the normal growth in liabilities, these public pensions saw their aggregate deficit rise by $262 billion in June alone."
The market decline pushed eight plans below the 90% funded mark as of June 30, 2022; now just 19 plans still stand above this benchmark, compared to 27 on May 31, 2022, and 46 at the close of 2021.
For more information and to view the full Milliman 100 Public Pension Funding Index, go to http://www.milliman.com/ppfi/. To see Milliman's full range of annual Pension Funding Studies, go to https://www.milliman.com/en/retirement-and-benefits/pension-funding-studies. To receive regular updates of Milliman's pension funding analysis, contact us at pensionfunding@milliman.com.
About Milliman
Milliman is among the world's largest providers of actuarial and related products and services. The firm has consulting practices in healthcare, property & casualty insurance, life insurance and financial services, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe. For further information, visit milliman.com.
View original content:
SOURCE Milliman, Inc. | https://www.kxii.com/prnewswire/2022/07/28/milliman-analysis-slump-june-market-causes-262-billion-drop-public-pension-funded-status/ | 2022-07-28T17:34:08Z |
Announced by CPT Group, Inc.
IRVINE, Calif., May 12, 2022 /PRNewswire/ -- CPT Group, Inc. announces a proposed Settlement in a class action lawsuit called Stevens v. Britax Child Safety, Inc., C.D. Cal. Case No. 2:20-cv-07373-MCS (the "Settlement").
What is this about? A Settlement has been reached with Britax Child Safety, Inc. ("Britax") relating to the sale of the Class Child Seats and allegations that the seats are defective and that purchasers paid more for the seats than they otherwise would have paid had they known of the defect. Plaintiff alleges violations of California consumer statutes and warranty laws Britax denies these allegations, denies any liability whatsoever and stands by the safety of the Class Child Seats. Britax further asserts that the Class Child Seats comply with all applicable laws and regulations. The Court has not decided who is right.
Who is affected? All persons who, when they were residents of California, purchased for personal or household use a new Britax Frontier ClickTight Harness-2-Booster or Britax Pioneer Harness-2-Booster Seat at any time from August 14, 2016, up to and including August 14, 2020, and the seat has a manufacturing date from August 14, 2016, to no later than September 30, 2019.
What does the Settlement provide? The Settlement provides monetary relief.
Monetary Relief: Britax will pay each Settlement Class Member $40 and, in addition, will pay Court-approved Attorneys' Fees and Expenses, a Service Award to Plaintiff, and notice and administration costs.
How do I get payment? If you are a Known Class Member, you do not need to do anything, and you will receive a payment from Britax through the Administrator. If you are an Unknown Class Member, you must file a Claim Form to receive payment, and you must submit your claim online at www.BritaxBoosterSeatSettlement.com or file a paper Claim Form by August 10, 2022. Paper Claim Forms are available at the website or by calling the following toll-free number: 1-888-412-2198.
What are my other options? You can do nothing, exclude yourself, or object to the Settlement.
Do Nothing: If you do nothing, you will give up your right to sue or continue to sue Britax for the claims in this case. If you are an Unknown Class Member and you do nothing, your rights will be affected, and you will not get a payment.
Exclude Yourself: If you do not want to be legally bound by the Settlement or receive any benefits from it, you must exclude yourself by August 10, 2022. If you do not exclude yourself, you will be legally bound by all orders of the Court, and you will not be able to start, continue or be part of any other lawsuit against Britax about the allegations of the case.
Object: If you do not exclude yourself from the Settlement, you may object to it or tell the Court what you don't like about the Settlement. Objections must be filed and served by August 10, 2022.
For details about your rights and options and how to exclude yourself or object, go to www.BritaxBoosterSeatSettlement.com.
What happens next? The Court has scheduled a hearing in this case for August 29, 2022, at 9:00 a.m., to consider whether to approve the Settlement and approve a Service Award to Plaintiff, award Attorneys' Fees and Expenses; as well as consider any objections. You or your attorney may attend and ask to appear at the hearing, but you are not required to do so. You may appear at the hearing in person or through your attorney at your own cost, but you are not required to do so.
How do I get more information? For more information and to view the full notice, go to www.BritaxBoosterSeatSettlement.com, or contact the Settlement Administrator by emailing BritaxBoosterSeatSettlement@cptgroup.com, or by calling toll-free 1-888-412-2198.
PLEASE DO NOT CONTACT THE COURT OR THE COURT CLERK'S OFFICE
CONTACT: Randi Martz
randi@cptgroup.com
View original content to download multimedia:
SOURCE CPT Group, Inc. | https://www.kxii.com/prnewswire/2022/05/12/if-you-were-california-resident-when-you-purchased-new-britax-frontier-clicktight-harness-2-booster-seat-or-britax-pioneer-harness-2-booster-seat-any-time-august-14-2016-up-including-august-14-2020-you-may-be-eligible-class-action-settlement/ | 2022-05-13T06:47:23Z |
SAN JOSE, Calif., Aug. 11, 2022 /PRNewswire/ -- Linqto, the Main Street investment platform for private technology market securities, announced today it has completed its acquisition of Trustline, a technology platform that delivers decentralized financial services in payments, trading, and lending. Built on XRP Ledger, Trustline uses this cutting-edge technology to provide more efficient and cost-effective financial services.
According to Linqto Founder and CEO, Bill Sarris, "We acquired Trustline for its advanced blockchain technology and IP including $200,000 worth of XRP grants issued from the XRPL Grants Program. Trustline will help us build on our vision to provide access, affordability and liquidity to accredited investors. But the most valuable asset we acquired is the new association with Matt Rosendin, a progressive thinker and leader in the global blockchain community."
With the acquisition of Trustline, Linqto intends to accelerate its development of the first and only decentralized exchange for private market securities in the world. Using Trustline's proprietary technology, Linqto's exchange will be auditable, publicly transparent, and 100% on blockchain.
"Trustline is thrilled to join the innovative and groundbreaking work that Linqto is doing in making private investing simple for individual investors who have been shut out of traditional private equity asset class," said Matt Rosendin, CEO of Trustline and now VP of Ledger at Linqto. "Our two companies are perfectly aligned to democratize private markets investing for qualified investors."
About Linqto:
Linqto is a leader in liquidity in the private sector, providing accredited investors access to affordable investment opportunities in the world's top unicorns. Private investing made simple. Learn more at https://www.linqto.com/.
About Trustline:
Trustline is a full stack financial services platform build on the XRP Ledger designed to deliver efficient and cost effective payments, trading, and lending services to accredited investors.
View original content to download multimedia:
SOURCE Linqto | https://www.mysuncoast.com/prnewswire/2022/08/11/linqto-completes-acquisition-trustline-move-towards-blockchain-powered-investment-exchange/ | 2022-08-11T14:25:28Z |
Three new cancer ratings and expanded equity measures
WASHINGTON, July 26, 2022 /PRNewswire/ -- U.S. News & World Report, the global authority in hospital rankings and consumer advice, today revealed the 2022-2023 Best Hospitals rankings to assist patients and their doctors in making informed decisions about where to receive quality care.
Now in its 33rd year, Best Hospitals evaluates hospitals in more than 30 medical and surgical services, including three new cancer ratings: Ovarian Cancer Surgery, Prostate Cancer Surgery and Uterine Cancer Surgery. Also new this year: an expanded set of health equity measures that highlights which hospitals provide more care to low income patients and which have racial disparities in certain surgical outcomes.
The 2022-2023 rankings highlight the top 20 hospitals named to the Honor Roll for delivering exceptional treatment across many areas of care. For the seventh consecutive year, Mayo Clinic claimed the top spot on the Honor Roll. Ranked at No. 2 this year is Cedars-Sinai Medical Center, NYU Langone Hospitals at No. 3.
In the specialty rankings, University of Texas MD Anderson Cancer Center ranked No. 1 in Cancer, the Cleveland Clinic is No. 1 in Cardiology & Heart Surgery and NYU Langone Hospitals is No. 1 in Neurology & Neurosurgery.
"For patients considering their options for where to get care, the Best Hospitals rankings are designed to help them and their medical professionals identify hospitals that excel in the kind of care they may need," said Ben Harder, chief of health analysis and managing editor at U.S. News. "The new cancer ratings provide patients facing surgery for prostate cancer or gynecological cancer with previously unavailable information to assist them in making a critical health care decision."
2022-2023 Best Hospitals Honor Roll
1. Mayo Clinic
2. Cedars-Sinai Medical Center
3. NYU Langone Hospitals
4. Cleveland Clinic
5. (Tie) Johns Hopkins Hospital
5. Tie) UCLA Medical Center
7. New York-Presbyterian Hospital-Columbia and Cornell
8. Massachusetts General Hospital
9. Northwestern Memorial Hospital
10. Stanford Health Care-Stanford Hospital
11. Barnes-Jewish Hospital
12. UCSF Health-UCSF Medical Center
13. Hospitals of the University of Pennsylvania-Penn Presbyterian
14. Brigham and Women's Hospital
15. Houston Methodist Hospital
16. Mount Sinai Hospital
17. University of Michigan Health-Ann Arbor
18. Mayo Clinic-Phoenix
19. Vanderbilt University Medical Center
20. Rush University Medical Center
Top Five Best Hospitals in Selected Specialties
- University of Texas MD Anderson Cancer Center
- Memorial Sloan Kettering Cancer Center
- Mayo Clinic
- Dana-Farber/Brigham and Women's Cancer Center
- UCLA Medical Center
- Cleveland Clinic
- Mayo Clinic
- Cedars-Sinai Medical Center
- New York-Presbyterian Hospital-Columbia and Cornell
- NYU Langone Hospitals
- NYU Langone Hospitals
- UCSF Health-UCSF Medical Center
- New York-Presbyterian Hospital-Columbia and Cornell
- Rush University Medical Center
- Johns Hopkins Hospital
The Best Hospitals methodology and Procedures & Conditions methodology factor objective measures such as survival rates, patient experience, level of nursing care and how successfully each hospital helps patients get back home. To calculate the Best Hospitals rankings for overall performance, specialties, states and metro areas, U.S. News evaluated each hospital's performance using a variety of measures from data provided by the Centers for Medicare & Medicaid Services, American Hospital Association, professional organizations and medical specialists. The Procedures & Conditions ratings are based entirely on objective patient care measures.
This year's rankings will be published in the U.S. News & World Report's "Best Hospitals 2023" guidebook (ISBN 9781931469999), available to order from the U.S. News Online Store.
For more information, visit Best Hospitals and use #BestHospitals on Facebook and Twitter.
About U.S. News & World Report
U.S. News & World Report is the global leader in quality rankings that empower consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives and communities. A multifaceted digital media company with Education, Health, Money, Travel, Cars, News and 360 Reviews platforms, U.S. News provides rankings, independent reporting, data journalism, consumer advice and U.S. News Live events. More than 40 million people visit USNews.com each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C.
View original content to download multimedia:
SOURCE U.S. News & World Report, L.P. | https://www.kxii.com/prnewswire/2022/07/26/us-news-reveals-2022-2023-best-hospitals/ | 2022-07-26T04:20:39Z |
Faron Pharmaceuticals Ltd
("Faron or Company")
Faron Announces Presentation of Biomarker Analysis at 2022 ASCO Annual Meeting Showing Promising
Clinical Benefit of Bexmarilimab in Patients with Low PD-L1 and High Clever-1 Levels
- Biomarker analyses indicate that the tumors of patients benefitting from treatment with bexmarilimab had:
- Adds to growing research to identify optimum patient group for macrophage-targeting immunotherapy following earlier finding that patients with low serum IFNy and TNFa levels (immunologically cold tumors) were more likely to experience clinical benefit
- Combination studies underway in both solid tumors and hematologic malignancies to further explore the clinical benefit of Clever-1 inhibition and potential of bexmarilimab to prime the immune system in patients unresponsive to existing therapies
Press Release, May 30, 2022 at 02:00 AM (EEST) / 07:00 AM (BST) / 09:00 AM (EDT)
TURKU, Finland and BOSTON, May 30, 2022 /PRNewswire/ -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that new biomarker data from patients treated with bexmarilimab as part of the ongoing phase I/II MATINS (Macrophage Antibody to Inhibit Immune Suppression) trial, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2022 Annual Meeting being held in Chicago, US from June 3 – 7. These data (Abstract #2645) will be featured in the "Developmental Therapeutics—Immunotherapy" session on Sunday, June 5, 2022 at 9:00 AM EDT.
The MATINS trial is investigating the safety and efficacy of bexmarilimab as a monotherapy in patients with solid tumors who have exhausted all treatment options. Faron's wholly-owned novel precision cancer immunotherapy targets Clever-1, a receptor known to be expressed on immunosuppressive macrophages in the tumor microenvironment. Bexmarilimab works by converting highly immunosuppressive M2 macrophages to immune stimulating M1 macrophages, which activates antigen presentation and promotes interferon gamma secretion by leukocytes. This can turn "cold" tumors into "hot" tumors; allowing the immune system to recognize and target cancer cells.
The biomarker analysis shows that the tumors of patients benefiting from bexmarilimab treatment expressed low levels of PD-L1 – a patient group that generally does not receive benefit from or is ineligible for treatment with currently approved checkpoint inhibitors. Median PD-L1 Combined Positive Score (CPS) was 1 (range 0-2) in patients that benefitted from bexmarilimab. The PD-L1 CPS score was 5 (range 0-100) for patients who did not benefit from bexmarilimab treatment. Further, the analysis showed that patients with higher levels of Clever-1 positive intra-tumoral cells were more likely to experience a clinical benefit when treated with bexmarilimab [15% vs 3%, respectively; p=0.038].
"While the arrival of currently available checkpoint inhibitors was, undoubtedly, one of the most exciting breakthroughs in cancer care, their low response rate in most tumor types continues to hinder their clinical application," said Petri Bono, MD, PhD., Chief Medical Officer, Terveystalo Finland and Principal Investigator of the MATINS trial. "There remains an urgent need for effective new treatment options, including novel assets that work synergistically with existing checkpoint inhibitors to ignite and amplify the patient's immune response."
These data build on Faron's continued research to identify the patient population most likely to benefit from bexmarilimab treatment and follow the Company's earlier findings, announced in December 2021, that patients with low baseline serum levels of serum interferon gamma (IFNy) and tumor necrosis factor alpha (TNFa) were more likely to experience clinical benefit following treatment with bexmarilimab. Those patients with immunologically cold tumors also exhibited an ignition of immune response, as indicated by increased levels of IFNy following therapy, which suggests bexmarilimab may serve as a catalyst for the immune system allowing initially checkpoint inhibitor resistant or ineligible patients to become responsive to PD-1 blockade.
"Using a validated staining technique, these preliminary biomarker analyses indicate that bexmarilimab treatment may benefit patients whose tumors express low levels of PD-L1 and higher levels of CLEVER-1 positive intra-tumoral cells, which is opposite to what is usually seen with checkpoint inhibitors and other T cell activating agents," said Marie-Louise Fjällskog, M.D., Ph.D., Chief Medical Officer of Faron. "We are encouraged by this data as it furthers our belief that bexmarilimab has the potential to bring the promise of immunotherapy to a much broader patient population both as a monotherapy and in combination with currently approved anti-PD-1/L1 therapies."
For more information please contact:
Investor Contact
Faron Pharmaceuticals
Julia Balanova
VP, Investor Relations
julia.balanova@faron.com
investor.relations@faron.com
Phone: +1 (917) 306-6096
Media Contact
Faron Pharmaceuticals
Eric Van Zanten
VP, Communications
eric.vanzanten@faron.com
Phone: +1 (610) 529-6219
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
faron@consilium-comms.com
Phone: +44 (0)20 3709 5700
About Bexmarilimab
Bexmarilimab is Faron's wholly-owned, investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid cell function. A novel anti-Clever-1 humanised antibody, bexmarilimab targets Clever-1 positive (Common Lymphatic Endothelial and Vascular Endothelial Receptor 1) tumour associated macrophages (TAMs) in the tumour microenvironment, converting these highly immunosuppressive M2 macrophages to immune stimulating M1 macrophages. In mouse models, bexmarilimab has successfully blocked or silenced Clever-1, activating antigen presentation and promoting interferon gamma secretion by leukocytes. Additional pre-clinical studies have proven that Clever-1, encoded by the Stabilin-1 or STAB-1 gene, is a major source of T cell exhaustion and involved in cancer growth and spread. Observations from clinical studies to date indicate that Clever-1 has the capacity to control T cell activation directly, suggesting that the inactivation of Clever-1 as an immune suppressive molecule could be more broadly applicable and more important than previously thought. As an immuno-oncology therapy, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules in both solid tumors and hematologic malignancies. Beyond immuno-oncology, it offers potential in infectious diseases, vaccine development and more.
About MATINS
The MATINS (Macrophage Antibody To INhibit immune Suppression) study is a first-in-human open label phase I/II clinical trial investigating the tolerability, safety and efficacy of bexmarilimab in ten different hard-to-treat metastatic or inoperable solid tumour cohorts - cholangiocarcinoma, colorectal cancer, cutaneous melanoma, ER+ breast cancer, gastric cancer, hepatocellular carcinoma, ovarian cancer, uveal melanoma, pancreatic cancer and anaplastic thyroid carcinoma - which are all known to host a significant number of Clever-1 positive tumour-associated macrophages (TAMs). The completed Part I of the trial dealt with tolerability, safety and dose escalation. The ongoing Part II is focused on identifying patients who show an increased number of Clever-1 positive TAMs and exploring safety and efficacy. Part III will be focused on assessing efficacy. Data from MATINS have shown that bexmarilimab has the potential to be the first macrophage immune checkpoint therapy. To date, the investigational therapy has been shown to be safe and well-tolerated, making it a low-risk candidate for combination with existing cancer therapies, and has demonstrated early signs of clinical benefit in patients who have exhausted all other treatment options.
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with solid tumors and hematologic malignancies, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated by the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com.
Forward Looking Statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should", "expect", "hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In particular, the early data from initial patients in the MATINS trial may not be replicated in larger patient numbers and the outcome of clinical trials may not be favourable or clinical trials over and above those currently planned may be required before the Company is able to apply for marketing approval for a product. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully licence its programmes within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Faron Pharmaceuticals Oy | https://www.wibw.com/prnewswire/2022/05/30/presentation-biomarker-analysis-asco/ | 2022-05-30T07:20:12Z |
Border patrol horse dies in the line of duty
Published: Sep. 14, 2022 at 2:01 PM CDT|Updated: 27 minutes ago
DEL RIO, Texas (Gray News) – A border patrol horse died in the line of duty, according to the U.S. Border Patrol Del Rio Sector.
Jayce, the agency’s mounted patrol partner, was on patrol near Carrizo Springs when he came in contact with a downed power line.
The horse fell to the ground and succumbed to his injuries. The rider was not hurt.
According to U.S. Border Patrol, Jayce served the agency “with honor for over 11 years.”
Copyright 2022 Gray Media Group, Inc. All rights reserved. | https://www.wibw.com/2022/09/14/border-patrol-horse-dies-line-duty/ | 2022-09-14T19:29:01Z |
CHICAGO, May 24, 2022 /PRNewswire/ -- Cinespace Studios, a global studio platform, announced today that Michael Scott Jr. will join the company in the newly created position of Director, Industry and Community Relations. Scott will report to Ashley Rice, President and Co-Managing Partner, and start with the company in June. He will be based in Chicago.
In this new role, Scott will provide strategic management for industry and community relations and develop local philanthropic and early education programs for Chicago. He will oversee the job training program that has been providing residents from underserved communities on the west and south sides with hands-on experience on productions filming at Cinespace Studios in below-the-line departments including Electric, Prop, Costumes, Locations, and Sound. The program is part of CineCares, a division of Cinespace dedicated to building initiatives that promote equity and inclusion in the Film and TV industry in communities where the platform operates.
"Michael has a proven track record for building programs and bringing resources to underserved communities. His wealth of experience and drive to make a positive impact will advance Cinespace's commitment to creating visible pathways for job opportunities and ensuring equal access in the film and TV industry," said President and Co-Managing Partner Ashley Rice.
"Cinespace Studios is an important part of the local film and television infrastructure. I am excited to join the organization and help lead efforts with our partners that will bring meaningful impact to our community," said Scott.
For the past seven years, Scott has served on the Chicago City Council as the 24th Ward Alderman. During his tenure, he beautified the ward, created an economic engine, dedicated more than 300 million dollars to capital and human infrastructure, and developed job training for residents. Over the course of his career, Scott has served at Chicago Public Schools, the Public Building Commission, After School Matter, and the Chicago Park District. The son of prominent leaders in the city of Chicago, he was raised into a legacy of service and is a graduate of Morehouse College.
About Cinespace Studios
Cinespace Studios is a best-in-class global platform of production facilities that supports content providers and their creatives. The platform is one of the largest sound stage operators globally with locations in Chicago, Toronto, and Studio Babelsberg in Germany. Cinespace Studios delivers the highest level of service while increasing the quality of the overall production experience and nurtures its local communities to support workforce development and crew diversity.
Media Contact:
Catherine Shin
Catherine.shin@cinespace.com / 818.827.7128
View original content to download multimedia:
SOURCE Cinespace Studios | https://www.mysuncoast.com/prnewswire/2022/05/24/michael-scott-jr-join-cinespace-studios-director-industry-community-relations/ | 2022-05-24T18:52:31Z |
SHENZHEN, China, May 31, 2022 /PRNewswire/ -- iQOO, an independent sub-brand of vivo, announced the international debut of iQOO Neo6. The new iQOO Neo6 delivers outstanding performance and a flagship-level gaming experience at a more affordable price point. Its unique features and design were crafted to appeal to smartphone users who seek a stylish device that offers a seamless user experience and excellent photography capabilities.
"The new iQOO Neo6 device stands out with its original exterior design and offers strong performance for an immersive gaming experience," said Nipun Marya, Chief Executive Officer of iQOO. "Not only does the affordable yet powerful device continue to strengthen the iQOO brand in performance and gaming, but it also provides top-tier photography experience, satisfying the day-to-day needs of gaming enthusiasts."
Powerful Performance
iQOO Neo6 is designed for performance. The device is equipped with Snapdragon® 870 5G Mobile Platform, 80W FlashCharge, 4700mAh battery, Extended RAM 2.0, and Enhanced UFS 3.1 technology, enabling uninterrupted multitasking and smooth gaming.
With the Snapdragon® 870 5G mobile platform, iQOO Neo6 provides robust performance in all usage scenarios. It ensures lower power consumption, excellent cooling, and powerful processing – achieving a perfect balance between the three. Furthermore, iQOO Neo6 features the all-around enhanced V6 UFS 3.1 high-speed memory chip that improves UFS performance by supporting the brand-new HID advanced defragmentation technology.
The Extended RAM 2.0 in iQOO Neo6 allows part of the ROM to be utilized as RAM. This way, the iQOO Neo6 8GB model offers a maximum of 12GB RAM, while the 12GB model tops out at 16GB of RAM. This improved feature enriches the user experience by reducing application startup time and optimizing memory usage to allow multiple applications to run smoothly at the same time.
iQOO Neo6 is also equipped with Defragmentation 2.0, a stream technology that prevents storage fragmentation, improves overall performance and eliminates lag. With Defragmentation 2.0, the device will classify and store data based on its different attributes, reducing the probability of file fragmentation by 25%.
The Cascade Cooling System in iQOO Neo6 is an innovative heat dissipation system that accelerates heat transfer. The five-layer 3D graphite cooling plates of the Cascade Cooling System fit closely with the heat source, making full use of the space in the device.
iQOO Neo6's single-IC and dual-cell design (20V/4A) of 80W FlashCharge can greatly reduce charging time. The 4700mAh battery gets a 50% battery in only 12 minutes. In addition, iQOO Neo6 has a smart charging mode that helps detect the user's sleep time and adjusts the charging time accordingly, extending the battery lifespan by 25%.
Superb Gaming Experience
iQOO Neo6 carries iQOO's gaming DNA and the pursuit of a premium gaming experience, featuring a 120Hz E4 AMOLED Display, 1200Hz Instant & 360Hz Touch Sampling Rate, Dual Stereo Speaker, and more.
The 120Hz E4 AMOLED Display supports a high refresh rate of 120Hz and can display 120 frames per second, providing smooth animation and picture transition for a superb gaming experience. The 120Hz E4 AMOLED Display is more eye-friendly and power-efficient.
The touch response speed is vital for a better gaming experience. iQOO Neo6 features a 1200Hz Instant & 360Hz Touch Sampling Rate. Many competitive games, especially first-person shooters, require a very high level of precision for aiming. The precise touch response on iQOO Neo6 allows users to adjust the touch recognition based on personal preference for smooth and continuous screen swiping, while the high touch response rate further improves touch sensitivity.
Compared with the Z-Axis Linear Motor, the X-Axis Linear Motor featured in the iQOO Neo6 starts faster, has stronger vibration, and feels more vivid and real. It brings better physical feedback during typing, gaming, and more. With 4D Game Vibration, the system can intelligently identify usage scenarios and use the linear motor and software algorithms to provide custom vibrations for a better gaming experience.
iQOO Neo6 features Dual Stereo Speaker to bring users a surround sound effect while gaming, listening to music or watching videos.
Excellent Photography in Everyday Scenarios
iQOO Neo6 has a 16MP front camera and a rear triple camera system consisting of a 64MP OIS Main Camera, an 8MP Wide-Angle Camera, and a 2MP Super Macro Camera. The main camera is equipped with a GW1P sensor and a 1/1.7" image sensor. GW1P sensor can achieve excellent image processing in bright or dark environments, ensuring ultra-clear photography. The main camera supports 4K/60fps video recording and uses OIS to minimize image blur caused by shaky hands, significantly improving the clarity of photos taken in low light, scenes requiring long exposure, or action-packed scenes.
Trendy Appearance
The new iQOO Neo6 presents a retro-futuristic design style that takes inspiration from factories, electronics, and the machine age, showcasing the extreme contrast between the past and future. The device will be available in two colors, Dark Nova and Cyber Rage.
Dark Nova is inspired by outer space - the hidden galaxies spread across time and space. Cyber Rage represents a journey through the bustling streets of the cyberpunk city under the flickering neon lights.
Availability
iQOO Neo6 series will be available in India starting from May 31st, 2022. iQOO Neo6 comes with the 8GB RAM+128GB ROM edition and 12GB RAM + 256GB ROM edition.
About iQOO
iQOO, an independent sub-brand of the vivo group, aims to bring cutting-edge industry technology to users more quickly and easily for enhanced experiences with high-performance devices. The iQOO brand deeply understands the performance needs of users and the collective desire for technological innovation by a new generation. Backed by vivo's strong capabilities and user-oriented innovation, iQOO has multiple product lines operating independently.
For more information, please visit www.iQOO.com.
View original content to download multimedia:
SOURCE Vivo | https://www.wibw.com/prnewswire/2022/05/31/iqoo-neo6-smartphone-series-makes-international-debut-bringing-premium-gaming-experience-users/ | 2022-05-31T10:49:48Z |
ISELIN, N.J., July 28, 2022 /PRNewswire/ -- Hexaware Technologies, a next-generation digital services provider, is one of the partners in the UNFUR Project, a campaign that raises awareness around the atrocities of the fur trade and attempts to create a sustainable alternative for fur and faux fur. The significant collaborators of Hexaware for this project are the International Anti-Fur Coalition (IAFC) and the University of Westminster.
The project creates digital fur fashion as NFTs that can be collected/purchased and the earnings will be directed to combat the fur trade. The campaign was announced at MET AMS, Europe's leading Metaverse festival and features a digital fur fashion collection that includes five pieces digitized as NFTs by Hexaware. The students from the University of Westminster's Fashion Institute created the head-turning designs for the collection. Paul van Raak, Creative Director- Mobiquity, part of Hexaware said, "The UNFUR project intentionally brings tension between buying a digital fur fashion piece (because it is considered beautiful) while you are aware that this should not be bought in the physical world. We use this duality as a trigger to drive the audience to bid on one of the UNFUR NFTs and by doing so support the fight against the fur industry."
This project unveils the opportunities that Metaverse can present for the fashion industry while eliminating limitations of the physical world. Hexaware is delighted to be a part of this initiative that enables leveraging its Metaverse competencies, taking a solid step towards exploring endless possibilities for fashion as NFTs and embracing an ethical and responsible way of protecting animals slaughtered for their precious fur. The campaign also strengthens the position of digital platforms as viable and sustainable options to bring in the next big revolution in the fashion industry.
The project has been recognized through various awards that are a testament to the impact it has created in the NFT domain. Some of the prestigious accolades received are – The FWA: Site of the Day, CSS Design Awards: Site of the Day, UI Design Award, UX Design Award, Innovation Award, Awwwards: Site of the Day, Developer Award.
Immanuel Kingsley , Metaverse Technology Officer at Hexaware Technologies said, "We are fortunate to have the chance of capitalizing on our curiosity of Metaverse to unfold a new dimension for the fashion industry while contributing to a cause that saves millions of animals from atrocities. Like innovation, exploring new possibilities in the Metaverse drives our efforts and this campaign provides the right boost for our future endeavors."
About Hexaware
Hexaware is a global IT, BPS and consulting services company empowering businesses worldwide to realize digital transformation at scale and speed.
Learn more about Hexaware at http://www.hexaware.com. Take an immersive 360° virtual tour of our campuses worldwide at https://www.hexawareimmersive.com
Logo: https://mma.prnewswire.com/media/530945/Hexaware.jpg
View original content:
SOURCE Hexaware Technologies Ltd. | https://www.wibw.com/prnewswire/2022/07/28/unfur-digital-fur-fashion-demonstrate-capabilities-metaverse-with-responsibility/ | 2022-07-28T13:08:56Z |
Photos of a struggling community reveal the lives of its most vulnerable residents
Jacopo Prisco
Kareema Hassan was at her local mosque in Toronto, Canada, for a nightly prayer called Taraweeh — camera and tripod in tow — when she captured a striking sign of the times.
It was the end of the holy month of fasting, Ramadan, in the spring of 2021. Government restrictions imposed in response to the coronavirus outbreak had just partially lifted, allowing a limited number of people to enter the building. Hassan, then 19, found herself next to a Quran bookshelf that had been blocked off with yellow caution tape to prevent the spread of infection through contact with the books, and the sight struck her as a stark reminder of life’s fragility.
She caught the moment in a stunning photograph titled “Yellow tape” that was part of the latest exhibition for Shoot for Peace, a grassroots mentorship program that teaches photography to at-risk young people in Toronto.
“It was one of the images that people were most attracted to at the exhibition,” said Yasmin Osman, the photographer and illustrator who started Shoot for Peace in 2015, when he was 22 years old. The name of the program is meant to evoke the dual meaning of “shoot,” which applies to both guns and cameras.
“I grew up in Regent Park in Toronto; my mom raised me by herself. There was a lot of gun violence in the neighborhood,” Osman said in a phone interview. “When I was 14, the neighborhood started getting torn down — there was a revitalization happening in the community, and I was documenting that with my mom’s cell phone.”
After high school, Osman was working as a preschool teacher, and was tasked with taking photos of the children using a reflex camera. He enjoyed it, and started documenting the neighborhood.
“My identity in the community became ‘that guy who takes photographs’; it became a side hustle,” Osman said. Eventually, that side hustle grew into a full-time career, and he left teaching behind. He’s since worked with major brands, and his exhibition “Dear Ayeeyo,” a tribute to his Somali grandmother, has toured internationally. But the desire to help young people stayed with him.
“So I was thinking to myself… how can I combat some of the issues that are happening in the neighborhood because of the gun violence?” Osman said. “And arts programming wasn’t something that existed too much, especially for boys.”
Creating a family
At first, Osman focused on working with boys. He approached a group of them hanging out near a basketball court, and offered to teach them how to take better photographs with their cell phones. “Does that mean we’re going to get likes on Instagram?” they asked, and that’s how the program started.
Osman’s efforts soon attracted the attention of Canon, which supplied the group with reflex cameras and lenses, allowing more students to take photographs at the same time using more sophisticated equipment.
Soon after, Shoot for Peace expanded with a course designed particularly for girls, and the program has since developed into a charity that allows anybody across the globe to volunteer or contribute by sending donations and purchasing items, making the opportunity absolutely free to students. The weekly course runs each year from January to September, when a joint exhibition takes place showcasing the work of all students, who range in age from 15 to 22.
The program is highly sought-after: More than 100 applications were filed for each course last year, but classes are limited to a maximum of 10 pupils. “Those who have not been accepted still have the opportunity to come to our studio space, get to know people and hang out,” Osman said. “It’s become something that people want to attach themselves to, because it oozes positivity and love.”
Some students from early cohorts have gone on to become professional photographers or YouTubers, although for many participants, the goal is just to make new friends or acquire a new skill. “Shoot for Peace has really created a family amongst us, and youth from different neighborhoods — some of them even in conflict, probably not able to be seen together outside of our space — are friends, hanging out together, really creating a sense of community,” Osman said.
“I was speaking to one of the youth once and I asked if he wanted to become a photographer, because he was really good at it,” he said. “But he replied ‘Oh no, I don’t want to become a photographer — but I’m really happy because I’ll have this skill with me forever.'”
Even for Osman, photography isn’t everything. He is also a cartoonist for the New Yorker, and he has Shoot for Peace to thank for it. It all started with a chat with a student who was inclined to take up painting but didn’t want to jeopardize his photography studies. That helped Osman understand that diverse interests can coexist, and he encouraged the pupil to pursue both. Following his own counsel, he started drawing again — a passion he had put aside to concentrate on photography — and sent his work to the magazine, which accepted it.
But don’t pin him down as a photographer and a cartoonist just yet. “A really important piece of my artistry is to be able to express how I actually feel through any medium,” he said. “Today it can be cartooning, but tomorrow it can be something else.”
Top image: “Yellow tape” by Kareema Hassan (2021). Shot at the end of Ramadan 2021 as coronavirus restrictions were partially lifted in Toronto, it’s meant as a reminder of the fragility of life and the importance of showing gratitude for the places, people and things we love.
The-CNN-Wire
™ & © 2022 Cable News Network, Inc., a WarnerMedia Company. All rights reserved. | https://localnews8.com/entertainment/cnn-style/2022/05/27/photos-of-a-struggling-community-reveal-the-lives-of-its-most-vulnerable-residents-2/ | 2022-05-27T22:54:16Z |
FLAGSTAFF, Ariz., May 18, 2022 /PRNewswire/ -- Arizona based self-storage developer and operator, Cooper Companies, Inc. (CCI), has announced the start of construction in June 2022 of 1683 West Route 66 in Flagstaff, AZ.
Reg Cooper, president of CCI, announced, "We are excited to be complementing our existing storage business in Flagstaff by developing an additional state of the art, 104,672 sq. ft., three-story building. This marque location along the iconic Route 66 is growing rapidly as an important arterial connecting downtown Flagstaff to the rapidly growing Westside of Flagstaff.
"Our new facility will feature energy-efficient climate control units, covered loading zones, and advance access control and security amenities. The facility will also include energy efficient mechanical equipment, environmental-friendly storm water retention, industry leading insulation RValues, provisions for a solar system and even a complimentary dog wash station for our customers. Located conveniently along West Route 66 and near the Home Depot, the property will either be branded under the Armour Self Storage or Extra Space Storage name."
The Grand Opening for this location is set for early 2023. The General Contractor of the project is TLW Construction; architecture will be completed by RKAA Architects, and civil engineering by SWI Engineering in Flagstaff.
About Us:
Cooper Companies Inc. develops, owns, and operates self-storage, office and industrial properties in Arizona, Texas, and Wisconsin. Since 1978, Cooper Companies has been focused primarily on self-storage properties operating under the name of Armour Self Storage and Extra Space Storage.
View original content to download multimedia:
SOURCE Cooper Companies, Inc. | https://www.wibw.com/prnewswire/2022/05/18/cooper-companies-inc-announces-start-construction-new-climate-controlled-self-storage-facility-along-west-route-66-flagstaff/ | 2022-05-18T20:16:50Z |
CUSTOMERS ARE PROVING TO MAKE STILLY THE SIGNATURE COCKTAIL OF SUMMER 2022
STILLWATER, Minn., July 18, 2022 /PRNewswire/ -- STILLY, the new brand of ready-to-drink cocktails in a can that was released to liquor stores across Minnesota earlier this month, is already making a big splash among consumers.
STILLY beverages are NOT seltzers, and they're not your ordinary cocktails in a can; they're an all-new category of unique adult beverages called a "stilly." A "stilly" is a light and refreshing cocktail made with premium vodka or other distilled spirits, fine bubbles, a squeeze of natural juices, and natural flavors. The exact ingredients and processes used to make a "stilly" are a closely guarded secret, but consumers are proving to love the taste of this unique and naturally refreshing beverage.
STILLY branded beverages hit liquor stores throughout Minnesota days before the 4th of July holiday. A little over two weeks later, consumers can find them in over 300 liquor stores across Minnesota. New stores are being added daily.
"We have been overwhelmed by the demand and could not be more excited for what's ahead," said Nick Barthelemy, CEO and Co-founder of STILLY SPIRITS, LLC., based out of Stillwater, MN. "We are already selling through supply into late summer and fall. We are thrilled people love our product as much as we do."
The company introduced three distinctly delicious flavors of the "vodka stilly" in a variety pack (6 cans/3 flavors) of 12 oz slim cans for $14.99. The three varieties available now include "Partymaker+" (cranberry lime), "Vibe Machine" (grapefruit), and "The Fuzz" (peach). More flavors will hit the market soon.
"We rarely see a launch this successful. Customers are buying out the product within days of it reaching stores," said Keith Donovan, general sales manager for Bellboy Corporation, the distributor of STILLY branded beverages. "We pre-sold the entire first run before it even hit the production line, and the demand from our customers continues to grow with every person who tastes it."
What started as an idea less than a year ago, with the support of family and friends, has turned into not only a new product line but a lifestyle brand. "We all live for the enjoyable moments in life. So we want to inspire people to take a moment, crack a STILLY and a smile, relax, have fun, and enjoy the STILLY Life, all while making memories together," said Barthelemy.
Later this summer, the company will launch a line of merchandise, including hats, T-shirts, coolers, golf accessories, boat flags, etc., to be sold on Stilly.com.
About STILLY™:
STILLY™ beverages are NOT seltzers, and they're not your ordinary cocktails in a can; they're an all-new category of unique adult beverages called a "stilly." A "stilly" is a light and refreshing cocktail made with premium vodka or other distilled spirits, fine bubbles, a squeeze of natural juices, and natural flavors. The exact ingredients and processes used to make a "stilly" are a closely guarded secret, but consumers are proving to love the taste of this unique and naturally refreshing beverage.
The company introduced three distinctly delicious flavors of the "vodka stilly" in a variety pack (6 cans/3 flavors) of 12 oz slim cans for $14.99, with more to be launched in the fall. The three varieties available now include "Partymaker+" (cranberry lime), "Vibe Machine" (grapefruit), and "The Fuzz" (peach). STILLY branded beverages can be found at more than 300 liquor stores throughout Minnesota.
STILLY™ is owned by STILLY SPIRITS LLC, based out of Stillwater, MN. For more information, go to Stilly.com and follow on social media @drinkstilly.
Distribution contact:
Keith Donovan
General Sales Manager
Bellboy Corporation
Kdonovan@bellboycorp.com
(612) 615-1412
Media contact:
Bridget Nelson Monroe
bridget@bellmontpartners.com
612-255-1110
View original content to download multimedia:
SOURCE STILLY SPIRITS, LLC | https://www.wibw.com/prnewswire/2022/07/18/stilly-new-ready-to-drink-cocktail-can-launches-across-minnesota-unprecedented-demand/ | 2022-07-18T20:55:23Z |
VANCOUVER, BC, June 9, 2022 /PRNewswire/ - LUXXFOLIO Holdings Inc. (the "Company" or "LUXXFOLIO") (CSE: LUXX) (OTCQB: LUXFF) (Frankfurt/Berlin: LUH) a vertically-integrated digital asset company is pleased to announce that BIGG Digital Assets Inc. ("BIGG") (CSE: BIGG) (OTCQX: BBKCF) has made a strategic investment of CAD $2.0 million into LUXXFOLIO for 12.5 million common shares, and 12.5 million warrants (the "Unit Offering"). Through this investment BIGG now owns ~15% of LUXXFOLIO.
BIGG's principal business units consist of Netcoins (Netcoins.ca), the online cryptocurrency brokerage that makes it easy for Canadians to buy, sell, and understand cryptocurrency, and Blockchain Intelligence Group (blockchaingroup.io), a leading developer of blockchain technology search, risk-scoring and data analytics solutions.
LUXXFOLIO had been seeking a strategic partner to help fund its next phase of growth in both the traditional Bitcoin mining vertical and more recently an entrance into a decentralized data storage vertical. Decentralized storage supports the advancements in cloud computing and includes high growth areas such as scientific research and development, AI (artificial intelligence) and 3-D modelling.
Ken MacLean, LUXXFOLIO President highlighted, "We are thrilled to welcome BIGG as a major shareholder in LUXXFOLIO. BIGG will be an excellent partner as we navigate the opportunities in the current volatile market. Mark Binns and his team support our vision, and with their investment, we can continue to be opportunistic on the execution of our 2022 plan.
Mark Binns, BIGG CEO, remarked, "BIGG is first and foremost a digital assets company - and complementary to our holdings in crypto forensics, crypto trading and Metaverse/NFT is crypto mining - a mainstay and essential component to the digital asset economy. We believe LUXXFOLIO can become a global leader in sustainable crypto mining, and has established an excellent beach head operation in New Mexico with significant expansion potential. The team at LUXXFOLIO, led by Ken MacLean, have built deep relationships in the crypto mining community and have grown the business through multiple crypto pricing cycles."
In connection with the investment into LUXXFOLIO, as long as BIGG maintains an equity interest in LUXXFOLIO of 10% or greater, BIGG is entitled to appoint one member to LUXXFOLIO's board of directors and will maintain certain pre-emptive rights.
The Unit Offering is comprised of one common share issued at $0.16 per share with one whole warrant exercisable into one common share at $0.21 for a period of 2 years. If over a period of 20 consecutive trading days, occurring at any time after the closing date of the Unit Offering, the volume-weighted average market closing price (the "VWAM") for the Company's common shares on the Canadian Securities Exchange (or such other Canadian exchange as applicable at the time) is equal to or greater than a VWAM of CAD$0.50 (the end of such 20 day period being the "Acceleration Event"), then the expiry date of the warrants may be accelerated by the Company (the "Acceleration Exercise") to a date not later than the 20th day that immediately follows the Acceleration Event. The Company has the option to offer further units with subsequent closings in the Unit Offering.
The Use of Proceeds will be for future capex and operating expenses, or other such areas approved by the Board of the Company.
- Q3 2022: 1,400 Miners
LUXXFOLIO Holdings Inc. is a publicly traded, vertically integrated digital asset company based in Canada. It operates an industrial scale cryptocurrency mining facility in the United States powered predominately by renewable energy with a focus on the blockchain ecosystem and generation of digital assets. LUXXFOLIO provides a liquid alternative for exposure to digital assets for the broader capital markets.
Follow us on:
- Twitter at LuxxfolioH
- The Company diligently posts updates through videos from the official company YouTube channel at: YouTube Channel
- Please join the conversation on our LUXXFOLIO Holdings supporter's Telegram group at: https://t.me/Luxxfolio
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "anticipated", "will be", or variations of such words and phrases or statements that certain actions, events, or results "will" occur. Forward-looking statements regarding the Company, its hosting operations, miners, and the Company's development of its growth strategy are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company and its subsidiaries to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
View original content to download multimedia:
SOURCE Luxxfolio Holdings Inc. | https://www.wibw.com/prnewswire/2022/06/09/luxxfolio-receives-strategic-investment-bigg-digital-assets/ | 2022-06-09T13:46:46Z |
NEW YORK, July 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kohl's Corporation ("Kohl's" or the "Company") (NYSE: KSS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Kohl's and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On May 20, 2022, Macellum Advisors GP, LLC ("Macellum"), "a long-term holder of nearly 5% of the outstanding common shares of Kohl's", issued a statement addressing "[t]his quarter's extremely disappointing results," which Macellum described as "simply a consequence of a weak Board and management configuration leading to a flawed strategic plan and an inability to execute." Macellum also stated that "the current Board appears to have withheld material information from shareholders about the state of Kohl's in the lead-up to this year's pivotal annual meeting," which "suggests to us a clear breach of fiduciary duty."
On this news, Kohl's stock price fell $5.84 per share, or 12.97%, to close at $39.20 per share on May 20, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
View original content to download multimedia:
SOURCE Pomerantz LLP | https://www.wibw.com/prnewswire/2022/07/14/shareholder-alert-pomerantz-law-firm-investigates-claims-behalf-investors-kohls-corporation-kss/ | 2022-07-14T00:47:19Z |
SAN DIEGO and SHANGHAI, June 9, 2022 /PRNewswire/ -- Degron Therapeutics ("Degron"), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable targets, today announced it has closed a $22 million Series A financing round led by Med-Fine Capital. Additional investors participating in the financing round included Dyee Capital, Baidu Venture, and NeuX Capital, along with Degron's seed investors, CO-WIN Ventures and Yuanbio Venture Capital.
Proceeds from the Series A financing will be used to advance the company's GlueXplorer® platform. GlueXplorer is a unique molecular glue-based targeted protein degradation platform to accelerate the development of novel drugs for previously undruggable targets in oncology, inflammation, metabolic disease, rare diseases, and other therapeutic areas. The company currently has three pipeline programs that have entered into the lead-optimization phase, including a first-in-class target with essential roles in a broad range of cancers and immune diseases.
"We are pleased to have such strong support from this syndicate of blue-chip investors who recognize the potential of our industry-leading platform to build a new type of biotechnology company," said Lily Zou, Ph.D., co-founder and CEO of Degron Therapeutics. "Small-molecule drugs have been the mainstay of disease treatments, but most disease targets remain undruggable. Our GlueXplorer platform has already yielded several preclinical candidates in disease areas including cancer, inflammatory diseases, and rare diseases. Our team of accomplished entrepreneurs, scientists, and clinicians, is poised to usher in a step-change in how we treat undruggable targets to realize our goal of significantly improving patients' lives."
Founded in 2021, Degron Therapeutics builds on research and technologies developed in the laboratory of ShanghaiTech University professor and company co-founder Yong Cang, Ph.D. Using its proprietary GlueXplorer platform, Degron has created a unique and expanding library of molecular glue compounds that enables the targeting of previously undruggable targets. Degron's platform uses a combination of phenotypic screening, proteomic screening, and artificial intelligence (AI) to predict novel targets and accelerate compound discovery. Beginning with a novel, patented scaffold, Degron has created more than 60 novel diverse cores and 6,000 compounds, of which almost all demonstrate binding to Cereblon (CBRN), an E3 ligase that promotes protein ubiquitination and degradation.
"Degron Therapeutics is building a platform that will unlock the future of small-molecule therapeutics. We are excited to partner with this world-class team as they pioneer the new frontier of molecular glue degraders and ultimately significantly improve how we treat diseases," said Daniel Hu, executive director of Med-Fine Capital.
As part of the financing, Jing Yu, Ph.D., partner of Med-Fine Capital, joins Degron's board of directors. Dr. Yu has scientific and clinical research experience as well as an extensive track record of successful investments across multiple segments and companies at different lifecycle stages.
About Degron Therapeutics
Degron Therapeutics is a biotechnology company advancing human health by developing novel medicines using its robust molecular glue-based targeted protein degradation drug discovery platform. The company's unique GlueXplorer® platform has created a rapidly expanding IP-protected compound library and screening system to develop a new class of small-molecule medicines that target previously undruggable disease targets. The company's pipeline includes a growing number of preclinical compounds for oncology, inflammation, metabolic disease, and rare diseases. For more information, please visit www.degrontx.com.
View original content to download multimedia:
SOURCE Degron Therapeutics | https://www.kxii.com/prnewswire/2022/06/09/degron-therapeutics-raises-22m-series-financing-accelerate-growth-expand-molecular-glue-based-targeted-protein-degradation-drug-discovery-platform/ | 2022-06-09T09:23:24Z |
New facility part of $300 million expansion to support EV growth
Michigan state officials, including Governor Gretchen Whitmer and U.S. Rep. Dan Kildee, attended
Public arts project honors talented people of Bay City
BAY CITY, Mich., Sept. 1, 2022 /PRNewswire/ -- SK Siltron CSS, a semiconductor wafer manufacturer, today celebrated the ribbon cutting of its new manufacturing facility in Bay City, Michigan, with state officials including Governor Gretchen Whitmer and U.S. Rep. Dan Kildee (MI-5) in attendance. The new facility is part of a $300 million expansion the company announced in July 2021 with critical support from the Michigan Economic Development Corporation. The expansion will both double the company's Michigan workforce and quadruple its manufacturing capacity over the next several years.
SK Siltron CSS manufactures wafers made of silicon carbide (SiC) that can be used in electric vehicles. SiC wafers are more efficient at handling high powers and conducting heat than normal silicon. When used in EV system components, this allows for a more efficient transfer of electricity from the battery to the motor, increasing the driving range of an EV by 5% to 10%.
SK Siltron CSS is a U.S. subsidiary of South Korea's SK Siltron, a global leader in semiconductor wafers. The companies are part of SK Group, South Korea's second-largest conglomerate, which has major operations in renewable energy, semiconductors, and life sciences across the U.S. The new Bay City manufacturing facility underscores SK Group's commitment to the state of Michigan and reaffirms its plans to increase its U.S. investments and assets to more than $50 billion and create tens of thousands of jobs in the U.S. by the end of 2025. SK Group companies currently have $13 billion in U.S. investments and assets and more than 4,000 U.S. employees.
"SK Siltron's commitment to Michigan will help us bring the semiconductor supply chain home, cut down shortages and delays, and create good-paying jobs for Michiganders in Bay City," said Governor Whitmer. "The products SK Siltron manufactures are the building blocks of countless products and industries: electric vehicles, solar panels, smartphones, and so much more. I am proud that Michigan was selected for this $300 million investment, proving that we have the skilled workforce, growing economy, and strong business-friendly environment conducive to attract projects from one of the world's most innovative companies. I will work with anyone to keep bringing supply chains home, build on our high-tech manufacturing leadership, and create opportunity for Michiganders in every region."
"This new manufacturing facility will create good-paying jobs in mid-Michigan and boost American manufacturing," Rep. Kildee said. "With new laws like the CHIPS and Science Act, we're bringing back manufacturing jobs to Michigan, fixing supply chains, and helping to lower costs for Michigan families. Making wafers and semiconductors here in Michigan will decrease our reliance on foreign-made goods and support good-paying jobs. Michigan has the best workers in the world, and I applaud SK Siltron for expanding their commitment to our community."
Emphasizing the transformative nature of this investment, SK Siltron CSS will work with local partners to train workers, focusing on critical initiatives to reskill and upskill workers for the sustained growth of the region. Specifically, SK Siltron CSS is proud to partner with Delta College through the Michigan New Jobs Training Program to support the skills needed for success in SiC wafer manufacturing.
Working closely with Delta College, SK Siltron CSS is structuring its training program to support the skills needed for employment while demonstrating its commitment to helping prepare Michigan workers for careers in advanced manufacturing. Because SK Siltron CSS is dedicated to advancing the careers of current employees and supporting their professional development, these opportunities are available to employees at all levels.
"SK Siltron CSS is thrilled to expand our presence in Michigan and reinforce our commitment to the entire Bay City community while creating high-paying jobs and new investment opportunities," said Jianwei Dong, Chief Executive Officer of SK Siltron CSS. "The exceptional people of Bay City and our strong local partners are the reason we were able to expand so aggressively in the area. The support we have received is truly unmatched. This significant investment in Bay City will further boost the confidence levels of not only our customers but also the entire electrical vehicle value chain to accelerate the pace of EV adoption."
"SK Siltron's high-profile commitment underscores the strength of our state's high-tech manufacturing workforce and represents a critical win as we continue to attract long-term investments from semiconductor companies from around the world," said Quentin Messer, Jr., CEO of the MEDC and President and Chair of the Michigan Strategic Fund. "We are grateful to SK Siltron and for the leadership and support of Gov. Whitmer, our legislative partners, and our partners at Bay Future, Inc. in securing this impactful project in Bay County. Today's ribbon cutting is delivering on Team Michigan's commitment that Michigan's economic recovery is experienced by all 10 million plus of our friends and neighbors."
"SK Siltron CSS is a world-class, high-technology company that could have chosen to invest anywhere in the world, and chose Bay County, Michigan. We are appreciative that they decided to choose to invest here and are thankful to all of those who assisted in making this project a reality. Our community, region, and state have a storied history of manufacturing, and this ribbon cutting and the size of this expansion and investment honors and embraces that legacy," said Bay Future, Inc. President and CEO Trevor Keyes. "This investment presents unique opportunities for members of our community. We are already seeing significant impact through the growth of SK Siltron CSS, as our neighbors, friends, and family members have had the opportunity to find new high-tech careers locally that have enhanced their quality of life and have made lasting, positive, impacts on our community."
To further highlight the commitment to Bay City, SK Group and SK Siltron CSS are revealing a public arts project that advances their community engagement efforts. The public arts initiative shines a spotlight on the people of Bay City who make up the fabric of the community and celebrates the diversity of the region. The public arts project is currently being held at Wenonah Park located at 111 Center Avenue in Bay City and will run through the end of September.
The Michigan Economic Development Corporation is the state's marketing arm and lead advocate for business development, job awareness, and community development with the focus on growing Michigan's economy. For more information on the MEDC and our initiatives, visit www.MichiganBusiness.org. For Pure Michigan® tourism information, your trip begins at www.michigan.org. Join the conversation on: Facebook, Instagram, LinkedIn, and Twitter.
SK Group, South Korea's second-largest conglomerate, is a collection of global industry-leading companies driving innovations in semiconductors, sustainable energy, telecommunications, and life sciences. Based in Seoul, SK invests in building sustainable businesses around the world with a shared commitment to reducing global greenhouse gas emissions and increasing the use of renewable energy.
SK companies combined have more than $106 billion in global annual revenue and employ more than 100,000 people worldwide. SK companies are investing billions of dollars in expanding their U.S. presence with business operations or partnerships in hydrogen energy and fuel cells, EV battery manufacturing and technology, energy storage solutions, pharmaceutical manufacturing, and development, semiconductors, and advanced materials. For more information, visit sk.com.
View original content to download multimedia:
SOURCE SK Siltron CSS | https://www.kxii.com/prnewswire/2022/09/01/sk-siltron-css-celebrates-ribbon-cutting-new-bay-city-michigan-manufacturing-facility/ | 2022-09-01T18:44:21Z |
NEW YORK, Aug. 24, 2022 /PRNewswire/ -- Weiss Law, a national shareholders' rights law firm, is investigating possible breaches of fiduciary duty and violations of the federal securities laws by the directors and officers of MicroStrategy Incorporated (NASDAQ: MSTR) ("MicroStrategy" or the "Company") concerning the Company's mounting losses tied to its Bitcoin purchases and holdings.
If you own MicroStrategy shares and wish to discuss this investigation, or share information which you have, or if you have any questions concerning this notice or your rights or interests, visit our website at
https://www.weisslaw.co/news-and-cases/mstr
Or contact:
Josh Rubin, Esq.
stocks@weisslaw.co
(212) 682-3025
THERE IS NO COST OR OBLIGATION TO YOU
Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients. For more information about the firm, please go to: http://www.weisslaw.co
View original content to download multimedia:
SOURCE Weiss Law | https://www.wibw.com/prnewswire/2022/08/24/shareholder-alert-weiss-law-investigates-microstrategy-incorporated/ | 2022-08-24T21:52:02Z |
CAMBRIDGE, Mass., April 13, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Michael Severino, M.D., is joining the company as CEO-Partner. Dr. Severino joins Flagship from AbbVie, Inc. where he served as Vice Chairman and President. As a CEO-Partner, Dr. Severino will play an instrumental role in Flagship Pioneering's efforts to create and develop groundbreaking innovations in human health and will serve as CEO of a Flagship company to be announced in due course.
With more than two decades of biopharmaceutical leadership, Dr. Severino has made significant contributions to the research, development, registration, and commercialization of more than a dozen approved therapies. In his eight years with AbbVie, he led efforts to build a strong pipeline and advance promising science for patients in the areas of hematologic oncology, immunology, and neuroscience. As Senior Vice President, Global Development and Corporate Chief Medical Officer at Amgen, Inc. he led an organization of more than 2,000 people in 35 countries and oversaw the company's R&D efforts across all therapeutic areas, including oncology, inflammation neuroscience, and metabolic disorders. Prior to joining Amgen, Dr. Severino was Senior Director at Merck & Co., Inc. where he was responsible for leading research in multiple areas, including clinical genomics, molecular profiling, and experimental medicine.
"Mike's stellar leadership in biopharmaceutical strategy and R&D will be an excellent addition to Flagship and our ecosystem of companies, and I am pleased to welcome him to our team," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering. "With a track record of developing innovative strategies, driving scientific, operational, and business excellence, and leading transformational change, Mike is an ideal fit for Flagship, where we invent, develop, and scale breakthrough innovations that improve lives."
"I am thrilled to take on this role and partner with the high-caliber team of world-class scientists, technologists, and business executives assembled by Flagship Pioneering," said Dr. Michael Severino. "I look forward to applying my experience across all phases of drug discovery, development, and commercialization at Flagship, to help make an important difference for patients."
Dr. Severino's appointment follows recent executive appointments to Flagship Pioneering including: Michelle C. Werner, CEO-Partner and CEO of Alltrna; Margo Georgiadis, CEO-Partner; Tom DiLenge, Senior Partner, Global Policy, Regulatory & Governmental Strategy; Vaithianathan "Palani" Palaniappan, Chief Technology Officer of Pioneering Medicines; Justine Levin-Allerhand, Senior Partner, Corporate Development; Kathy Biberstein, General Counsel and Executive Partner; and Dr. Stephen Hahn, CEO-Partner and CEO of Harbinger Health, among others.
Michael Severino is an accomplished executive with more than two decades of leadership experience in the biopharmaceutical industry and has made significant contributions to the development, registration, and/or commercialization of more than a dozen approved therapies. He joined AbbVie in 2014 as EVP of R&D and Chief Scientific Officer and was promoted to Vice Chairman and President in 2018. In that capacity, he assumed leadership of functions including Business Development and Corporate Strategy while maintaining overall responsibility for R&D. In his eight years with AbbVie, Dr. Severino led efforts to build a strong pipeline and advance promising science for patients in the areas of hematologic oncology, immunology, and neuroscience.
Prior to joining AbbVie in 2014, Dr. Severino was Senior Vice President, Global Development and Corporate Chief Medical Officer at Amgen, Inc. During his tenure at Amgen, he served in multiple leadership positions, including VP, Global Development; VP, Therapeutic Area Head, General Medicine and Inflammation; and Therapeutic Area Head, Inflammation Global Clinical Development. As Senior Vice President he led an organization of more than 2,000 people in 35 countries and oversaw the company's R&D efforts across all therapeutic areas, including oncology, inflammation neuroscience and metabolic disorders. Prior to joining Amgen, Dr. Severino was Senior Director at Merck & Co., Inc. where he was responsible for leading research in multiple areas, including clinical genomics, molecular profiling, and experimental medicine.
Dr. Severino earned his Bachelor of Science in Biochemistry from the University of Maryland, College Park, where he graduated summa cum laude in 1987 and was a member of the Phi Beta Kappa Society. In 1993, he earned his M.D. from the Johns Hopkins University, where he was a member of the Alpha Omega Alpha Honor Medical Society. Dr. Severino completed his residency and post-doctoral training at Massachusetts General Hospital and Harvard Medical School.
Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $140 billion in aggregate value. To date, Flagship has deployed over $2.6 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 42 transformative companies, including Axcella Therapeutics (NASDAQ: AXLA), Codiak Biosciences (NASDAQ: CDAK), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ: SGTX).
View original content to download multimedia:
SOURCE Flagship Pioneering | https://www.kxii.com/prnewswire/2022/04/13/flagship-pioneering-expands-leadership-team-with-appointment-michael-severino-ceo-partner/ | 2022-04-13T14:00:11Z |
A Killeen man accused of capital murder of multiple people had a dismissal of charges and bond reduction denied by a district judge Friday.
Cedric Marks, 47, who has been incarcerated since Feb. 3, 2019, and held in lieu of bonds totaling more than $2 million, filed for a writ of habeas corpus — a hearing where the prosecution has to show just cause to have someone detained, and the lack of it can have a suspect released.
Judge Steven Duskie of the 426th District Court denied the request.
Marks is charged with capital murder of multiple persons, a capital felony; burglary of a habitation with intent to commit a felony, a first-degree felony; tampering with evidence, a third-degree felony; and various misdemeanor charges.
Bell County District Attorney Henry Garza is seeking the death penalty for Marks, who allegedly killed Temple residents Jenna Scott, 28, and Michael Swearingin, 32, on Jan. 3, 2019.
Marks has maintained his innocence while Maya Maxwell, his alleged accomplice, told investigators that she and Marks hid Swearingin’s car in Austin to distract authorities.
Arrest affidavits in the case said the victims were killed in Austin and the bodies taken to Clearview, Okla., where the bodies were discovered in a shallow grave.
Autopsy reports listed Scott’s cause of death as homicidal violence due to multiple traumatic injuries while Swearingin was strangled. He had contusions, cuts, and abrasions on his body. | https://www.tdtnews.com/news/central_texas_news/article_b39e05c8-ee8f-11ec-a4f9-4b29959ba559.html | 2022-06-17T23:44:05Z |
Man hears screaming, finds woman chained in abandoned house
Published: May. 23, 2022 at 6:13 PM EDT|Updated: 44 minutes ago
CHICAGO (WLS) – It’s a disturbing story out of Chicago, where a man said he heard someone screaming for help from an abandoned home over the weekend.
The man called police, who then found a 36-year-old woman chained up inside the building on the city’s south side.
The woman said she was abducted, taken to the basement and attic, raped and handcuffed and chained inside the house.
She said she was there for four or five days.
The woman was released from a hospital Sunday morning in good condition.
Police are still searching for the abductor. Neighbors say the home has been vacant for more than 30 years. It’s among about half a dozen homes on the block that are abandoned.
Copyright 2022 WLS via CNN Newsource. All rights reserved. | https://www.mysuncoast.com/2022/05/23/man-hears-screaming-finds-woman-chained-abandoned-house/ | 2022-05-23T22:58:15Z |
LOS ANGELES, June 1, 2022 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Okta, Inc. ("Okta" or the "Company") (NASDAQ: OKTA).
Class Period: March 5, 2021 – March 22, 2022
Lead Plaintiff Deadline: July 19, 2022
If you are a shareholder who suffered a loss, click here to participate.
The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) Okta had inadequate cybersecurity controls; (2) as a result, Okta's systems were vulnerable to data breaches; (3) Okta ultimately did experience a data breach caused by a hacking group, which potentially affected hundreds of Okta customers; (4) Okta initially did not disclose and subsequently downplayed the severity of the data breach; (5) all the foregoing, once revealed, was likely to have a material negative impact on Okta's business, financial condition, and reputation; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View original content to download multimedia:
SOURCE The Law Offices of Frank R. Cruz, Los Angeles | https://www.wibw.com/prnewswire/2022/06/01/okta-investors-have-opportunity-lead-okta-inc-securities-fraud-lawsuit/ | 2022-06-01T17:25:15Z |
FRISCO, TX (Silver Star Nation) – The 2022 NFL Draft is about to begin in Las Vegas. The Dallas Cowboys have some big holes to fill after losing key starters during the off-season.
Silver Star Nation’s Tobin McDuff and Cowboys insider Mickey Spagnola are at the Star in Frisco, Texas to break down the first and second round expectations for America’s Team. | https://cw33.com/sports/silver-star-nation/mickey-and-tobin-preview-cowboys-2022-nfl-draft/ | 2022-04-29T03:11:59Z |
MILWAUKEE, Sept. 1, 2022 /PRNewswire/ -- Ademi LLP is investigating Forma Therapeutics (NASDAQ: FMTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk.
Click here to learn how to join the action: https://www.ademilaw.com/case/forma-therapeutics-holdings-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Ademi LLP alleges Forma Therapeutics' financial outlook and prospects are excellent and yet Forma Therapeutics holders will receive only $20 per share. The transaction agreement unreasonably limits competing bids for Forma Therapeutics by imposing a significant penalty if Forma Therapeutics accepts a superior bid. Forma Therapeutics insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Forma Therapeutics' board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Forma Therapeutics.
If you own Forma Therapeutics common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/forma-therapeutics-holdings-inc
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:
SOURCE Ademi LLP | https://www.mysuncoast.com/prnewswire/2022/09/01/shareholder-alert-ademi-llp-investigates-whether-forma-therapeutics-holdings-inc-has-obtained-fair-price-its-transaction-with-novo-nordisk/ | 2022-09-01T16:27:51Z |
WASHINGTON, Aug. 2, 2022 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) announced that The TJX Companies Inc., of Framingham, Massachusetts, has agreed to pay a $13 million civil penalty for selling, offering for sale, and distributing previously recalled consumer products. It has further agreed to maintain a compliance program to ensure that it meets the obligations of the law and this settlement going forward. The agreement settles charges that the firm knowingly sold, offered for sale, and distributed approximately 1,200 recalled products from 21 separate voluntary corrective actions during a five-year period from March 2014 through October 2019.
Federal law prohibits the sale, offer for sale, or distribution in commerce of a consumer product that is subject to voluntary corrective action, such as a recall, that has been publicly announced and taken in consultation with CPSC.
CPSC staff charged that TJX sold, offered for sale, and distributed the recalled products through its brick-and-mortar retail stores including T.J. Maxx, Marshalls, HomeGoods and online. The majority of the post recall sales were products recalled due to the risk of infant suffocation and death including the Kids II Rocking Sleepers, Fisher-Price Rock 'n Play Sleepers, and Fisher-Price Inclined Sleeper Accessory for Ultra-Lite Day & Night Play Yards.
On November 26, 2019, CPSC and TJX jointly issued a press release announcing that TJX had sold, offered for sale, and distributed 19 separate recalled products. After the press release was announced, TJX reported to staff that it subsequently discovered previous sales of three additional recalled products.
In addition to paying the $13 million civil penalty, TJX will maintain a compliance program and system of internal controls to ensure that the company complies with the Consumer Product Safety Act (CPSA), including a program for the appropriate identification, quarantine, and disposal of recalled products. TJX will also maintain internal controls designed to ensure TJX's compliance with the CPSA, requiring TJX to review claims, report safety concerns, implement corrective and preventive actions when compliance deficiencies or violations are identified, and establish senior management oversight of TJX's compliance program. TJX has also agreed to file annual reports regarding the compliance program and system of internal controls for a period of 5 years.
TJX's settlement of this matter does not constitute an admission by TJX, or a determination by the Commission, that TJX knowingly violated the CPSA.
The Commission voted 4-0-1 to provisionally accept the settlement.
CPSC Chair & Commissioner Statements:
About the U.S. CPSC
The U.S. Consumer Product Safety Commission (CPSC) is charged with protecting the public from unreasonable risk of injury or death associated with the use of thousands of types of consumer products. Deaths, injuries, and property damage from consumer product-related incidents cost the nation more than $1 trillion annually. CPSC's work to ensure the safety of consumer products has contributed to a decline in the rate of injuries associated with consumer products over the past 50 years.
Federal law prohibits any person from selling products subject to a Commission ordered recall or a voluntary recall undertaken in consultation with the CPSC.
For lifesaving information:
- Visit CPSC.gov.
- Sign up to receive our e-mail alerts.
- Follow us on Facebook, Instagram @USCPSC and Twitter @USCPSC.
- Report a dangerous product or a product-related injury on www.SaferProducts.gov.
- Call CPSC's Hotline at 800-638-2772 (TTY 301-595-7054).
- Contact a media specialist.
Release Number: 22-195
View original content to download multimedia:
SOURCE U.S. Consumer Product Safety Commission | https://www.kxii.com/prnewswire/2022/08/02/tjx-agrees-pay-13-million-civil-penalty-selling-offering-sale-distributing-recalled-products/ | 2022-08-02T17:59:16Z |
SHANGHAI, May 31, 2022 /PRNewswire/ -- Boqii Holding Limited ("Boqii" or the "Company") (NYSE: BQ), a leading pet-focused platform in China, today announced that its board of directors has decided to increase the total number of Class A ordinary shares reserved for awards to be granted to the eligible participants under the Company's existing Amended and Restated 2018 Global Share Plan by 4,000,000 Class A ordinary shares, which will be used to retain and attract talent to drive the long-term success of Boqii. After this increase, a total of 12,987,836 Class A ordinary shares are available for issuances pursuant to awards to be granted under Boqii's Amended and Restated 2018 Global Share Plan. Such increase will not result in any immediate dilution to the shareholders of Boqii until any additional Class A ordinary shares are issued pursuant to awards granted under Boqii's Amended and Restated 2018 Global Share Plan.
About Boqii Holding Limited
Boqii Holding Limited (NYSE: BQ) is a leading pet-focused platform in China. We are the leading online destination for pet products and supplies in China with our broad selection of high-quality products including global leading brands, local emerging brands, and our own private label, Yoken and Mocare, offered at competitive prices. Our online sales platforms, including Boqii Mall and our flagship stores on third-party e-commerce platforms, provide customers with convenient access to a wide selection of high-quality pet products and an engaging and personalized shopping experience. Our Boqii Community provides an informative and interactive content platform for users to share their knowledge and love for pets.
For more information, please visit: http://ir.boqii.com/.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission (the "SEC"), in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties.
Further information regarding such risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
For investor and media inquiries, please contact:
Boqii Holding Limited
Investor Relations
Tel: +86-21-6882-6051
Email: ir@boqii.com
DLK Advisory Limited
Tel: +852-2857-7101
Email: ir@dlkadvisory.com
View original content:
SOURCE Boqii Holding Limited | https://www.kxii.com/prnewswire/2022/05/31/boqii-increases-its-esop-pool/ | 2022-05-31T10:41:58Z |
NEW YORK, July 29, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amazon.com, Inc. (NASDAQ: AMZN).
To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/amazon-com-inc-loss-submission-form-2/?id=30351&from=4
This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired shares of Amazon common stock between July 30, 2021, and April 28, 2022, inclusive.
Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until September 6, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
According to a filed complaint, Amazon.com, Inc. issued materially false and/or misleading statements and/or failed to disclose that: 1) defendants knew or recklessly disregarded that the Company's infrastructure and fulfillment network investments substantially outpaced demand; 2) those investments were a massive, self-imposed, undue drain on Amazon's financial condition; 3) contrary to defendants' public statements and undisclosed to investors, defendants had already implemented cutbacks to Amazon's fulfillment capacity by July 2021; and 4) as a result of defendants' misrepresentations and omissions, Amazon's common stock traded at artificially inflated prices during the class period.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original content:
SOURCE Jakubowitz Law | https://www.mysuncoast.com/prnewswire/2022/07/29/amzn-shareholder-alert-jakubowitz-law-reminds-amazon-shareholders-lead-plaintiff-deadline-september-6-2022/ | 2022-07-29T11:23:06Z |
Powered by its purpose and values, Crowe is recognized for fostering a trusting, inclusive, flexible and sustainable workplace
CHICAGO, April 11, 2022 /PRNewswire/ -- Crowe LLP, a public accounting, consulting and technology firm in the U.S. with offices around the world, has again been named to the Fortune 100 Best Companies to Work For® list. The award is based on an analysis of survey responses from more than 4.5 million U.S. employees at Great Place to Work-Certified™ organizations. The list's methodology evaluates an organization's level of trust, respect, camaraderie and more based on how it enables each person – regardless of who they are and what they do – to be a full member of the organization and can reach their highest potential.
"It's not one person, program or policy that allows us to become part of this list of distinguished companies," said Crowe CEO Mark Baer. "We make Crowe a great place to work together – operating from the foundation of our purpose and values, implementing changes based on feedback and working as a team to shape better tomorrows for each other, our clients and our communities. We're incredibly proud that our employees feel the same way and that we've made this prestigious list."
Many Crowe benefits can be attributed to making it a great place to work.
Since 2016, Crowe has provided personnel with the flexibility to work where it's most convenient and they're most productive. While many companies struggled with converting to full-time remote work environments in 2020, Crowe was able to easily make the transition thanks to this mobility model.
Last year, the firm instituted Time When You Need It, an open approach to time off. This empowers personnel to work with their coaches to take the time they need – whether it's time for resting and recharging, caring for themselves or a family member when sick or being present for important life events. Internal feedback has shown that this – combined with expanded firmwide holidays, including week-long closures in the summer and winter – has helped Crowe personnel achieve better work-life balance. This is evident in the Great Place to Work® survey responses, with 90% of Crowe respondents noting they are able to take time off from work when they think it's necessary.
Crowe refreshed its core purpose and values in 2021, and over the year, found several ways to help its workforce connect with and embrace the concepts.
For example, Crowe rallied around its "stewardship" value in summer 2021, providing each team member with Crowe Gives Back Bucks to direct to the nonprofit organization of their choice. With those contributions and many partners matching contributions, the initiative totaled more than $1 million in donations.
According to the Great Place to Work survey, 93% of Crowe respondents said they feel good about the ways the firm contributes to the community.
From building an internship-to-employment pipeline at multiple historically Black colleges and universities to establishing formal DE&I goals to hold the firm accountable, Crowe is committed to nurturing an inclusive environment that allows everyone to come to work as their authentic selves. This information is detailed in the Crowe 2021 U.S. Transparency Report.
"Our success is dependent on how we engage, develop, reward and maximize each person's experience every single day," Baer said. "It's critical that we maintain an inclusive culture where everyone is working toward a common purpose."
For more information on what makes Crowe a great place to work, visit Crowe Careers.
Crowe LLP is a public accounting, consulting and technology firm with offices around the world. Crowe uses its deep industry expertise to provide audit services to public and private entities. The firm and its subsidiaries also help clients make smart decisions that lead to lasting value with its tax, advisory and consulting services. Crowe is recognized by many organizations as one of the best places to work in the U.S. As an independent member of Crowe Global, one of the largest global accounting networks in the world, Crowe serves clients worldwide. The network consists of more than 200 independent accounting and advisory services firms in more than 130 countries around the world.
Twitter: @CroweUSA
LinkedIn: Crowe
View original content to download multimedia:
SOURCE Crowe LLP | https://www.mysuncoast.com/prnewswire/2022/04/11/crowe-again-named-one-fortune-100-best-companies-work-2022/ | 2022-04-11T17:06:55Z |
PASADENA, Calif. , May 24, 2022 /PRNewswire/ -- JRW Realty, a nationwide commercial real estate brokerage dedicated to finding and delivering net-leased properties, has facilitated the sale and closing of Point Mallard Centre, a multi-retail shopping center in Decatur, Ala., anchored by a 45,600-square-foot Publix. The firm sourced and closed the shopping center on behalf of an institutional buyer that is actively acquiring net-leased and value-add focused properties.
Small shops, restaurants and medical centers account for another 16,800 square feet of the center, which is located near Interstate 65 on the south side of the north Alabama town. Pricing and terms for the transaction were not disclosed.
Joel Staffilino, president of multi-tenant retail at JRW Realty, said this kind of project – a secure necessity business anchoring diverse businesses – is the kind his agency's buyers seek.
"When considering multi-tenant properties, our clients look for creditworthy net-leased anchors with surrounding essential businesses," Staffilino said. "Point Mallard Centre and its accompanying Publix meet those criteria. We are excited to have done our part in helping this deal come to fruition."
The transaction continues JRW Realty's strategy of finding and aiding in the closing on net-leased properties backed by essential businesses. To date, JRW Realty has facilitated the closing of more than 16 million square feet of commercial space.
"Our processes have shown that we can take properties from contract to closing in as few as 28 days," Staffilino said. "When we can find the right kind of property, our clients are able and willing to move quickly in order to solidify their portfolios and help bring their investors the solid returns they are looking for."
About JRW Realty
JRW Realty is a commercial real estate brokerage firm that has closed on more than 900 properties valued at more than $3.6 billion on behalf of its clients. JRW Realty's team places special focus on due diligence, reviewing over 100 properties each week and only choosing to source for clients the best 3-4% according to their rigorous acquisition criteria. For more information, visit www.jrwrealty.com.
Multi-Tenant Retail Sourcing Contact
Joel Staffilino, President - Multi-Tenant Retail
jstaffilino@jrwrealty.com
(513) 227-4502
Single-Tenant Net Lease Sourcing Contact
Melinda Marston, President - STNL
CA DRE #01950977
melinda@jrwrealty.com
(626) 696-2910
Media Inquiries
press@jrwrealty.com
View original content to download multimedia:
SOURCE JRW Realty | https://www.mysuncoast.com/prnewswire/2022/05/24/jrw-realty-helps-institutional-buyer-acquire-publix-anchored-center-alabama/ | 2022-05-24T17:21:15Z |
NEW YORK, May 4, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Natera, Inc..
Shareholders who purchased shares of NTRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/natera-inc-loss-submission-form/?id=26681&from=4
CLASS PERIOD: This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive.
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company's non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (2) the Company's screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (3) as a result of defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants' statements about the company's business, operations, and prospects lacked a reasonable basis.
DEADLINE: June 27, 2022 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/natera-inc-loss-submission-form/?id=26681&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NTRA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 27, 2022. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content:
SOURCE The Gross Law Firm | https://www.wibw.com/prnewswire/2022/05/04/shareholder-alert-gross-law-firm-notifies-shareholders-natera-inc-class-action-lawsuit-lead-plaintiff-deadline-june-27-2022-nasdaq-ntra/ | 2022-05-04T10:47:26Z |
CAMILLA -- The Mitchell County Sheriff’s office notified residents on its Facebook page of a "kidnapping scam" that has been reported at least twice since Sunday.
According to the sheriff's post, the scam typically begins with a phone call saying a family member is being held captive. The caller may allege your daughter has been kidnapped, and you'll hear a female screaming in the background. Another variant of the fraud has a family member being held because he/she caused an auto accident, is injured and won't be allowed to go to the hospital until damages are paid.
Callers will typically provide the victim with specific instructions to ensure a safe return of the family member. You may be ordered to stay on the line until money is wired. The caller may claim not to have received the money and may demand more payment.
The following is taken directly from a Federal Bureau of Investigation Press Release and explains how to avoid becoming a victim:
* Incoming calls come from an outside area code, sometimes from Puerto Rico with area codes (787), (939) and (856).
* Calls do not come from the alleged kidnapped victim's phone.
* Callers go to great lengths to keep you on the phone.
* Callers prevent you from calling or locating the "kidnapped" victim.
* Ransom money is only accepted via wire transfer service.
If you receive a phone call from someone who demands payment of a ransom for a kidnapped victim, the following should be considered:
* Try to slow the situation down. Request to speak to the victim directly. Ask, "How do I know my loved one is OK?"
* If the callers don't let you speak to the victim, ask them to describe the victim or describe the vehicle the victim drives, if applicable.
* Listen carefully to the voice of the kidnapped victim if he/she speaks.
* Attempt to call, text or contact the alleged victim via social media. Request that the victim call back from his or her cellphone.
* While staying on the line with the alleged kidnappers, try to call the alleged kidnap victim from another phone.
* To buy time, repeat the caller's request and tell them you are writing down the demand or tell the caller you need additional time to meet their demands.
* Don't directly challenge or argue with the caller. Keep your voice low and steady.
* Request the alleged kidnapper allow the victim to call you back from his/her cellphone.
* At the earliest opportunity, notify your local police department.
To help prevent this scam, check privacy settings on social media accounts and revisit the information you publicize on those accounts. The more information available to the public, the more information scammers can use to convince you into believing a scam is real. | https://www.albanyherald.com/local/mitchell-sheriff-warns-of-kidnapping-scam/article_f26d67fa-c633-11ec-af1f-8f2f0e6f13ef.html | 2022-04-27T15:43:36Z |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.